先端医療シリーズ21　乳癌の最新医療

出版社： 先端医療技術研究所
著者：
発行日： 2003-06-06
分野： 臨床医学：一般  >  癌/腫瘍一般
ISBN： 4925089277
電子書籍版： 2003-06-06 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

12,571 円(税込)

電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

6,286 円(税込)

購入する

商品紹介

分子生物学から診断、治療はもちろん、患者ケアーと予防に至るまで、乳癌診療に関係する重要な問題について最先端の情報を豊富な図表をもとに、理解しやすく記述。

目次

  • 先端医療シリーズ21　乳癌の最新医療

    ―目次―

    序　文
    序　章
    1. 乳癌診療の課題と展望
    2. 乳癌研究の課題と展望
    第１章　乳癌の分子生物学
    1. 乳癌の分子疫学
    2. 乳癌とHER2
    3. 乳癌とアロマターゼ
    4. 乳癌のホルモン依存性の分子機構
    5. 乳癌とｴｽﾄﾛｼﾞｪﾝﾚｾﾌﾟﾀｰ(ER-aとER-b)
    第２章　乳癌の病理と診断
    1. 非浸潤性乳癌の病理と診断
    2. 細胞診による乳癌の早期診断
    3. HER2発現の検査法(免疫組織化学とFISH)
    4. 乳癌の腫瘍マーカー最近の進歩
    5. 分子ﾏｰｶｰによる微小転移の診断
    （ﾘﾝﾊﾟ節・血中・骨髄）
    6. 乳癌の予後：免疫組織学と分子病理
    7. 多型性DNAﾏｰｶｰによる乳癌の予後診断
    第３章　画像診断＆装置の進歩
    1. 乳癌のスクリーニング＆確定診断
    2. 再発乳癌の画像診断
    3. マンモグラフィー
    4．超音波診断の新しい流れ
    5．ＭＲＩ
    6．ＰＥＴ
    7. 乳管内視鏡
    8. Mammotome
    第４章　センチネルリンパ節生検
    1. センチネルリンパ節生検（概説）
    2. センチネルリンパ節生検の実施手技
    3. センチネルリンパ節生検の標識物質の選択
    4. センチネルリンパ節生検の臨床応用（海外の現況を含む）

    第５章　家族性乳癌
    1. 家族性乳癌の遺伝子診断
    2. BRCA1、BRCA2乳癌の臨床病理学的特徴
    3. 家族性乳癌の治療と予防
    4. 家族性乳癌のカウンセリング
    第６章　治療に関する最近の動向
    1. 抗がん剤感受性試験
    2. 骨転移とﾋﾞｽﾌｫｽﾌｫﾈｰﾄ製剤　ASCOｶﾞｲﾄﾞﾗｲﾝに
    準じた標準的使用方法
    3. 乳癌治療における臨床試験とEBM
    4. 新しい治療法の開発（血管新生阻害薬、免疫療法の可能
    性、生物学的治療の探求の現状）
    5. 新しい抗がん剤の開発
    第７章　乳腺内視鏡手術
    1. 乳腺部分切除術
    2. 乳腺全摘術
    3. 内視鏡下腋窩リンパ郭清
    4. 内視鏡下乳房再建
    第８章　乳房温存療法
    1. 乳房温存療法の課題と展望
    2. 乳房温存手術の病理検査
    3. 乳房温存手術の実際
    4. 乳房温存療法とデイサージャリー
    5. 整容を目指した乳房温存手術の手技
    6. 乳房内再発の要因とその治療法
    第９章　内分泌療法
    1. 内分泌療法の課題と展望
    2. LH-RH アゴニストの効用
    3. アロマターゼ阻害剤の開発と効用
    4. 内分泌療法の効果予測：DNAﾏｲｸﾛｱﾚｲの応用
    第１０章 薬物療法
    術前薬物療法
    1. 術前薬物療法の課題と展望
    2. 術前薬物療法の実際
    3. 術前薬物療法の効果判定
    術後および再発時の薬物療法
    4. 予後因子・予測因子に応じた治療方法の選択
    5. 術後抗癌剤治療の実際
    6. 外来抗癌剤療法の実際
    7. 補助化学・内分泌療法の治療成績
    第１１章　放射線療法
    1. 放射線療法の現状と展望
    2. 乳房温存療法における放射線治療
    3. 乳房切除療法後のアジュバント放射線治療
    第１２章　疫学・予防と患者ケア
    1. 増加を続ける乳癌
    2. 乳癌罹患のリスクファクター
    3. 初期治療後のフォローアップ
    4. 薬物療法の妊娠に与える影響
    5. 乳癌患者と家族へのケア
    6. インフォームドコンセント

    技術資料編

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

序章

P.4 掲載の参考文献
1) 霞 富士雄:特別講演;乳癌診療の最前線, 第38回日本医学放射線学会秋期臨床大会抄録集. Nipp Act Radial 62 (11):337, 2002
 
2) 蒔田益次郎:第7回日本乳管内視鏡研究会抄録集. JAMD 2002
 
3) Rosen PP:Breast Pathology, Diagnosis by Needle Core Biopsy. Lippencott Williams & Wilkins 1999
 
4) 霞 富士雄, 坂元吾偉 監修:マンモトーム生検, 改訂第2版, J&J2002
 
5) M Noguchi:Lymph Node Dissection and Sentinel Lymph Node Biopsy. Maeda Shoten Co., 2002
 
6) 澤木正孝, 伊藤良則:乳癌における分子標的治療の 実際― HER2, トラスツズマブーPharma Medica 20 (8):19-23, 2002
 
7) 小林 直, 山崎博之, 平野明夫 ほか:Neoadjuvant chemotherapy癌の臨床46 (5):741-748, 2000
 
8) Fisher. B, Bryant J, Wolmark, N, et al:Effect of Preoperative Chemotherapy on the Outcome of Women With Operable Breast cancer. J Clin Oncol 16 (8):2672-2685, 1998
PubMed
9) The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group:Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer:First results of the ATAC randomized trial. Lancet 359:2131-2139, 2002
 
10) American Society for Therapeutic Radiology and Oncology (ASTRO):44Th Annual Meeting scientific Abstract 2002
 
P.9 掲載の参考文献
1) Tsukamoto F, Miyoshi Y, Koyama H, Watatani M, Sasa M, Shiba E, Takami S, Inazawa J, Noguchi S:Detection of chromosomal aneusomy by fluorescence in situ hybridization in fine-needle aspirates from breast tumors:application to the preoperative diagnosis of breast carcinoma. Cancer 90:373-378, 2000
 
2) Tsukamoto F, Miyoshi Y, Egawa C, Kasugai T, Takami S, Inazawa J, Noguchi S:Clinicopathologic analysis of breast carcinoma with chromosomal aneusomy detected by fluorescence in situ hybridization. Cancer 93:165-170, 2001
PubMed
3) International (Ludwig) Breast Cancer Study Group:Prognostic importance of occult axillary lymph node micrometastases from breast cancers. Lancet 335:1565-1568, 1990
 
4) Yeatman TJ, Cox CE:The significance of breast cancer lymph node micrometastases. Surg Oncol Clin N Am 8:481-496, ix, 1999
 
5) Noguchi S, Aihara T, Nakamori S, Motomura K, Inaji H, Imaoka S, Koyama H:The detection of breast carcinoma micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. Cancer 74:1595-1600, 1994
PubMed
6) Noguchi S, Aihara T, Motomura K, Inaji H, Imaoka S, Koyama H:Histologic characteristics of breast cancers with occult lymph node metastases detected by keratin 19 mRNA reversetranscriptase-polymerase chain reaction. Cancer 78:1235-1240, 1996
 
7) Noguchi S, Aihara T, Motomura K, Inaji H, Imaoka S, Koyama H:Detection of breast cancer micrometastases in axillary lymph nodes by means of reverse transcriptase-polynierase chain reaction. Comparison between MUC1 mRNA keratin 19 mRNA amplification. Am J Pathol 148:649-656, 1996
PubMed
8) Masuda N, Tamaki Y, Sakita I, Ooka M, Ohnishi T, Kadota M, Aritake N, Okubo K, Monden M:Clinical significance of micrometastases in axillary lymph nodes assessed by reverse transcription-polymerase chain reaction in breast cancer patients. Clin Cancer Res 6:4176-4185, 2000
PubMed
9) Aihara T, Fajiwara Y, Ooka M, Sakita I, Tamaki Y, Monden M:Mammaglobin B as a novel marker for detection of breast cancer micrometastases in axillary lymph nodes by reverse transcription-polymerase chain reaction. Breast Cancer Res Treat 58:137-140, 1999
 
10) Ooka M, Sakita I, Fujiwara Y, Tarnaki Y, Yamamoto H, Aihara T, Miyazaki M, Kadota M, Masuda N, Sugita Y, Iwao K, Monden M:Selection of mRNA markers for detection of lymph node micrometastases in breast cancer patients. Oncol Rep 7:561-566, 2000
 
11) Muller P, Schlimok G:Bone marrow "micrometastases"of epithelial tumors:detection clinical relevance. J Cancer Res Clin Oncol 126:607-618, 2000
PubMed
12) Ikeda N, Miyoshi Y, Motomura K, Inaji H, Koyama H, Noguchi S:Prognostic significance of occult bone marrow micrometastases of breast cancer detected by quantitative polymerase chain reaction for cytokeratin 19 mRNA. Jpn J Cancer Res 91:918-924, 2000
PubMed
13) Ooka M, Tamaki Y, Sakita I, FUjiwara Y, Yamamoto H, Miyake Y, Sekimoto M, Ohue M, Sugita Y, Miyoshi Y, Ikeda N, Noguchi S, Monden M:Bone marrow micrometastases detected by RT-PCR for mammaglobin can be an alternative prognostic factor of breast cancer. Breast Cancer Res Treat 67:169-175, 2001
 
14) Miyoshi Y, Ando A, Takamura Y, Taguchi T, Tamaki Y, Noguchi S:Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues. Int J Cancer 97:129-132, 2002
PubMed
15) Egawa C, Miyoshi Y, Takamura Y, Taguchi T, Tamaki Y, Noguchi S:Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer. Int J Cancer 95:255-259, 2001
PubMed
16) Egawa C, Miyoshi Y, Takamura Y, Taguchi T, Tamaki T, Noguchi S:Increased expression of BRCal mRNA predicts favorable response to anthracyline containing chemotherapy in breast cancers. Breast Cancer Res Treat, in press, 2003
 
17) Monzo M, Rosell R, Sanchez JJ, Lee JS, O' Brate A, Gonzalez-Larriba JL, Alberola V, Lorenzo JC, Nunez L, Ro JY, Martin C:Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol 17:1786-1793, 1999
 
18) Hasegawa S, Miyoshi Y, Egawa C, Ishitobi M, Tamaki Y, Monden M, Noguchi S:Mutational analysis of the class I beta-tubulin gene in human breast cancer. Int J Cancer 101:46-51, 2002
 
19) Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wie S, Tan-Chiu E, Ford L, Wolmark N:Tamoxifen for prevention of breast cancer:report of the National Surgical Adjuvant Breast Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388, 1998
 
20) Ikeda N, Miyoshi Y, Yoneda K, Shiba E, Sekihara Y, Kinoshita M, Noguchi S:Frequency of BRCA2 BRCA2 germline mutations in Japanese breast cancer families. Int J Cancer 91:83-88, 2001
PubMed
21) Miyoshi Y, Iwao K, Ikeda N, Egawa C, Noguchi S:Genetic polymorphism in CYP17 breast cancer risk in Japanese women. Eur J Cancer 36:2375-2379, 2000
PubMed
22) Miyoshi Y, Iwao K, Ikeda N, Egawa C, Noguchi S:Breast cancer risk associated with polymorphism in CYP19 in Japanese women. Int J Cancer 89:325-328, 2000
PubMed
23) ve Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, glas A, Delahaye L, ver Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R:A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009, 2002
 
24) Iwao K, Matoba R, Ueno N, Ando A, Miyoshi Y, Matsubara K, Noguchi S, Kato K:Molecular classification of primary breast tumors possessing distinct prognostic properties. Hum Mol Genet 11:199-206, 2002
PubMed

第1章 乳癌の分子生物学

P.18 掲載の参考文献
1) Fisher B, Costantino JP:Tamoxifen for prevention of breast cancer:report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 91:1891-1892, 1999
 
2) Hamajima N, Iwata H, Obata Y, et al:No association of the 5'promoter region polymorphism of CYP17 with breast cancer risk in Japan. Jpn J Cancer Res 91:880-885, 2000
PubMed
3) Miyoshi Y, Iwao K, ikeda N, et al:Genetic polymorphism in CYP17 and breast cancer risk in Japanese women. Eur J Cancer 36:2375-2379, 2000
PubMed
4) Spurdle A, Hopper J, Dite G, et al:CYP17 promoter polymorphism and breast cancer risk in Australian women under age forty years. J Natl Cancer Inst 92:1674-1681, 2000
PubMed
5) Feigelson H, Coetzee G, Kolonel L, et al:A polymorphism in the CYP17 gene increase the risk of breast cancer. Cancer Res 57:1063-1065, 1997
 
6) Bergman-Jungestrom M, Gentile M, Lundin A-C, et al:Association between CYP17 gene polymorphism and risk of breast cancer in young women. Int J Cancer 84:350-353, 1999
PubMed
7) Feigelson H, Shames L, Pike M, et al:Cytochrome P450c17αgene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res 58:585-587, 1998
 
8) Nedelcheva Kristensen V, Haraldsen EK, et al:CYP17 and breast cancer risk:the polymorphism in the 5' flanking area of the gene does not influence binding to Sp-1. Cancer Res 59:2825-2828, 1999
PubMed
9) Miyoshi Y, Iwao K, Ikeda N, et al:Breast cancer risk associated with polymorphism in CYP19 in Japanese women. Int J Cancer 89:325-328, 2000
PubMed
10) Kristensen VN, Andersen TI, Lindblom A, et al:A rare CYP19 (aromatase) variant may increase the risk of breast cancer. Pharmacogenetics 8:43-48, 1998
PubMed
11) Haiman CA, Hankinson SE, Spiegelman D, et al:A tetranucleotide repeat polymoiphism in CYP19 artd breast cancer risk. Int J Cancer 87:204-210, 2000
 
12) Baxter SW, Choong DY, Eccles DM, et al:Polymorphic variation in CYP19 and the risk of breast cancer. Carcinogenesis 22:347-349, 2001
PubMed
13) Siegelmann-Danieli N, Buetow KH:Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk. Br J Cancer 79:456-463, 1999
PubMed
14) Miyoshi Y, Takahashi Y, Egawa C, et al:Breast cancer risk associated with CYP1A1 genetic polymorphisms in Japanese women. Breast J 8:209-215, 2002
PubMed
15) Taioli E, Bradlow HL, Garbers SV, et al:Role of estradiol metabolism and CYP1A1 polymorphisms in breast cancer risk. Cancer Detect Prev 23:232-237, 1999
PubMed
16) Thompson PA, Shields PG, Freudenheim JL, et al:Genetic polymorphisms in catechol-O-methyltransferase, menopausal status, and breast cancer risk. Cancer Res 58:2107-2110, 1998
PubMed
17) Lavigne JA, Helzlsouer KJ, Huang HY, et al:An association between the allele coding for a low activity variant of catechol-0-methyltransferase and the risk for breast cancer. Cancer Res 57:5493-5497, 1997
 
18) Iwase H, Greenman JM, Barnes DM, et al:Sequence variants of the estrogen receptor (ER) gene found in breast cancer patients with ER negative and progesterone receptor positive tumors. Cancer Lett 108:179-184, 1996
PubMed
19) Helzlsouer KJ, Selmin O, Huang HY, et al:Association between glutathione S-transferase M1, P1, and T1 genetic polymorphisms and development of breast cancer. J Natl Cancer Inst 90:512-518, 1998
PubMed
20) Charrier J, Maugard CM, Le Mevel B, et al:Allelotype influence at glutathione S-transferase M1 locus on breast cancer susceptibility. Br J Cancer 79:346-353, 1999
PubMed
21) Sjalander A, Birgander R, Hallmans G, et al:p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis 17:1313-1316, 1996
PubMed
22) Healey CS, Dunning AM, Teare MD, et al:A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability. Nat Genet 26:362-364, 2000
PubMed
23) Chouchane L, Ahmed SB, Baccouche S, et al:Polymorphism in the tumor necrosis factor-alpha promotor region and in the heat shock protein 70 genes associated with malignant tumors. Cancer 80:1489-1496, 1997
PubMed
P.21 掲載の参考文献
1) Downward J, Yarden Y, Mayes E, et al:Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequence. Nature (London) 307:521-527, 1984
PubMed
2) 木村幹彦, 津田 均:ErbBフ ァミリーとしての ErbB2.癌と宿主14:179-185, 2002
 
3) Kari C, Chain TQ, de Quadros MR, Rodeck U:Targetting the epidermal growth factor receptor in cancer:Apoptosis takes center stage. Cancer Res 63:1-5, 2003
 
4) Artega CL:Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Sem Oncol 29:3-9, 2002
 
5) Costa S, Stamm H, Almendral A, et al:Predictive value of EGF receptor in breast cancer. Lancet 2:158, 1988
 
6) Lohrisch C, Piccart M:A Overview of HER2.Semin Oncol 28 (Suppl 18):3-11, 2001
 
7) Fleishman SJ, Schlessinger J, Ben-Tal N:A putativemolecular-activation switch in the transmembranedomain of erbB2. Proc Natl Acad Sci USA 99 (25):15937-15940, 2002
PubMed
8) Kim KM, Shin EY, Moon JH, Heo TH, Lee JY, Chung Y, Lee YJ, Cho HM, Shin SU, Kang CY:Both the epitope specificity and isotype are important in the antitumor effect of monoclonal antibodies against Her-2/neu antigen. Int J Cancer 102 (4):428-434, 2002
 
9) Perez SA, Sotiropoulou PA, Mamalaki A, et al:HER-2/neu-derived peptide 884-899 is expressed by human breast, colorectal and pancreaticadenocarcinomas and I recognized by in-vitro-induced spedific CD4+Tcell clones. Cancer Immunol Immunother 50:615-624, 2002
 
10) Spiridon CI, Ghetie MA, Uhr J, Marches R, Li JL, Shen GL, Vitetta ES:Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. Clin Cancer Res 8 (6):1720-1730, 2002
PubMed
11) Uherek C, Tonn T, Uherek B, Becker S, Schnierle B, Klingemann HG, Wels W:Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood 100 (4):1265-1273, 2002
PubMed
12) Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, Knutson KL, Schiffman K:Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 20 (11):2624-2632, 2002
 
13) Moscatello DK, Montgomery RB, Sundareshan P, et al:Transformational and altered signal transduction by a naturally occurring mutant EGF receptor. Oncogene 13:85-96, 1996
PubMed
14) Moscatello DK, Holgado-Madruga M, Emlet DR, et al:Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J Biol Chem 273:200-206, 1998
PubMed
15) Dittmar T, Husemann A, Schewe Y, Nofer JR, Niggemann B, Zanker KS, Brandt BH:Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of c-erbB-2 receptor via EGFR. FASEB J 16 (13):1823-1825, 2002
PubMed
16) Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J, Arteaga CL:PKB/Akt mediates cell-cycle progression by phosphorylation of p27 (Kip1) at threonine 157 and modulation of its cellular localization. Nat Med 8 (10):1145-1152, 2002
PubMed
17) Timms JF, White SL, O'Hare MJ, Waterfield MD:Effects of ErbB-2 overexpression on mitogenic signalling and cell cycle progression in human breast luminal epithelial cells. Oncogene 21 (43):6573-6586, 2002
 
18) Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL:Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 62 (14):4132-4141, 2002
PubMed
19) Tari AM, Lim SJ, Hung MC, Esteva FJ, Lopez-Berestein G:Her2/neu induces all-trans retinoic acid (ATRA) resistance in breast cancer cells. Oncogene 21 (34):5224-5232, 2002
PubMed
20) Kim S, Zagozdzon R, Meisler A, Baleja JD, Fu Y, Avraham S, Avraham H:Csk homologous kinase (CHK) and ErbB-2 interactions are directly coupled with CHK negative growth regulatory function in breast cancer. J Biol Chem 277 (39):36465-36470, 2002
PubMed
21) Lu Y, Zi X, Zhao Y, et al:Insulin-like growth factor-I receptor signaling and resistance to trastumab (Herceptin) . Natl Cancer Inst 93:1852-1857, 2001
 
22) Tsai PW, Shiah SG, Lin MT, Wu CW, Kuo ML:Up-regulation of vascular endothelial growth factor C in breast cancer cells by heregulin-betal:Acritical role of p38/NF-kB signaling pathway. J Biol Chem 2002[epub ahead of print]
 
23) Romieu-Mourez R, Landesman-Bollag E, Seldin DC, Sonenshein GE:Protein kinase CK2 promotes aberrant activation of nuclear factor-kappaB, transformed phenotype, and survival of breast cancer cells. Cancer Res 62 (22):6770-6778, 2002
PubMed
24) Zhang L, Bewick M, Lafrenie RM:EGFR and ErbB2 differentially regulate Raf-1 translocation and activation. Lab Invest 82:71-78, 2002
PubMed
25) Asada S, Choi Y, Yamada M, Wang SC, Hung MC, Qin J, Uesugi M:External control of Her2 expression and cancer cell growth by targeting a Ras-linked coactivator. Proc Natl Acad Sci USA 99 (20):12747-12752, 2002
PubMed
26) Ryo A, Liou YC, Wulf G, Nakamura M, Lee SW, Lu KP:PIN1 is an E2F target gene essential for Neu/Ras-induced transformation of mammary epithelial cells. Mol Cell Biol 22 (15):5281-5295, 2002
PubMed
27) Wu K, Zhang Y, Xu XC, Hill J, Celestino J, Kim HT, Mohsin SK, Hilsenbeck SG, Lamph WW, Bissonette R, Brown PH:The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res 62 (22):6376-6380, 2002
PubMed
28) Kumar-Sinha C, Ignatoski KW, Lippman ME, Ethier SP, Chinnaiyan AM:Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. Cancer Res 63 (1):132-139, 2003
PubMed
29) Wilson KS, Roberts H, Leek R, Harris AL, Geradts J:Differential gene expression patterns in HER2/neu-positive and-negative breast cancer cell lines and tissues. Am J Pathol 161 (4):1171-1185, 2002
PubMed
30) Scott GK, Marden C, Xu F, Kirk L, Benz CC:Transcriptional repression of ErbB2 by histone deacetylase inhibitors detected by a genomically integrated ErbB2 promoter-reporting cell screen. Mol Cancer Ther 1 (6):385-392, 2002
 
31) Atalay A, Crook T, Ozturk M, Yulug IG:Identification of genes induced by BRCal in breast cancer cells. Biochem Biophys Res Commun 299 (5):839-846, 2002
 
32) Tan M, Jing T, Lan KH, Neal CL, Li P, Lee S, Fang D, Nagata Y, Liu J, Arlinghaus R, Hung MC, Yu D:Phosphorylation on tyrosine-150f p34 (Cdc2) by ErbB2 inhibits p34 (Cdc2) activation and is involved in resistance to taxol-induced apoptosis. Mol Cell 9 (5):993-1004, 2002
 
33) Munster PN, Marchion DC, Basso AD, Rosen N:Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway. Cancer Res 62 (11):3132-3137, 2002
 
34) Tikhomirov O, Carpenter G:Identification of ErbB-2 kinse domain motifs required for geldanamycin-induced degradation. Cancer Res 63:39-43, 2003
 
35) Chiosis G, Lucas B, Shtil A, Huezo H, Rosen N:Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase. Bioorg Med Chem 10 (11):3555-3564, 2002
PubMed
36) Kamalati T, Jolin HE, Fry MJ, et al:Expression of the BRK tyrosine kinase in mammary epithelial cells enhances the coupling of EGF signaling to PI 3 kinase and Akt, via erbB3 phosphorylation. Oncogene 19:5471-5476, 2000
 
37) Fukuzawa H, Noguchi Y, murakami Y, et al:Mitogen-activated protein/extracellular signal-regulated kinase (MEK) inhibitors restore anoikis sensitivity in human breast cancer cell lines with a constitutively activated extracellular-regulated kinase (ERK) pathway. Mol Cancer Ther 1:303-309, 2002
 
38) Debnath J, Mills KR, Collins NL, et al:The role of apoptosis in creating and maintaining luminal space within nirmal and oncogene-expressing mammary acini. Cell 111:29-40, 2002
 
39) Muthuswamy SK, Li D, Lelievre S, et al:ErbB2, but not ErbB1, reinitiates proliferation nd induces luminal repopulation in epithelial acini. Na Cell Biol 3:785-792, 2001
PubMed
40) Arteaga CL, Moulder SL, Yakes FM:HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer. Semin Oncol 29 (3 Suppl 11):4-10, Review, 2002
 
41) Lee S, Yang W, Lan KH, Sellappan S, Klos K, Hortobagyi G, Hung MC, Yu D:Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells. Cancer Res 62 (20):5703-5710, 2002
PubMed
42) Debnath J, Mills KR, Collins NL, Reginato MJ, Muthuswamy SK, Brugge JS:The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini. Cell 111 (1):29-40, 2002
PubMed
43) Bhat-Nakshatri P, Sweeney CJ, Nakshatri H:Identification of signal transduction pathways involved in constitutive NF-kB activation in breast cancer cells. Oncogene 21:2066-2078, 2002
PubMed
44) Habib AA, Chatterjee S, Park SK, et al:The epidermal growth factor receptor engages receptor interacting protein and nuclear factor-kB (NF-kB)-inducing kinase to activate NF-kB. Identification of a novel receptor-tyrosine kinase signalosome. J Biol Chem 276:8865-8874, 2001
 
45) Grant SL, Hammacher A, Douglas AM, et al:A unexpected and functional interaction between gp130 and the EGF receptor family in breast cancer cells. Oncogene 21:460-474, 2002
PubMed
P.28 掲載の参考文献
1) Miller WR, Hawkins RA, Forrest APM:Significance of aromatase activity in human breast cancer. Cancer Res 42:3365-3368, 1982
 
2) Perel E, Wilkins D, Killinger DW:The conversion of androstenedione to estrone, estradiol and testosterone in breast tissue. J Steroid Biochem 13:89-94, 1980
 
3) Sasano H, Nagura H, Harada N, et al:Immunolocalization of aromatase and other steroidogenic enzymes in human breast disorders. Human Pathology 25:530-535, 1994
PubMed
4) Sasano H, Kimura M, Shizawa S, et al:Aromatase and steroid receptors in gynecomastia and malebreast carcinoma:an immunohistochemical study. Journal of Clinical Endocrinology & Metabolism 81:3063-3067, 1996
PubMed
5) Sasano H, Frost AR, Saitoh R, et al:Aromatase and 17 beta-hydroxysteroid dehydrogenase type 1 inhuman breast carcinoma. Journal of Clinical Endocrinology & Metabolism 81:4042-4046, 1996
 
6) Sasano H, Kaga K, Sato S, et al:Aromatase cytochrome P450 gene expression in endometrial carcinoma. British Journal of Cancer 74:1541-1544, 1996
PubMed
7) Sasano H, Harada N:Intratumoral aromatase in human breast, endometrial, and ovarian malignancies. Endocrine Review 19:593-607, 1998
 
8) Bulun SE, Price TM, Aitken J, et al:A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction afterreverse transcription. J Clin Endocrinol Metab 77:1622-1528, 1993
 
9) Bulun SE, Sharda G, Rink J, Sharma S, Simpson ER:1996 Distribution of aromatase P560 transcripts and adipose fibroblasts in the human breast. J Clin Endocrinol Metab 81:1273-1277
 
10) Bulun SE, Mahendroo MS, Price T, et al:Alink between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts by competitive PCR. J Clin Endocrinol Metab 77:1622-1628, 1993
 
P.32 掲載の参考文献
1) Ogawa S, Inoue S, Watanabe T, et al:The complete primary structure of humart estrogen receptor beta (hER beta) and its heterodimerization with ER alpha in vivo and in vitro. Biochem Biophys Res Commun 243:122-126, 1998
 
2) Maruyama K, Endoh H, Sasaki-Iwaoka H, et al:A novel isoform of rat estrogen receptor beta with 18 amino acid insertion in the ligand binding domain as a putative dominant negative regular of estrogen action. Biochem Biophys Res Commun 246:142-147, 1998
PubMed
3) Maruyama S, Fujimoto N, Asano K, et al:Suppression by estrogen receptor beta of AP-1 mediated transactivation through estrogen receptor alpha. J Steroid Biochem Mol Biol 78:177-184, 2001
 
4) Petz LN, Ziegler YS, Loven MA, et al:Estrogen receptor alpha and activating protein-1 mediate estrogen responsiveness of the progesterone receptor gene in MCF-7 breast cancer cells. Endocrinology 143:4583-4591, 2002
PubMed
5) Zhang Z, Maier B, Santen RJ, et al:Membrane association of estrogen receptor alpha mediates estrogen effect on MAPK activation. Biochem Biophys Res Commun 294:926-933, 2002
PubMed
6) Bates SE, Davidson NE, Valverius EM, et al:Expression of transforming growth factor alpha and its messenger ribonucleic acid in human breast cancer:its regulation by estrogen and its possible functional significance. Mol Endocrinol 2:543-555, 1988
PubMed
7) Osborne CK, Coronado EB, Kitten LJ, et al:Insulin-like growth factor-II (IGF-II):a potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor. Mol Endocrinol 3:1701-1709, 1989
PubMed
8) Knabbe C, Lippman ME, Wakefield LM, et al:Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48:417-428, 1987
PubMed
9) Inoue S, Orimo A, Hosoi T, et al:Genomic binding-site cloning reveals an estrogen-responsive gene that encodes a RING finger protein. Proc Natl Acad Sci USA 90:11117-11121, 1993
PubMed
10) Urano T, Saito T, Tsukui T, et al:Efp targets 14-3-3σ for proteolysis and promotes breast tumour growth. Nature 417:871-875, 2002
 
11) Wang TT, Phang JM:Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res 55:2487-2489, 1995
PubMed
12) Perillo B, Sasso A, Abbondanza C, et al:17beta-estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogen-responsive elements present in the coding sequence. Mol Cell Biol 20:2890-2901, 2000
PubMed
13) Bouras T, Southey MC, Chang AC, et al:Stanniocalcin 2 is an estrogen-responsive gene coexpressed with the estrogen receptor in human breast cancer. Cancer Res 62:1289-1295, 2002
PubMed
14) Seth P, Krop I, Porter D, et al:Novel estrogen and tamoxifen induced genes identified by SAGE (Serial Analysis of Gene Expression). Oncogene 21:836-843, 2002
PubMed
15) Bronzert DA, Pantazis P, Antoniades HN, et al:Synthesis and secretion of platelet-derived growth factor by human breast cancer cell lines. Proc Natl Acad Sci USA 84:5763-5767, 1987
PubMed
16) Buteau-Lozano H, Ancelin M, Lardeux B, et al:Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells:a complex interplay between estrogen receptors alpha and beta. Cancer Res 62:4977-4984, 2002
 
17) Purohit A, Newman SP, Reed MJ:The role of cytokines in regulating estrogen synthesis:implications for the etiology of breast cancer. Breast Cancer Res 4:65-69, 2002
PubMed
18) Rochefort H, Chalbos D, Cunat S, et al:Estrogen regulated proteases and antiproteases in ovarian and breast cancer cells. J Steroid Biochem Mol Biol 76:119-124, 2001
 
19) Briozzo P, Morisset M, Capony F, et al:In vitro degradation of extracellular matrix with Mr 52,000 cathepsin D secreted by breast cancer cells. Cancer Res 48:3688-3692, 1988
PubMed
20) Prest SJ, May FE, Westley BR:The estrogen-regulated protein, TFF1, stimulates migration of human breast cancer cells. FASEB J 16:592-594 2002
PubMed
21) Kondapaka SB, Fridman R, Reddy KB:Epidermal growth factor and amphiregulin up-regulate matrix metalloproteinase-9 (MMP-9) in human breast cancer cells. Int J Cancer 70:722-726, 1997
PubMed
22) Dunn SE, Ehrlich M, Sharp NJ, et al:A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res 85:3353-3361, 1998
 
23) Guise TA:Molecular mechanisms of osteolytic bone metastases. Cancer 88 (12 Suppl):2892-2898, 2000
 
24) Powell GJ, Southby J, Danks JA, et al:Localization of parathyroid hormone-related protein in breast cancer metastases:increased incidence in bone compared with other sites. Cancer Res 51:3059-3061, 1991
PubMed
25) Bouizar Z, Spyratos F, Deytieux S, et al:Polymerase chain reaction analysis of parathyroid hommone-related protein gene expression in breast cancer patients and occurrence of bone metastases. Cancer Res 53:5076-5078, 1993
PubMed
26) Kurebayashi J, Sonoo H:Parathyroid hormone-related protein secretion is inhibited by oestradiol and stimulated by antioestrogens in KPL-3C human breast cancer cells. Br J Cancer 75:1819-1825, 1997
PubMed
27) Funk JL, Wei H:Regulation of parathyroid hormone-related protein expression in MCF-7 breast carcinoma cells by estrogen and antiestrogens. Biochem Biophys Res Commun 251:849-854, 1998
PubMed
28) 紅林淳―:乳がんに対する内分泌療法の考え方-耐性獲得のメカニズムと対策-血液・腫瘍科 45:201-206, 2002
 
29) Kurebayashi. J:Endocrine-resistant breast cancer:underlying mechanisms and strategies for overcoming resistance. Breast Cancer, 2003 (in Press)
 
30) Kurebayashi J, Otsuki T, Moriya T, et al:Hypoxia reduces hormone responsiveness of human breast cancer cells. Jpn J Cancer Res 92:1093-1101, 2001
PubMed
31) Stoner M, Saville B, Wormke M, et al:Hypoxia induces proteasome-dependent degradation of estrogen receptor alpha in ZR-75 breast cancer cells. Mol Endocrinol 16:2231-2242, 2002
PubMed
P.38 掲載の参考文献
1) Green S, Walter P, Greene G, et al:Cloning of the human oestrogen receptor cDNA. J Steroid Biochem 24:77-83, 1986
PubMed
2) Mosselman S, Polman J, Dijkema R:ERβ:identification and characterization of a novel human estrogen receptor. FEBS Lett 392:49-53, 1996
 
3) 加藤茂明, 清水孝雄編:細胞膜・核内レセプターと脂溶性シグナル分子.実験医学増刊 18:223-260, 2000
 
4) 岩瀬弘敬, 大本陽子:「ER のvariantsおよびER α, ER βの臨床病理学的意義」乳癌の診断と治療―最新の研究動向―日本臨床 58:154-158, 2000
 
5) 岩瀬弘敬, 山下啓子, 遠山竜也, 大本陽子, 小林俊三:エストロゲンレセプターの分子機構とホルモン依存性.乳癌の臨床 15:490-496, 2000
 
6) Harvey JM, Clark GM, Osborne CK, et al:Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to a adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474-1481, 1999
 
7) Osborne CK, Yochmowitz MG, Knight WA 3rd, etal:The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46:2884-2888, 1980
PubMed
8) Roodi N, Bailey LR, Kao WY, et al:Estrogen receptor gene analysis in estrogen receptor-positive and receptor negative primary breast cancer. J Natl Cancer Inst 87:446-451, 1995
PubMed
9) Iwase H, Iwata H, Omoto Y, Toyama T, Hara Y, Ando Y, Ito Y, Fujii Y, Kobayashi S:DNA methylation analysis at diatal and proximal promotor regions of the oestrogen receptor gene in breast cancers. Br J Cancer 80:1982-1986, 1999
 
10) Fuqua SA, Wiltschke C, Zhang QX, et al:A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Res 60:4026-4029, 2000
PubMed
11) Zhang Z, Yamashita H, Toyama T, et al:Estrogen Receptor alfa mutation (A-to-G transition at mucleotide 908) is not found in different types of breast lesions from Japanese wpmen. Breast Cancer 10:70-73, 2003
 
12) Krege JH, Hodgin JB, Couse JF, et al:Generation and reproductive phenotypes of mice lacking estrogen receptor beta. Proc Natl Acad Sci USA 95:15677-15682, 1998
PubMed
13) Paech K, Webb P, Kuiper GG, et al:Differential ligand activation of estrogen receptors ER α and ER β at API sites. Science 277:1508-1510, 1997
 
14) Roger P, Sahla ME, Makela S, et al:Decreased expression of estrogen receptor beta protein in proliferative prinvasive mammary tumors. Cancer Res 61:2537-2541, 2001
PubMed
15) Moore JT, McKee DD, Slentz-Kesler K, et al:Cloning and characterization of human estrogen receptor β inforrms. Biochem Biophys Re Commun 247:75-78, 1998
 
16) Ogawa S, Inoue S, Watanabe T, et al:Molecular cloning and characterization of human estrogen receptor β cx:apotential inhibitor of estrogen action in human. Nucleic Acids Res 26:3505-3512, 1998
 
17) Saji S, Omoto Y, Shimizu C, et al:Expression of estrogen receptor (ER) (beta) cx protein in ER (alpha)-positive breast cancer:specific correlation with progesterone receptor. Cancer Res 63:4849-4853, 2002
 
18) Hanstein B, Liu Hong, Yancisin MC, Brown M:Function analysis of a novel estrogen receptor-β isoform. Mol Endocrinol l 13:129-137, 1999
 

第2章 乳癌の病理と診断

P.44 掲載の参考文献
1) Moriya T, Kasami M, Akiyama F, et al:A proposal for histopathological diagnosis of ductal carcinoma in situ of the breast. Breast Cancer 7:321-325, 2000
PubMed
2) Tavassoli FA:Ductal intraepithelial neoplasia (IDH, AIDH and DCIS) . Breast Cancer 7:315-320, 2000
PubMed
3) Page DL, Anderson TJ, Rogers LW:Carcinoma in situ (CIS) . In Diagnostic histopatholoogy of the breast. Ed by Page and Anderson, Churchill Livingstone, Edinburgh, 157-192, 1987
 
4) Tavassoli FA:Ductal intraepithelial neoplasmia. In Pathology of the breast. 2 nd Ed, Appleton and Lange, Stamford, 205-324, 1999
 
5) Tavassoli FA, Norris HJ:Acomparison of the results of long-term follow-up for atypical intraductal hyperplasia and intraductal hyperplasia of the breast. Cancer 65:518-529, 1990
 
6) 森谷卓也, 真鍋俊明:乳腺症―多彩な部分像―病理と臨床12:682-689, 1994
 
7) 森谷卓也, 鈴木 貴, 遠藤希之 ほか:ADH, ALH と乳腺上皮内増殖性病変.病理と臨床 19:460-466, 2001
Medical*Online
8) Page DL, et al:Atypical hyperplastic lesions of thefemale breast. A long-term follow up study. Cancer 55:2698-2808, 1985
 
9) 森谷卓也, 秋保信彦, 三浦弘守 ほか:乳管内増殖性病変に対する穿刺吸引細胞診.診断成績と細胞像の特徴に関する検討.日本臨床細胞学会雑誌 40:531-539, 2001
 
10) Brem RF, Schoonjans JM, Sanow L, Gatewood OMB:Relaiability of histologyic diagnosis of breast cancer with stereotactic vacuum-assisted biopsy. Am Surg 67:388-392, 2001
 
11) Moriya T, Silverberg SG:Intraductal carcinoma (Ductal carcinoma in situ) of the breast. Analysis of pathologic findings of 85 pure intraductal carcinomas. Int J Surg Pathol 3:83-92, 1995
 
12) Patchefsky AS, Schwartz GF, Finkelstain SD, et al:Heterogeneity of intraductal carcinoma of the breast. Cancer 63:731-741, 1989
 
13) 秋山 太, 坂元吾偉:平坦型 (flat type) 乳管内癌.病理と臨床 19 (臨増):195-199, 2001
 
14) The consensus conference committee:Consensus conference on the classification of ductal carcinoma in situ. Cancer 80:1798-1802, 1997
PubMed
15) Holland R, et al:Ductal carcinoma in situ. A proposal for a new classification. Sem Diagn Pathol 11:167-180, 1994
 
16) Silverstein MJ:Prognostic classification of breast ductal carcinoma in situ. Lancet 345:1154-1157, 1995
PubMed
17) Lagios MD:Duct carcinoma in situ. Pathology and treatment. Surg Clin North Am 70:853-871, 1990
PubMed
18) Wells WA, et al:Pathologists' agreement with experts and reproducibility of breast ductal carcinoma in situ classification schemes. Am J Surg Pathol 24:651-659, 2000
PubMed
19) Moriya T, Silverberg SG:Intraductal carcinoma (Ductal carcinoma in situ) of the breast. A comparison of pure noninvasive tumors with those including different proportions of infiltrating carcinoma. Cancer 74:2972-2978, 1994
PubMed
20) Silverstein MJ:The University of Southern California/van Nuys prognostic index. In Ductal carcinoma in situ of the breast, Second Ed., Edited by Silverstein MJ, Lippincott Williarns and Wilkins, Philadelphia, 459-473, 2002
 
21) 今村 洋, 坂元吾偉, 秋山 太 ほか:非浸潤性乳管癌の自然史.乳癌の臨床8:128-128, 1993
 
P.48 掲載の参考文献
1) 池永素子:乳腺細胞診の基礎.日獨医報 47 (3), 2002
 
2) 坂元吾偉:乳腺腫瘍病理アトラス, 篠原出版, 東泉, 1987
 
3) 池永素子:細胞診でどこまで言えるか.乳癌の臨床 18 (1):40, 2003
Medical*Online
4) 矢谷隆―:細胞診を学ぶ人のために, 医学図書, 東京, 1990
 
P.51 掲載の参考文献
1) Ross JS, McKenna BS:The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 16:554-568, 2001
 
2) Slamon DJ, Clark GM, Wong SG, et al:Human breast cancer:correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
PubMed
3) Seshadri R, Firgaira FA, Horsfall DJ, et al:Clinical significance of HER-2/neu oncogene amplificationin primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 11:1936-1942, 1993
 
4) Leitzel K, Teramoto Y, Konrad K, et al:Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Onco 113:1129-1135, 1995
 
5) Yamauchi H, O'Neill A, Gelman R, et al:Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neuprotein. J Clin Oncol 15:2518-2525, 1997
 
6) Schechter AL, Hung MC, Vaidyanathan L, et al:Theneu gene:an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science 229:976-978, 1985
 
7) Jones JT, Akita RW, Sliwkowski MX:Binding specificities and affinities of egf domains for ErbB receptors. FEBS Lett 447:227-231, 1999
PubMed
8) Baselga J, Tripathy D, Mendelsohn J, et al:Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol 26:78-83, 1999
PubMed
9) Cobleigh MA, Vogel CL, Tripathy D, et al:Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648, 1999
PubMed
10) Jacobs TW, et al:Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER2/neu in breast cancer. J Clin Oncol 17:1974-1982, 1999
 
11) Schaller G, Evans K, Papadopoulos S, et al:Current use of HER2 tests. Ann Oncol 12 Suppl 1:S97-100, 2001
 
P.56 掲載の参考文献
1) Anonymous:Recommended breast cancer surveillance guidelines. J Clin Oncol l 5:2149-2156, 1997
 
2) Bast RC, Ravdin P, Hayes DF, et al:2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer:clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1865-1878, 2001
 
3) Gion M, Mione R, Leon AE, et al:Comparison of the diagnostic accuracy of CA27.29 and Cal5.3 in primary breast cancer. Clin Chem 45:630-637, 1999
 
4) Fanger GR, Houghton RH, Retter MW, et al:Detection of mammaglobin in the sera of patients with breast cancer. Tumor Biol 23:212-221, 2002
 
5) Kurebayashi J, Yamamoto Y, Tanaka K, et al:Significance of serum carcinoembryonic antigen and CA15-3 in monitoring advanced breast cancer patients treated with systemic therapy:a large-scale retrospective study. Breast Cancer 10:38-44, 2003
PubMed
6) 稲治英生, 菰池佳史, 元村和由 ほか:乳癌手術後のフォローアップ.日医師会誌 125:1727-1729, 2001
 
7) Suarez M, Perez-Castejon MJ, Jimenez A, et al:Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers. Q J Nucl Med 46:113-121, 2002
PubMed
8) Therasse P, Arbuck SG, Eisenhauer EA, et al:New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer lnst 92:205-216, 2000
 
9) 菅野康吉, 河合 忠, 石井 勝 ほか:EIA キットによる血清 ErbB-2 の臨床的検討.癌と化療 21:1255-1262, 1994
Medical*Online
10) Sugano K, Ushiama M, Fukutomi T, et al:Combined measurement of the c-erbB-2 protein in breast carcinoma tissues and sera is useful as a sensitive tumor marker for monitoring tumor relapse. Int J Cancer (Pred Oncol) 89:329-336, 2000
 
11) Wu JT:C-erbB2 oncoprotein and its soluble ectodomain:a new potential tumor marker for prognosis, early detection and monitoring Patients undergoing Herceptin treatment. Clin Chim Acta 322:11-19, 2002
PubMed
12) 稲治英生, 元村和由, 野口眞三郎 ほか:TO 乳癌の診断と治療.Breast Cancer Today 10:2-8, 1994
 
13) Zhao Y, Verselis SJ, Klar N, et al:Nipple fluid carcinoembyonic antigen and prostate-specific antigen in cancer-bearing and tumor-free breasts. J Clin Oncol 19:1462-1467, 2001
 
14) Sauter ER, Chervoneva I, Diamandis A, et al:Prostate-specific antigen and insulin-like growth factor binding Protein-3 in nipple aspirate fluid are associated with breast cancer. Cancer Detect Prev 26:149-157, 2002
PubMed
15) Mitchell G, Sibley PEC, Wilson APM, et al:Prostate-specific antigen in nipple aspiration fluid:menstrual cycle variability and correlation with serum prostate-specific antigen. Tumor Biol 23:287-297, 2002
 
16) Inaji H, Koyama H, Motomura K, et al:ErbB-2 protein levels in nipple discharge:role in diagnosis of early breast cancer. Tumor Biol 14:271-278, 1993
PubMed
17) Briasoulis E, Andreopoulou E, Tolis CF, et al:G-CSF induces elevation of circulating CA15-3 in breast carcinoma patients treated in an adjuvant setting. Cancer 91:909-917, 2001
 
18) von Mensdorf-Pouilly S, Gourevitch MM, Kenemans P, et al:An enzyme-linked immunosorbent assay for the measurement of circulating antibodies to polymorphic epithelial mucin (MUC 1). Tumor Biol 19:186-195, 1998
 
P.63 掲載の参考文献
1) Solakoglu O, et al:Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors. Proc Natl Acad Sci USA 99:2246-2251, 2002
PubMed
2) O'Sullivan GC, et al:Micrometastases in esophagogastric cancer:high detection rate inresected rib segments. Gastroenterology 116:543-548, 1999
 
3) Scheunemann P, et al:Tumorigenic potential of apparently tumor-free lymph nodes. N Engl J Med 340:1687, 1999
PubMed
4) Heiss MM, et al:Individual development and uPA-receptor expression of disseminated tumor cells in bone marrow:areference to early systemic disease in solid cancer. Nat Med 1:1035-1039, 1995
 
5) Shibata K, et al:Detection of ras gene mutations in peripheral blood of carcinoma patients using CD45 immunomagnetic separation and nested mutant allele specific amplification. Int J Oncol 12:1333-1338, 1998
PubMed
6) Kataoka A, et al:RT-PCR Detection of breast cancer cells in sentinel lylnph nodes. Int J Oncol 16:1147-1152, 2000
 
7) Mori M, et al:Detection of cancer micrometastases in lymph nodes by reverse transcriptase-polymerase chain reaction. Cancer Res 55:3417-3420, 1995
PubMed
8) Mori M, et al:Molecular detection of circulating solid carcinoma cells in the peripheral blood:the concept of early systemic disease. Int J Cancer 68:739-743, 1996
PubMed
9) Mori M, et al:Clinical significance of molecular detection of carcinoma cells in lymph nodes and peripheral blood by reverse transcription-polymerase chain reaction in patients with gastrointestinal or breast carcinomas. J Clin Oncol 16:128-132, 1998
PubMed
10) Etoh T, et al:Clinical significance of K-Ras mutation in intraoperative tumor drainage blood from patients with colorectal carcinoma. Ann Surg Oncol 8:407-412, 2001
PubMed
11) Braun S, et al:Implications of Occult Metastatic Cells for Systemic Cancer Treatment in Patients With Breast or Gastrointestinal Cancer. Surg Oncol 20:334-346, 2001
 
12) Braun S, et al:Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 342:525-533, 2000
PubMed
13) Hawes D, et al:Detection of Occult Metastasis in Patients With Breast Cancer Semin Surg Oncol 20:312-318, 2001
PubMed
P.68 掲載の参考文献
1) Goldhirsch A, Glick JH, Gelber RD, et al:Meeting highlights:International consensus panel on the treatment of primary breast cancer. J Clin Oncol 19:3817-3827, 2001
 
2) 日本乳癌学会編:臨床・病理乳癌取扱い規約第 14版, 金原出版, 東京, 2000
 
3) 坂元吾偉編:取扱い規約に沿った腫瘍鑑別診断アトラス, 乳腺, 文光堂, 東京, 1992
 
4) Bloom HJG, Richardson WW:Histological grading and prognosis in breast cancer. Br J Cancer 11:359-377, 1957
 
5) Elston CW, Ellis IO:Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer:experience from a larger study with long-temm follow-up. Histopathology 19:403-410, 1991
 
6) Tsuda H, Akiyama F, Kurosumi M, et al:Evaluation of the interobserver agreement in the number of mitotic figures of breast carcinoma as simulation of quality monitoring in the Japan National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) protocol. Jpn J Cancer Res 91:451-457, 2000
PubMed
7) Cutler SJ, Black MM, Friedell GH, et al:Prognostic factors of the female breast. Cancer 19:75-82, 1966
 
8) Le Doussal V, Tubiana-Hulin M, Friedman S, et al:Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). Cancer 64:1914-1921, 1989
PubMed
9) Tsuda H, Akiyama F, Kurosumi M, et al:Establishment of histological criteria for high-risknode-negative breast carcinoma for the Japan National Surgical A Adjuvant Study of Breast Cancer (NSAS-BC) protocol. Jpn J Clin Oncol 28:486-491, 1998
PubMed
10) Dalton LW, Page DL, Dupont WD:Histologic grading of breast carcinoma. A reproducibility study. Cancer 73:2765-2770, 1994
PubMed
P.71 掲載の参考文献
1) Takita K, Sato T, Miyagi M, et al:Correlation of loss of alleles on short arms of chromosomes 11 and 17 with metastasis of primary breast cancer to lymph nodes. Cancer Res 52 (14):3914-3917, 1992
PubMed
2) Harada Y, Katagiri T, Akiyama F, et al:Genetic studies of 457 breast cancers. Clinicopathologic parameters compared with genetic alterations. Cancer 74 (8):2281-2286, 1994
PubMed
3) Piao Z, Malkhosyan SR:Frequent loss Xq25 on the inactive X chromosome in primary breast carcinomas is associated with tumor grade and axillary lymphnode metastasis. Genes Chromosomes Cancer 33 (3):262-269, 2002
 
4) van den Berg J, Johannsson O, Hakansson S, et al:Allelic loss at chromosome 13q12-q13 is associated with poor prognosis in familial and sporadic breast cancer. Br J Cancer 74 (10):1615-1619, 1996
PubMed
5) Utada Y, Haga S, Kajiwara T, et al:Allelic loss at 8p22 region as a prognostic factor in large and estrogen receptor negative breast carcinomas. Cancer 88 (6):1410-1416, 2000
PubMed
6) Hirano A, Utada Y, Haga S, et al:Allelic losses as prognostic markers for breast cancers. Int J Clin Oncol 6 (1):6-12, 2001
PubMed
7) Utada Y, Emi M, Yoshimoto M, et al:Allelic loss at 1p34-36 predicts poor prognosis in node-negative breast cancer. Clin Cancer Res 6 (8):3193-3198, 2000
PubMed
8) Nagahata T, Kosaka N, Shimizu M, et al:Molecular diagnosis for breast cancer. JMAJ 45 (6):265-270, 2002
 
9) 長幡武光, 江見 充:乳癌の遺伝子診断.癌の臨床47 (6):501-507, 2001
 

第3章 画像診断&装置の進歩

P.77 掲載の参考文献
1) 厚生省がん研究助成金「地域がん登録」研究班(主任研究者:大島 明):報告書, 2000
 
2) 厚生省統計情報部編:人口動態統計, 1950-1998 厚生統計協会, 東京
 
3) 厚生省老人保健推進費等補助金「老人保健推進に関する調査研究事業」 (主任研究者:久道 茂):がん検診の有効性評価に関する研究班報告書.日本公衆衛生協会, 1998
 
4) Kerlikowske K, et al:Efficacy of screening mammography:a meta-analysis. JAMA 273:149-154, 1995
PubMed
5) Ohuchi N, et al:Comparison of false negative rates among breast cancer screening modalities with or without mammography-Miyagi trial. Jpn J Cancer Res 86:501-506, 1995
PubMed
6) Morimoto T, et al:Effectiveness of mammographic screening for breast cancer in women aged over 50 years in Japan. Jpn J Cancer Res 88:778-784, 1997
PubMed
7) 日本乳癌検診学会ガイドライン作成委員会編:マンモグラフィを導入した乳癌検診システムのガイドライン, 篠原出版新社, 東京, 1997
 
8) 日本医学放射線学会・日本放射線技術学会マンモグラフイガイドライン委員会編:マンモグラフィガイドライン, 医学書院, 東京, 1999
 
9) 川島博子ほか:乳癌の画像診断と放射線治療のすべて-MRI-臨床放射線 45:1300-1314, 2000
 
10) 戸崎光宏 ほか:乳癌の画像診断と放射線治療のすべて:マルチスライス CT-乳癌の拡がり診断における dynamic MD-CT の有用性―臨床放射線 45:1323-1328, 2000
 
11) Flanagan FL, et al:PET in breast cancer. Semin Nucl Med 28:290-302, 1998
PubMed
12) Ohta M, et al:Comparative efficacy of positron emission tomography and ultrasonography in preoperative evaluation of axillary lymph node metastases in breast cancer. Breast Cancer 7:99-103, 2000
PubMed
13) 松江寛人 ほか:乳管造影による診断.乳腺診断アトラス, 金原出版, 1988
 
P.86 掲載の参考文献
1) 福田 護, 宮本圭子, 橋詰倫太郎 ほか:癌検診の意義と限界乳癌.Jpn J Cancer Chemother 29:1900-1906, 2002
 
2) Harris JR, et al:Breast cancer (1-3). N Engl J Med 327:319-328, 390-398, 473-480, 1992
 
3) 日本乳癌学会編:臨床・病理乳癌取扱い規約, 第 14版, 金原出版, p58-68, 2000
 
4) 野口眞三郎 ほか:進行・再発乳癌の治療方針と薬物療法.臨床外科 57:501-509, 2002
 
5) 宮川国久, 森山紀之:外科治療後の画像診断による経過観察.画像診断 21:996-1002, 2001
 
6) Del Turco MR, et al:Intensive diagnostic follow-up after treatment of primary breast cancer. JAMA 271:1593-1597, 1994
 
7) 菱沼民生 ほか:乳癌骨転移症例における予後因子の検討-予後予測と治療方針.J Jpn Soc Cancer Ther 32:179-185, 1997
 
8) 野口眞三郎, 池田 正, 園尾博司:進行・再発乳癌の治療方針と薬物療法.臨床外科 57:501-509, 2002
 
9) Rosenman J, et al:The role of computed tomography in the evaluation of past-mastectomy locally recurrent breast cancer. Int J Radiol Oncol Biol Phys 14:57-62, 1988
 
10) 村上昌雄:局所進行・局所再発乳癌と炎症性乳癌の治療.臨放 45:1441-1453, 2000
 
11) Takeda A, et al:The modified tangential irradiation technique for breast cancer:how to cover the entire axillary region. Int J Radiol Oncol Biol Phys 46:815-822, 2000
 
12) 土屋眞― ほか:乳癌におけるMRI画像診断とその病理学的検証.乳癌の臨床17:222-228, 2002
 
13) 直居 豊:乳癌転移病巣への放射線治療脳転移.臨放 45:1457-1459, 2000
 
14) 堀川典子, 吉村 均, 王本哲郎 ほか:放射線治療後トレミフェン高用量の維持療法によって長期改善の得られた乳癌骨転移の3症例.乳癌の臨床 17:235-240, 2002
 
15) 林真也, 星博昭:乳癌転移病巣への放射線治療骨転移.臨放 45:1460-1466, 2000
 
16) 宇野弘―, 呉 勁, 留森貴志 ほか:FDG-PET は乳癌診療体系を変えるか.画像診断 21:1003-1010, 2001
 
P.92 掲載の参考文献
1) マンモグラフィガイドライン委員会:マンモグラフィガイドライン, 医学書院, 東京, 1999
 
2) 大貫幸二, 大内憲明:乳腺疾患の画像診断―外来診療における画像診断の位置づけ.外科治療 85:128-134, 2001
Medical*Online
3) 東野英利子, 角田博子, 秋山 太:マンモグラフイ診断の進め方とポイント, 金原出版, 東京, 2001
 
4) 齋藤美穂子, 山田隆之, 大貫幸二 ほか:新しい画像診断法 (1) Digital mammography.乳癌の臨床 17:291-295, 2002
 
5) 齋藤美穂子, 大貫幸二, 山田隆之 ほか:マンモグラフィ併用検診における Computer-aided detection (CAD) system の有用性.日本乳癌検診学会誌 11:251-256, 2002
 
P.98 掲載の参考文献
1) R Uchida, Y Hagiwara, T Irie:Electro-scanning Diagnostic Equipment, Proceedings of 19th Japan Society of Ultrasonics in Medicine, Tokyo, p66-67, 1971
 
2) R Uchida, Y Hagiwara, T Irie:Electro-scanning Diagnostic Equipment. Journal of Japan Medical Electronics 71/72[2]:58-62, 1972
 
3) 渡辺隆紀:腫瘤の形状.New Wave of Breast and Thyroid Sonology 3:12, 2000
 
4) 植野 映:リアルタイム乳房超音波診断, 南江堂, 東京, p59-74, 1991
 
5) 遠藤登喜子, 植野 映, 久保田光博ほか:腫瘤像非形成病変について.New Wave of Breast and Thyroid Sonology 5:41-44, 2002
 
6) 植野 映, 東野英利子, 角田博子ほか:超音波誘導下組織生検.日乳癌検診学会誌 9:257-266, 2000
 
P.102 掲載の参考文献
1) 平松秀子, 池田 正, 平松京― ほか:乳房温存療法における MRM の役割.臨床放射線 44:573-580, 1999
 
2) 天野吾郎, 大内憲明, 石田孝宣 ほか:三次元MRIにより乳癌進展の解析:多数切片作成による病理組織像との対比.乳癌の臨床 12:640-641, 1997
 
3) 中村清吾, 西尾 剛, 阿部令彦:乳房温存療法適応適応決定における三次元MRIの有用性.乳癌の臨床 11:679-685, 1996
 
4) 山本裕, 紅林淳―, 山本 滋 ほか:原発乳癌における乳房造影MRI検査の有用性と生物学的バックグラウンドに関する検討.乳癌の臨床 17:132-136, 2002
Medical*Online
5) 関 恒明, 蜂屋順―:MRマンモグラフィ.癌の臨床 46:525-534, 2000
Medical*Online
6) Kaiser WA, Zeitler E:MR imaging of the breast; Fast imaging sequences with and without Gd-DTPA. Radiology 170:681-686, 1989
PubMed
7) Stack JP, Redmond OM, Codd MB, et al:Breast disease;Tissue charactarization with Gd-GTPA enhancemenet profiles. Radiology 174:491-494, 1990
 
8) Harms SE, Flamig DP, Hesley KL, et al:MR imaging of the breast with rotating delivery of excitation off resonance; clinical experience with pathologic correlation. Radiology 187:493-501, 1993
PubMed
9) 川島博子:脂肪抑制法併用 dynamic MR imaging による乳癌診断ー病理組織像との対比-.日本医放会誌 56:459-469, 1996
 
10) 白石明彦, 鈴木賢, 野津 聡ほか:3D?ダイナミック MRI による乳癌の造影パターンと拡がり診断-特に乳管内進展の程度との相関について-日本医放会誌 59:122-130, 1999
 
11) Takeshi Nagasima, Masato Suzuki, Masaru Miyazaki, et al:Dynamic-enhanced MRI predicts metastatic potential of invasive ductal breast cancer. Breast cancer 9:226-230, 2002
 
12) Seigo Nakamura,Hironori Kenjo, Koyu Suzuki, et al:Efficancy of 3D-MR mammography forbreast conserving surgery after neoadjuvant chemotherapy. Breast cancer 9:15-919, 2002
 
13) 草間 律, 土屋眞―, 天野 純ほか:乳腺 MRI 検査における乳房変形を防ぐ工夫-Transparent Dressing (Tegaderm) の使用経験とその有用性について―乳癌の臨床 17:86-90, 2002
 
P.107 掲載の参考文献
1) Adler LP, Crowe JP, al-Kaisi NK, et al:Evaluation of breast masses and axillary lymph nodes with[F-18]2-deoxy-2-fluoro-D-glucose PET. Radiology 187:743-750, 1993
PubMed
2) Hubner KF, Smith GT, Thie JA, et al:The potential of F-18-FDG PET in breast cancer:detection of primary lesions, axillary lymph node metastases, or distant metastases. Clin Pos Imag 3:197-205, 2000
PubMed
3) Avril N, Rose CA, Schelling M, el al:Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose:use and limitations. J Clin Oncol 18:3495-3502, 2000
 
4) Schirrmeister H, Kuhn T, Guhlmann A, et al:Fluorine-182-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer:comparison with the standard staging procedures. Eur J Nucl Med 28:351-358, 2001
 
5) Crippa F, Seregni E, Agresti R, et al:Association between[18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and P53 in primary breast cancer:apreliminary observation. Eur J Nucl Med 25:1429-1434, 1998
 
6) Buck A, Schirrmeister H, Kuhn T, et al:FDG uptake in breast cancer:correlation with biological and clinical prognostic parameters. Eur J Nucl Med 29:1317-1323, 2002
 
7) Noh D-Y, Yun I-J, Kang H-S, et al:Detection of cancer in augmented breasts by positron emission tomography. Eur J Surg 165:847-851, 1999
PubMed
8) Utech CI, Young CS, Winter PE:Prospective evaluation of fluorine-18 fluorodeoxyglucose positron emission topography in breast cancer for staging of the axilla related to surgery and immunocytochemistry. Eur J Nucl Med 23:1588-1593, 1996
 
9) Adler LP, Faulhaber PF, Schnur KC, et al:Axillary lymph node metastases:screening with[F-18 2-deoxy-2-fluoro-D-glucose-(FDG) PET. Radiology 203:323-327, 1997
PubMed
10) Crippa F, Agresti R, Seregni E, et al:Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer. J Nucl Med 39:4-8, 1998
PubMed
11) Smith IC, Ogston KN, Whitford P, et al:Staging of the axilla in breast cancer:accurate in vivo assessment using Positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. Ann Surg 228:220-227, 1998
PubMed
12) Avril N, Schelling M, Dose J, et al:Utility of PET in breast cancer. Clin Pos Imag 2:261-271, 1999
 
13) Greco M, Crippa F, Agresti R, et al:Axillary lymph node staging in breast callcer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography:clinical evaluation and alternate management. J Natl Cancer Inst 93:630-635, 2001
 
14) van der Hoeven JJM, Hoekstra OS, Comans EFI, et al:Determinants of diagnostic perfoumance of[F-18-fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer. Ann Surg 236:619-624, 2002
 
15) Yang J-H, Nam SJ, Lee TS, et al:Comparison of intraoperative frozen section analysis of sentinel node with preoperative positron emission tomography in the diagnosis of axillary lymph node status in breast cancer patients. Jpn J Clin Oncol 31:1-6, 2001
 
16) Eubank WB, Mankoff DA, Takasugi J, et al:18Fluorodeoxyglucose positron emission tomographyto detect mediastinal or internalmammary metastases in breast cancer. J Clin Oncol 19:3516-3523, 2001
PubMed
17) Avril N, Menzel M, Dose J, et al:glucose metabolism of breast cancer assessed by 18F-FDG PET:histologic and immunohistochemical tissue analysis, J Nucl Med 42:9-16, 2001
PubMed
18) Bos R, van der Hoeven JJM, van der Wall E, et al:Biologic correlates of 18fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 20:379-387, 2002
 
19) Smith IC, Welch AE, Hutcheon AW, et al:Positron emission tomography using[18F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 18:1676-1688, 2000
 
20) Schelling M, Avril A, Nahrig J, et al:Positron emission tomography using[18F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer, J Clin Oncol 18:1689-1695, 2000
 
21) Tiling R, Linke R, Untch M, et al:18F-FDG PET and 99mTc-sestamibi scintimammography for monitoring breast cancer respone to neoaadjuvant chemotherapy:a comparative study. Eur J Nucl Med 28:711-720, 2001
 
22) Burcombe RJ, Makris A, Pittam M, et al:Evaluation of good clinical response to neoadjuvant chemotherapy in primary breast cancer using[18F-fluorodeoxyglucose positron emission tomography. Eur J Cancer 38:375-379, 2002
PubMed
23) Dehdashti F, Flanagan FL, Mortimer JE, et al:Positron emission tomographic assessment of "metabolic flare"to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med 26:51-56, 1999
PubMed
24) Mortimer JE, Dehdashti F, Siegel BA, et al:Metabolic flare:indicator of hormone responsiveness in advanced breast cancer, J Clin Oncol 19:2797-2803, 2001
 
25) Moon DH, Maddahi J, Silverman DHS, et al:Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med 39:431-435, 1998
PubMed
26) Bender H, Kirst J, Palmedo H, et al:Value of 18fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma. Anticancer Res 17:1687-1692, 1997
PubMed
27) Kim T-S, Moon WK, Lee D-S, et al:Fluorodeoxy-glucose positron emission topography for detection of recurrent or metastatic breast cancer. Word J Surg 25:829-834, 2001
 
28) Cook GJ, Houston S, Rubens R, et al:Detection of bone metastases in breast cancer by 18FDG PET:differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 16:3375-3379, 1998
PubMed
29) Schirrmeister H, Guhlmann A, Kotzerke J, et al:Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol 8:2381-2389, 1999
PubMed
30) Liu C-S, Shen Y-Y, Lin C-C, et al:Clinical impact of [18F]FDG-PET in patients with suspected recurrent breast cancer based on asymptomatically elevated tumor marker serum levels:a preliminary report. Jpn J Clin Oncol 32:244-247, 2002
 
31) Oshida M, Uno K, Suzuki M, et al:Predicting the prongoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F-D-glucose. Cancer 82:2227-2234, 1998
PubMed
32) Vranjesevic D, Filmont JE, Meta J, et al:Whole-body 18F-FDG PET and conventional imaging for predicting outcome in previously treated breast cancer patients. J Nucl Med 43:325-329, 2002
PubMed
P.116 掲載の参考文献
1) 蒔田益次郎, 難波 清, 坂元吾偉:乳管内視鏡と内視鏡的乳管内生検法.乳癌の臨床 5 (4):606-615, 1990
Medical*Online
2) Makita M, Sakamoto G, Akiyama F, et al:Duct endoscopy and endoscopic biopsy in the evaluation of nipple discharge. Breast Cancer Research and Treatment 18:179-188, 1991
PubMed
3) 蒔田益次郎:特集, 乳癌診療の最前線, 乳管内視鏡診断.癌の臨床 46 (5):563-570, 2000
 
4) 蒔田益次郎, 秋山 太, 高橋かおるほか:異常乳頭分泌を呈する乳管内病変の肉眼拡大像と組織所見.乳癌の臨床 16 (2):132-136, 2001
Medical*Online
5) 蒔田益次郎, 難波 清, 青山英子 ほか:異常乳頭分泌症例における乳管内病変の内視鏡診断-乳管内視鏡分類について-.乳癌の臨床 11 (1):134-141, 1996
Medical*Online
6) Makita M, Akiyama F, Gomi N, et al:Endoscopic classification of intraductal lesions and histological diagnosis. Breast Cancer 9 (3):220-225, 2002
PubMed
7) 蒔田益次郎, 青山英子, 水谷三浩 ほか:乳管内視鏡による腫瘤非触知異常乳頭分泌症例の診断指針.乳癌の臨床 12 (4):706-710, 1997
 
8) 坂元吾偉:乳腺腫瘍病理アトラス, 改訂第2版, 篠原出版, 東京, p9-39, 1995
 
9) 蒔田益次郎, 難波 清, 青山英子 ほか:異常乳頭分泌を呈する乳癌の乳管内進展部分の内視鏡分類と臨床像.乳癌の臨床 11 (2):303-309, 1996
Medical*Online
10) 蒔田益次郎, 難波 清, 青山英子 ほか:異常乳頭分泌を呈する乳癌の乳管内進展部分の内視鏡分類と病理.乳癌の臨床 12 (1) 204-210, 1997
Medical*Online
11) 蒔田益次郎, 秋山 太, 木村聖美 ほか:乳管内視鏡による主乳管への乳管内進展の評価.乳癌の臨床16 (3):274-278, 2001
 
12) 蒔田益次郎, 霞 富士雄:異常乳頭分泌を伴う乳癌に対する乳房温存手術の工夫.手術 56 (10):1498-1502, 2002
 
P.123 掲載の参考文献
1) Parker SH, et al:Nonpalpable breast lesions; Stereotaxic automated large-core biopsies. Radiology 180:403-407, 1991
PubMed
2) Parker SH, et al:Performing a Breast Biopsy with a Directional, Vacuum-assisted Biopsy Instrument. Radio Graphics 17:1223-1252, 1997
 
3) 窪田智行, 秋山 太, 高橋かおるほか:Mammotome にてクリップ挿入し切除部位を決め得た乳癌の1例.乳癌の臨床 14 (2):271-274, 1999
 
4) Takahashi K, Saito M, Makita M, et al:Surgery for Ductal Carcinoma in Situ. Breast Cancer 7:337-340, 2000
PubMed
5) 高橋かおる, 斉藤光江, 蒔田益次郎 ほか:非浸潤性乳管癌 (DCIS) の乳房温存治療.臨床放射線 45:1435-1440, 2000
 
6) Diaz LK, Wiley EL, Venta LA:Are malignant cells displaced by large-gauge needle core biopsy of the breast? AJR 173:1303-1313, 1999
PubMed

第4章 センチネルリンパ節生検

P.127 掲載の参考文献
1) Cox CE, Bass SS, McCann CR, et al:Lymphatic mapping and sentinel lymph node biopsy in patients with breast cancer. Annu Rev Med 51:525-542, 2000
PubMed
2) Cody HS III, Fey J, Akhurst T, et al:Complementarity of blue dye and isotope in sentinel node localization for breast cancer:Univariate and multivariate analysis of 966 procedures. Ann Surg Oncol 8:13-19, 2001
 
3) Noguchi M, Motomura K, Imoto S, et al:A multicenter validation study of sentinel lymph node biopsy by the Japanese Breast Cancer Society. Breast Cancer Res Treat 63:31-40, 2000
 
4) Morrow M, Rademker AW, Bethke KP, et al:Learning sentinel node biopsy:Results of prospective randomized trial of two techniques. Surgery 126:714-722, 1999
 
5) Uren RF, Howman-Giles RB, Thompson JF, et al:Mammary lymphoscintigraphy in breast cancer. J Nucl Med 36:1775-1780, 1995
PubMed
6) O'Hea BJ, Hill ADK, El-Shirbiny AM, et al:Sentinel lymph node biopsy in breast cancer:Initial experience at Memorial Sloan-Kettering Cancer Center. J Am Coll Surg 186:423-327, 1998
 
7) Krag D, Weaver D, Ashikaga T, et al:The sentinel node in breast cancer. A multicenter validation study. New Engl J Med 339:941-946, 1998
PubMed
8) Harlow S, Weaver D, Ashikaga T:Extra-axillary sentinel lymph nodes in breast cancer. Breast Cancer 6:159-165, 1999
PubMed
9) Noguchi M:Sentinel lymph node biopsy in breast cancer:An overview of the Japanese experience. Breast Cancer 8:184-193, 2001
PubMed
10) Paganelli G, De Cicco C, Cremonesi M, et al:Optimized sentinel node scintigraphy in breast cancer. Q J Nucl Med 42:49-53, 1998
PubMed
11) Linehan DC, Hill ADK, Tran KN, et al:Sentinel lymph node biopsy in breast cancer:Unfiltered radioisotope is superior to filtered. J Am Coll Surg 188:377-381, 1999
 
12) 神野浩光, 池田 正, 和田真弘 ほか:乳癌におけるセンチネルリンパ節生検手技の最適化.日本臨床外科学会雑誌 63 (増刊号):240, 2002
 
13) Roumen RMH, Geuskens LM, Valkenburg JGH:In search of the true sentinel node by different injection techniques in breast cancer patients. Eur J Surg Oncol 25:347-351, 1999
 
14) Tanis PJ, Nieweg OE, Olmos RAV, et al:Anatomy and physiology of lymphatic drainage of the breast from the perspective of sentinel node biopsy. J Am Surg 192:399-409, 2001
 
15) Noguchi M, Tsugawa K, Miwa K, et al:Internal mammary chain sentinel lymph node identification in breast cancer. J Surg Oncol 73:75-80, 2000
PubMed
16) Van der Ent FWC, Kengen RAM, Van der Pol HAG, et al:Halsted Revisted:Internal mammary sentinel lymph node biopsy in breast cancer. Ann Surg 234:79-84, 2001
 
17) Noguchi M:Sentinel lymph node biopsy and breast cancer. Br J Surg 89:1-14, 2002
PubMed
18) Noguchi M:Relevance and practicability of internal mammary sentinel node biopsy for breast cancer. Breast Cancer 9:329-336, 2002
PubMed
19) Noguchi M:Internal mammary sentinel node biopsy for breast cancer? Is it practicable and relevant? (Review). Oncol Report 9:461-468, 2002
 
20) Turner RR, Ollila DW, Stern S, et al:Optimal histopathologic examination of the sentinel lymph node for breast carcinoma staging. Am J Surg Pathol 23:263-267, 1999
PubMed
21) Noguchi M:Therapeutic relevance of breast cancer micrometastases in sentinel lymph nodes. Br J Surg 89:1505-1515, 2002
PubMed
22) Dowlatshahi K, Fan M, Snider HC, Habib FA:Lymph node micrometastases from breast carcinoma:reviewing the dilemma. Cancer 80:1188-1197, 1997
PubMed
23) Fiztgibbons PL, Page DL, Weaver D, et al:Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124:966-978, 2000
 
24) Veronesi U, Paganelli G, Galimberti V, et al:Sentinel node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph nodes. Lancet 349:1864-1867, 1997
PubMed
25) Viale G, Bosari S, Mazzarol G, et al:Intraoperative examination of axillary sentinel lymph nodes in breast carcinoma patients. Cancer 85:2433-2438, 1999
PubMed
26) Bedrosian I, Reynolds C, Mick R, et al:Accuracy of sentinel lymph node biopsy in patients with large primary breast tumors. Cancer 88:2540-2545, 2000
PubMed
27) Viale G, Maiorano E, Mazzarol G, et al:Histologic detection andclinical implications of micro-metastases in axillary sentinel lymph nodes for patients with breast carcinoma. Cancer 92:1378-1384, 2001
 
28) Czerniecki BJ, Scheff AM, Callans LS, et al:Immunohistochemistry with pancytokeratins improves the sensitivity of sentinel lymph node biopsy in patients with breast carcinoma. Cancer 85:1098-1103, 1999
PubMed
29) Chu KU, Turner RR, Hansen NM, et al:Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection? Ann Surg 4:536-541, 1999
PubMed
30) Reynolds C, Mick R, Donohue JH, et al:Sentinel lymph node biopsy with metastasis:Can axillary dissection be avoided in some patients with breast cancer?J Clin Oncol 17:1720-1726, 1999
PubMed
31) Noguchi M:Does regional treatment improve the survival in patients with operable breast cancer? Breast Cancer Res Treat 76:269-282, 2002
PubMed
32) Ross MI:Sentinel node dissection in early-stage breast cancer:Ongoing prospective randomized trials in the USA. Ann Surg Oncol 8:77-81, 2001
 
33) 井本 滋, 長谷部孝裕:Observational study on sentinel node biopsy in breast cancer. 第 10 回日本乳癌学会総会 (プログラム抄録集) , pp117, 2002
 
34) Noguchi M, Tsugawa T, Kawahara F, et al:Dye-guided sentinel lymphadenectomy in clinically node negative and node positive breast cancer patients. Breast Cancer 5:381-387, 1998
 
P.134 掲載の参考文献
1) Cox CE, Haddad F, Bass S, et al:Lymphatic mapping in the treatment of breast cancer. Oncology (Huntingt) 12:1283-1292, 1998
PubMed
2) Morton DL:Intraoperative lymphatic mapping and sentinel lymphadenectomy:community standard care or clinical investigation? Cancer J Sci Am 3:328-330, 1997
PubMed
3) Euhus DM, Peters GN, Leitch AM, et al:Validatingthe performance of the mammary sentinel lymph node team. J Surg Oncol 79:209-215, 2002
PubMed
4) 草別智行, 末益公人, 菅又徳孝 ほか:新しい乳癌の手術-Sentinel node (SN) biopsy を用いたリンパ節転移陰性乳癌縮小手術 . 日本外科系連合学会誌 26:163-166, 2001
 
5) Takei H, Suemasu K, Kurosumi M, et al:Sentinel lymph node biopsy without axillary dissection after an intraoperative negative histological investigation in 358 invasive breast cancer cases. Breast Cancer 9:344-348, 2002
PubMed
6) Cimmino W, Brown AC, Szocik JF, et al:Allergic reactions to isosulfan blue during sentinel node biopsy a common event. Surgery 130:439-442, 2001
 
7) Giuliano AE, Jones RC, Brennan M, et al:Sentinel lymphadenectomy in breast cancer. J Clin Oncol 15:2345-2350, 1997
PubMed
8) Veronesi U, Paganelli G, Galimberti V, et al:Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 349:1864-1867, 1997
PubMed
9) Morrow M, Rademaker AW, Bethke KP, et al:Learning sentinel node biopsy:results of a prospective randomized trial of two techniques. Surgery 126:714-722, 1999
PubMed
10) Cody HS 3rd, Fey J, Akhurst T, et al:Complementarity of blue dye and isotope in sentinel node localization for breast cancer:univariate and multivariate analysis of 966 procedures. Ann Surg Oncol 8:13-19, 2001
PubMed
11) Albertini JJ, Lyman GH, Cox C, et al:Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 276:1818-1822, 1996
PubMed
12) McMasters KM, Tuttle TM, Carlson DJ, et al:Sentinel lymph node biopsy for breast cancer:a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol 18:2560-2566, 2000
 
13) Schwartz GF, Giuliano AE, Veronesi U, et al:Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19-22, 2001, Philadelphia, Pennsylvaniania. Cancer 94:2542-2551, 2002
 
14) 佐藤―彦, 田巻国義, 平出星夫 ほか:RI 法による乳癌センチネルリンパ節生検の実際-RI コロイド取り込みに関する各種因子の検討に基づく手技-. 手術 56:6-12, 2002
 
15) Cox CE:Lymphatic mapping in breast cancer:combination technique. Ann Surg Oncol 8:67-70, 2001
 
16) 元村和由, 菰池佳史, 稲治英生 ほか:特集, リンパ節転移, II. Sentinel Node 3. 乳癌の Sentinel Node Naviagation Surgery. 外科 63:823-829, 2001
 
P.140 掲載の参考文献
1) Alazraki NP, Eshima D, Eshima LA, et al:Lymphoscintigraphy, the sentinel node concept, and the intraoperative gamma probe in melanoma, breast cancer, and other potential cancers. Semin Nucl Med 27:55-67, 1997
PubMed
2) 横山邦彦, 道岸隆敏, 絹谷清剛 ほか:ラジオアイソトープによるセンチネルリンパ節の検出.消化器外科23:1689-1696, 2000
 
3) Uren RF, Thompson JF, Howman-Giles RB:Lymphatic drainage of the skin and breast, Harwood, Amsterdam, p1-20, 1999
 
4) Paganelli G, De Cicco C, Cremonesi M, et al:Optimized sentinel node scintigraphy in breast cancer. Q J Nucl Med 42:49-53, 1998
PubMed
5) Tsopelas C:Particle size analysis of 99mTc-labeled and unlabeled antimony trisulfide and rhenium sulfide colloids intended for lymphoscintigraphic application. J Nucl Med 42:460-466, 2001
 
6) Nakamura K, Futiii H, Kitagawa Y, et al:Preparation of 99mTc-colloid with particle size as you like for sentinel node detection (abstract). J Nucl Med 42:20P, 2001
 
7) Linehan DC, Hill AD, Tran KN, et al:Sentinel lymph node biopsy in breast cancer:unfiltered radioisotope is superior to filtered. J Am Coll Surg 188:377-381, 1999
PubMed
8) Pijpers R, Meljer S, Hoekstra OS, et al:Impact of lymphoscintigraphy on sentinel node identification with technetium-99m-colloidal albumin in breast cancer. J Nucl Med 38:366-368, 1997
 
9) Uren RF, Howman-Giles R, Renwick SB, et al:Lymphatic mapping of the breast:locating the sentinel lymph nodes. World J Surg 25:789-793, 2001
PubMed
10) Sato K, Uematsu M, Saito T, et al:Sentinel lymph node identification fbr patients with breast cancer using large-size radiotracer particles:technetium-99m-labeled tin colloids produced excellent results. Breast J 7:388-391, 2001
 
11) Motomura K, Inaji H, Komoike Y, et al:Combination technique is superior to dye alone in identification of the sentinel node in breast cancer patients. J Surg Oncol 76:95-99, 2001
PubMed
12) 井本 滋:乳癌治療における Sentinel Node Navigation Surgery の意義.日本外科学会雑誌 101:311-314, 2000
 
13) Jinno H, Ikeda T, Matsui A, et al:Sentinel lymph node biopsy in breast cancer using technetium-99m tin colloid of different sizes. Biomed Pharmacother 56:213s-216s, 2002
PubMed
14) 石根正博, 久松和史, 中村和民 ほか:99mTc標識フチン酸による乳癌センチネルリンパ節シンチグラフイの検出能.臨床放射線 46:1483-1490, 2001
 
15) Vera DR, Wallace AM, Hoh CK, et al:Asynthetic macromolecule for sentinel node detection:99mTc-DTPA-mannosyl-dextran. J Nucl Med 42:951-959, 2001
 
16) 石山公―, 左志隆士, 片寄喜久:Superparamagnetic iron oxide (Ferumoxides) の乳房内投与下MR lymphographyによる腋窩リンパ節描出の試み:MRIによるセンチネルリンパ節同定に向けての初期経験.日本医学放射線学会雑誌62:744-746, 2002
 
17) Mattrey RF, Kono Y, Baker K, et al:Sentinel lymph node imaging with microbubble ultrasound contrast material. Acad Radiol 9 (Suppl 1):S231-S235, 2002
 
P.150 掲載の参考文献
1) Giuliano AE, Jones RC, Brennan M, et al:Sentinel lymphadenectomy in breast cancer. J Clin Oncol 15:2345-2350, 1997
PubMed
2) Krag D, Weaver D, Ashikaga T, et al:The sentinel node in breast cancer:A multicenter validation study. N Engl J Med 339:941-946, 1998
PubMed
3) Veronesi U, Paganelli G, Galimberti V, et al:Sentinel-node biopsy to avoid axillary dissection in breast cancer with clmically negative lymph-nodes. Lancet 349:1864-1867, 1997
PubMed
4) Cox CE, Pendas S, Cox JM, et al:Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. Ann Surg 227:645-653, 1998
PubMed
5) Tafra L Lannin DR Swanson MS et al:Multicenter trial of sentinel node biopsy for breast cancer using both technetium sulfur colloid and isosulfan blue dye. Ann Surg 233:51-59, 2001
PubMed
6) McMasters KM, Tuttle TM, Carlson DJ, et al:Sentinel lymph node biopsy for breast cancer:a suitable altemative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol 18:2560-2566, 2000
 
7) Motomura K, Inaji H, Komoike Y, et al:Sentinel node biopsy in breast cancer patients with clinically negative lymph-nodes, Breast Cancer 6:259-262, 1999
PubMed
8) Motomura K, Inaji H, Komoike Y, et al:Sentinel node biopsy guided by indocyanin green dye in breast cancer patients. Japanese Journal of Clinical Oncology 29:604-607, 1999
PubMed
9) Motomura K, Inaji H, Komoike Y, et al:Gamma probe and ultrasonographically-guided fine-needle aspiration biopsy of sentinel lymph nodes in breast cancer patients. Eur J Surg Oncol 27:141-145, 2001
PubMed
10) Giuliano AE, Kirgan DM, Guenther JM, et al:Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 220:391-401, 1994
PubMed
11) Albertini JJ, Lyman GH, Cox C, et al:Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 276:1818-1822, 1996
PubMed
12) Motomura K, Inaji H, Komoike Y, et al:Combination technique is superior to dye alone in identification of the sentinel node in breast cancer. J Surg Oncol 76:95-99, 2001
PubMed
13) Morrow M,Rademaker AW, Bethke KP, et al:Learning sentinel node biopsy:Results of a prospective randomized trial of two techniques. Surgery 126:714-722, 1999
PubMed
14) Linehan DC,Hill ADK, Akhurst T, et al:Intrademmal radiocolloid and intraparenchymal blue dye injection optimize sentinel node identification in breast cancer patients. Ann Surg Oncol 6:450-454, 1999
 
15) Derossis AM, Fey J, Yeung H, et al:A trend analysis of the relative value of blue dye and isotope localization in 2,000 consecutive cases of sentinel node biopsy for breast cancer. J Am Coll Surg 193:473-478, 2001
PubMed
16) Mateos JJ, Vidal-Sicart S, Zanon G, et al:Sentinel lymph node biopsy in breast cancer patients:subdermal versus peritumoural radiocolloid injection. Nucl Med Commun 22:17-24, 2001
PubMed
17) Boolbol SK, Fey JV, Borgen PI, et al:Intradermal isotope injection:a highly accurate method of lymphatic mapping in breast carcinoma. Ann Surg Oncol 8:20-24, 2001
PubMed
18) Martin RC, Derossis AM, Yeung H, et al:Intradermal isotope injection is superior to intramammary in sentinel node biopsy for breast cancer. Surgery 130:432-438, 2001
PubMed
19) Motomura K, Komoike Y, Hasegawa Y, et al:Intradermal radioisotope injection is superior to subdermal injection for the identification of the sentinel node in breast cancer patients. J Surg Oncol 82:91-96, 2003
PubMed
20) McMasters KM, Wong SL, Martin RC 2nd, et al:Dermal injection of radioactive colloid is superior to peritumoral injection for breast cancer sentinel lymph node biopsy:results of a multiinstitutional study. Ann Surg 233:676-687, 2001
PubMed
21) Guenther JM:Subareolar versus peritumoral injection of location of sentinel lymph node. Ann Surg 231 (4):614-615, 2000
PubMed
22) Smith LF, Cross MJ, Klimberg VS, et al:Subareolar injection is a better technique for sentinel lymph node biopsy. Am J Surg 180:434-437, 2000
PubMed
23) Bauer TW, Spitz FR, Callans LS, et al:Subareolar and peritumoral injection identify similar sentinel nodes for breast cancer. Ann Surg Oncol 9:169-176, 2002
PubMed
24) Tanis PJ, Nieweg OE, Valdes Olmos RA, et al:Anatomy and physiology of lymphatic drainage of the breast from the perspective of sentinel node biopsy. J Am Coll Surg 192:399-409, 2001
PubMed
25) Bass SS, Cox CE, Salud CJ, et al:The effects of postinjection massage on the sensitivity of lymphatic mapping in breast cancer. J Am Coll Surg 192:9-16, 2001
PubMed
26) Flett MM, Going JJ, Station PD, et al:Sentinel node localization in patients with breast cancer. Br J Surg 85:991-993, 1998
 
27) Weiser MR, Montgomery LL, Susnik B, et al:Is routine intraoperative frozen-section examination of sentinel lymph nodes in breast cancer worthwhile? Ann Surg Oncol 7:651-655, 2000
PubMed
28) Rahusen FD, Pijpers R, Van Diest PJ, et al:The implementation of the sentinel node biopsy as a routine procedure for patients with breast cancer. Surgery 128:6-12, 2000
PubMed
29) Tanis PJ, Boom RP, Koops HS, et al:Frozen section investigation of the sentinel node in malignant melanoma and breast cancer. Ann Surg Oncol 8:222-226, 2001
PubMed
30) Chao C, Wong SL, Ackermann D, et al:Utility of intraoperative frozen section analysis of sentinel lylnph nodes in breast cancer. Am J Surg 182:609-615, 2001
PubMed
31) Veronesi U, Paganelli G, Galimberti V, et al:Sentinel lymph node biopsy and axillary dissection in breast cancer:Results in a large series. J Natl Cancer Inst 91:363-373, 1999
 
32) Veronesi U, Paganelli G, Galimberti V, et al:Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 349:1864-1867, 1997
PubMed
33) Viale G, Bosari S, Mazzarol G, et al:Intraoperative examination of axillary sentinel lymph nodes in breast carcinoma patients. Cancer 85:2433-2438, 1999
PubMed
34) van Diest PJ, Torrenga H, Borgstein PJ, et al:Reliability of intraoperative frozen section and imprint cytological investigation of sentinel lymph nodes in breast cancer. Histopathology 35:14-18, 1999
PubMed
35) Rubio IT, Korourian S, Cowan C, et al:Use of touch preps for intraoperative diagnosis of sentinel lymph node metastases in breast cancer. Ann Surg Oncol 5:689-694, 1998
PubMed
36) Ratanawichitrasin A, Biscotti CV, LeVy L, et al:Touch imprint cytological analysis of sentinel lymph nodes for detecting axillary metastases in patients with breast cancer. Br J Surg 86:1346-1348, 1999
PubMed
37) Henry-Tillman RS, Korourian S, Rubio IT, et al:Intraoperative touch preparation for sentinel lymph node biopsy:A4-year experience. Ann Surg Oncol 9:333-339, 2002
 
38) Motomura K, Inaji H, Komoike Y, et al:Intraoperative sentinel lymph node examination by imprint cytology and frozen sectioning during breast surgery. Br J Surg 87:597-601, 2000
PubMed
39) Turner RR, Ollila DW, Krasne DL, et al:Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma. Ann Surg 226:271-278, 1997
PubMed
40) Turner RR, Ollila DW, Krasne DL, et al:Optimal histopathologic examination of the sentinel lymph node for breast carcinoma staging. Am J Surg Pathol 23:263-267, 1999
 
41) Dowlatshahi K, Fan M, Bloom KJ, et al:Occult metastases in the sentinel lymph nodes of patients with early stage breast carcinoma. Cancer 86:990-996, 1999
PubMed
42) Wong SL, Chao C, Edwards MJ, et al:The use of cytokeratin staining in sentinel Iymph node biopsy for breast cancer. Aln J Surg 182:330-334, 2001
 
43) Motomura K, Komoike Y, Inaji Y, et al:Multiple sectioning and immunohistochemical staining of sentinel nodes in patients with breast cancer. Br J Surg 89:1032-1034, 2002
 
44) Veronesi U, Valagussa P:Inefficacy of internal mammary nodes dissection in breast cancer surgery. Cancer 47:170-175, 1981
PubMed
45) Veronesi U, Cascinelli N, Greco M, et al:Prognosis of breast cancer patients after mastectomy and dissection of internal mammary nodes. Ann Surg 202:702-707, 1985
PubMed
46) Sugg SL, Ferguson DJ, Posner MC, et al:Should internal mammary nodes be sampled in the sentinel lymph node era?Ann Surg Oncol 7:188-192, 2000
PubMed
47) Morrow M, Foster RS Jr:Staging of breast cancer; Anew rationale for internal mammary node biopsy. Arch Surg 116:748-751, 1981
 
48) Johnson N, Soot L, Nelson J, et al:Sentinel node biopsy and intemal mammary lymphatic mapping in breast cancer. Am J Surg 179:386-388, 2000
 
49) van der Ent FW, Kengen RA, van der Pol HA, et al:Halsted revisited:internal mammary sentinel Iymph node biopsy in breast cancer. Ann Surg 234:79-84, 2001
 
50) Dupont E, Cox CE, Nguyen K, et al:Utility of internal mammary lymph node removal when noted by intraoperative gamma probe detection. Ann Surg Oncol 8:833-836, 2001
PubMed
51) Tumer RR, Chu KU, Qi K, et al:Pathologic features associated with nonsentinel lymph node metastases in patients with metastatic breast carcinoma in a sentinel lymph node. Cancer 89:574-581, 2000
 
52) Kamath VJ, Giuliano R, Dauway EL, et al:Characteristics of the sentinel lymph node in breast cancer predict further involvement of higher-echelon nodes in the axilla:astudy to evaluate the need for complete axillary lymph node dissection?Arch Surg 136:688-692, 2001
 
53) Chu KU, Turner RR, Hansen NM, et al:Do all patients with sentinel node metastasis from breat carcinoma need complete axillary node dissection? Ann Surg 229:536-541, 1999
 
54) Chu KU, Turner RR, Hansen NM, et al:Sentinel node metastasis in patients with breast carcinoma accurately predicts immunohistochemically detectable nonsentinel node metastasis. Ann Surg Oncol 6:756-761, 1999
PubMed
55) Reynolds C, Mick R, Donohue JH, et al:Sentinel lymph node biopsy with metastasis:Can axillary dissection be avoided in some patients with breast cancer? J Clin Oncol 17:1720-1726, 1999
PubMed
56) Wong SL, Edwards MJ, Chao C, et al:University of Louisville Breast Cancer Sentinel Lymph Node Study Group. Predicting the status of the nonsentinel axillary nodes:amulticenter study. Arch Surg 136:563-568, 2001
 
57) Weiser MR, Montgomery LL, Tan LK, et al:Lymphovascular invasion enhances the prediction of non-sentinel node metastases in breast cancer patients with positive sentinel nodes. Ann Surg Oncol 8:145-149, 2001
PubMed
58) Abdessalam SF, Zervos EE, Prasad M, et al:Predictors of positive axillary lymph nodes after sentinel lymph node biopsy in breast cancer. Am J Surg 182:316-320, 2001
PubMed
59) Cohen LF, Breslin TM, Kuerer HM, et al:Identification and evaluation of axillary sentinel lymph nodes in patients with breast carcinoma treated with neoa (lluvant chemotherapy. Am J Surg Pathol 24:1266-1272, 2000
 
60) Fernandez A, Cortes M, Benito E, et al:Gamma probe sentinel node localization and biopsy in breast cancer patients treated with a neoa adjuvant chemotherapy scheme. Nucl Med Commun 22:361-366, 2001
 
61) Julian TB, Patel N, Dusi D, et al:Sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer. Am J Surg 182:407-410, 2001
PubMed
62) Tafra L, Verbanac KM, Lannin DR, et al:Preoperative chemotherapy and sentinel lymphadenectomy for breast cancer. Am J Surg 182:312-315, 2001
PubMed
63) Mmmounas EP, Brown A, Smith R, et al:Accuracy of sentinel node biopsy after neoadjuvant chemotherapy in breast cancer:Updated results from NSABP B-27. Proc ASCO 140, 2002
 

第5章 家族性乳癌

P.162 掲載の参考文献
1) ynch HT, Lynch JF:Breast cancer genetics in an oncology clinic:328 consecutive patients. Cancer Genet Cytogenet 22:369-371, 1986
 
2) 野水 整, 土屋敦雄, 渡辺文明 ほか:家族性乳癌の臨床.野水 整, 土屋敦雄編集:家族性乳癌, 篠原出版新社, 東京, p7-16, 1996
 
3) Statement of the American Society of Clinical Oncology:Genetic testing for cancer susceptibility, adopted on February 20, 1996. J clin Oncol 14:1730-1736, 1996
 
4) 矢野憲―, 三木義男:遺伝子診断.日本臨床58 増刊乳癌の診断と治療-最新の研究動向―:527-532, 2000
 
5) Howlett NG, Taniguchi T, Olson S, et al:Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297:606-609, 2002
PubMed
6) Hahn SA, Greenhalf B, Ellis I, et al:BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 95:214-221, 2003
PubMed
7) 森崎裕子, 森崎隆幸:DHPLC法を用いた遺伝子多型・変異解析.Bioベンチャー 2:94-99, 2002
Medical*Online
8) Ishioka C, Suzuki T, Fitz Gerald M, et al:Detection of heterozygous tnmcating mutations in the BRCAl and APC genes by using a rapid screening assay in yeast. Proc Natl Acad Sci 94:2449-2453, 1997
 
9) Hendenfalk I, Duggan D, Chen Y, et al:Gene-expression profiles in hereditary breast cancer. N Engl J Med 344:539-548, 2001
PubMed
10) Hacia JG, Brody LC, Chee MS, et al:Detection of heterozygous mutations in BRCAI using hig density oligonucleotide arrays and two-colour fluorescence analysis. Nature Genet 14:441-447, 1996
 
11) 日本衛生検査所協会ホームページ:(http://www.jrcla.or.jp/) 「ヒト遺伝子検査受託に関する倫理指針」 (同ホームページのメインメニューから, 「広報・お知らせコーナー」に入る)
 
12) 「Primer3」のアドレス:http://www-genome.wi.mit.Edu/cgi-bin/primer/primer3www.cgi
 
13) BICのアドレス:http://research.nhgri.nih.gov/bic/ (使用前に簡単な登録が必要であるが, 無償であり, 手続きも簡単である)
 
14) The Human Gene Mutation Database:http://archive.uwcm.ac.Uk/uwcm/mg/hgmd0.html (遺伝子ごとにmutationについて整理, 分類されている.参考文献にも到達しやすい)
 
15) OMIMのホームページ:http://www.ncbi.nlm.nih.gov/omim
 
16) Ikeda N, Miyoshi Y, Yoneda K, et al:Frequency of BRCAI and BRCA2 germline mutations in Japanese breast cancer families. Int J Cancer 91:83-88, 2001
 
17) Ford D, Easton DF, Stratton M, et al:Genetic heterogeneity and penetrance analysis of the BRCAI and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consonium. Am J Hum Genet 62:676-689, 1998
 
18) 三好康雄, 野口眞三郎:家族性乳癌の診断と治療.癌と化学療法 29:512-522, 2002
Medical*Online
19) Narod SA:Modifiers of risk of hereditary breast and ovarian cancer. Nat Rev Cancer 2:113-123, 2002
PubMed
20) Takano M, Aida H, Tsuneki I, et al:Mutational analysis of BRCAI gene in ovarian and breast-ovarian cancer families in Japan. Jpn J Cancer Res 88:407-413, 1997
 
21) Inoue R, Ushijima T, Fukutomi T, et al:BRCA2 germline mutations in Japanese breast cancer families. Int J Cancer (Pred. Oncol) 74:199-204, 1997
 
22) Inoue R, Fukutomi T, Ushijima T, et al:Gemmline Mutation of BRCAI in Japanese breast cancer families. Cancer Res 55:3521-3524, 1995
 
23) Kijima G, Murakami Y, Ohuchi N, et al:Nonsense mutation at codon 630f the BRCAI gene in Japanese breast cancer patients. Jpn J Cancer Res 89:837-841, 1998
 
24) Katagiri T, Emi M, Ito I, et al:Mutations in the BRCAI gene in Japanese breast cancer patients. Hum Mutat 7:334-339, 1996
 
25) Sekine M, Nagata H, Tsuji S, et al:Mutational analysis of BRCAI and BRCA2 and clinicopathologic analysis of ovarian cancer in 82 Ovarian cancer families:Two common founder mutations of BRCAI in Japanese population. Clin Cancer Res 7:3144-3150, 2001
 
26) Matsushima M, Kobayashi K, Emi M, et al:Mutation analysis of the BRCAI gene in 76 Japanese ovarian cancer patients:Four germline mutations, but no evidence of somatic mutation. Hum Mol Genet 4:1953-1956, 1995
 
27) Katagiri T, Kasumi F, Yoshimoto M, et al:High proportion of missense mutations of the BRCAl and BRCA2 genes in Japanese breast cancer families. J Hum Genet 43:42-48, 1998
 
28) Yamashita Y, Sagawa T, Fujimoto T, et al:BRCAl mutation testing for Japanese patients with ovarian cancer in breast cancer screening. Breast Cancer Res Treat 58:11-17, 1999
 
29) Noguchi S, Kasugai T, Miki Y, et al:Clinicopathologic analysis of BRCA1-or BRCA2-associated hereditary breast carcinoma in Japanese women. Cancer 85:2200-2205, 1999
PubMed
30) Aida H, Takakuwa K, Nagata H, et al:Clinical features of ovarian cancer in Japanese women with gemm-line mutations of BRCA1. Clin Cancer Res 4:235-240, 1998
 
31) Miki Y, Katagiri T, Kasumi F, et al:Mutation analysis in the BRCA2 gene in primary breast cancers. Nature Genet 13:245-247, 1996
PubMed
32) Struewing JP, Hartge P, Wacholder S, et al:The risk of cancer associated with specific mutations of BRCAI and BRCA2 among Ashkenazi Jews. N Engl JMed 336:1401-1408, 1997
 
33) Johannesdottir G, Gudmundsson J, Bergthorsson JT, et al:High prevalence of the model 5 mutation in icelandic breast and ovarian cancer patients. Cancer Res 56:3663-3665, 1996
 
34) Dobrovic A, Simpfendorfer D:Methylation of the BRCAI gene in sporadic breast cancer. Cancer Res 57:3347-3350, 1997
 
35) Montagna M, Santacatterina M, Torri A, et al:Identification of a 3kb Alu-mediated BRCAI gene rearrangement in two breast/ovarian cancer families. Oncogene 18:4160-4165, 1999
 
36) Yan H, Papadopoulos N, Marra G, et al:Conversion of diploidy to haploidy. Nature 403:723-724, 2000
PubMed
37) Perrin-Vidoz L, Sinilnikova OM, Stoppa-Lyonnet D, et al:The nonsense-mediated mRNA decay pathway triggers degradation of most BRCAI mRNAs bearing premature termination codons. Hum Mol Genet 11:2805-2814, 2002
 
38) Vallon-Christersson J, Cayanan C, Haraldsson K, et al:Functional analysis of BRCAI C-terminal missense mutations identified in breast and ovarian cancer families. Hum Mol Genet 10:353-360, 2001
 
39) Fackenthal JD, Cartegni L, Krainer AR, et al:BACA2 T2722R is a deleterious allele that causes exon skipping. Am J Hum Genet 71:625-631, 2002
 
40) Willimms RS, Glover JN:Structural consequences of acancer-causing BRCA1-BRCT missense mutation. JBiol Chem 278:2630-2635, 2003
 
41) Kanamori M, Fukutomi T, Sugita M, et al:Family history of breast cancer and breast cancer risk in Japan. Breast cancer 3:161-165, 1996
 
42) Sakayoshi M, Kawahara M, Shiraishi K, et al:Evaluation of the diagnostic accuracy of the stop codon (SC) assay for identifying Protein-truncating mutations in the BRCAI and BRCA2 genes in familial breast cancer. J Hum Genet 48:130-137, 2003
 
P.174 掲載の参考文献
1) Ikeda N, Miyoshi Y, Yoneda K, et al:Frequency of BRCAI and BRCA2 germline mutations in Japanese breast cancer families. Int J Cancer 91:83-88, 2001
 
2) 池田宜子, 三好康雄, 野口眞三郎:遺伝性乳癌.癌の臨床46:437-442, 2000
 
3) Lakhani SR, Jacquemier J, Sloane JP, et al:Multifactorial analysis of differences betweensporadic breast cancers and cancers involving BRCAI and BRCA2 mutations. J Natl Cancer Inst90:1138-1145, 1998
 
4) Marcus JN, Watson P, Page DL, et al:Hereditary breast cancer:pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 77:697-709, 1996
PubMed
5) Noguchi S, Kasugai T, Miki Y, et al:Clinicopathologic analysis of BRCA1-or BRCA2-associated hereditary breast carcinoma in Japanese women. Cancer 85:2200-2205, 1999
PubMed
6) Miyoshi Y, Iwao K, Ikeda N, et al:Acceleration ofchromosomal instability of BRCA1-associatedhereditary breast cancers by p53 abnormality. Breast J 8:77-80, 2002
 
7) Thorlacius S, Olafsdottir G, Tryggvadottir L, et al:Asingle BRCA2 mutation in male and female breastcancer families from Iceland with varied cancerphenotypes. Nat Genet 13:117-119, 1996
 
8) 池田宜子, 三好康雄, 野口眞三郎:家族性腫瘍を理解する (第11回 乳癌) .消化器外科 NURSING 6:75-81, 2001
 
9) Sekine M, Nagata H, Tsuji S, et al:Mutationalanalysis of BRCAI and BRCA2 andclinicopathologic analysis of ovarian cancer in 82 Ovarian cancer families:two common foundermutations of BRCAI in Japanese population. Clin Cancer Res 7:3144-3150, 2001
 
10) Stoppa-Lyonnet D, Ansquer Y, Dreyfus H, et al:Familial invasive breast cancers:worse outcome related to BRCAI mutations. J Clin Oncol 18:4053-4059, 2000
 
11) Turner BC, Harrold E, Matloff E, et al:BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy:implications for breast-conserving management in patients with BRCAIIBRCA2 mutations. J Clin Oncol 17:3017-3024, 1999
PubMed
12) Haffty BG, Harrold E, Khan AJ, et al:Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet 359:1471-1477, 2002
PubMed
13) Hoogerbrugge N, Bult P, de Widt-Levert LM, et al:High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer. J Clin Oncol 21:41-45, 2003
PubMed
P.178 掲載の参考文献
1) 野水 整, 土屋敦雄, 阿部力哉:家族性乳癌.癌の臨床44:1048-1052, 1998
 
2) 野水 整, 阿部力哉:乳癌多発家系―家族性乳癌の臨床的検討―癌の臨床33:477-481, 1987
 
3) Nomizu T, Tsuchiya A, Abe R, et al:Aclinical study of familial cancer in Japan, Weber W ed:Familial Cancer Control, Springer-Verlag, Berlin, p 105-111, 1992
 
4) 野水 整, 土屋敦雄, 安斉圭― ほか:家族性乳癌よりみた両側乳癌.乳癌の臨床6:522-523, 1991
 
5) 野水 整, 土屋敦雄, 渡辺文明 ほか:家族性乳癌の臨床, 阿部力哉監修, 野水 整, 土屋敦雄編集:家族性乳癌, 篠原出版, 東京, p7-16, 1996
 
6) Nomizu T, Tsuchiya A, Kanno M, et al Clinicopathological features of hereditary breast cancer. Breast Cancer 4:239-242, 1997
PubMed
7) 野水 整, 土屋敦雄, 阿部力哉:わが国における遺伝性乳癌の臨床病理学的検討.癌の臨床44:433-440, 1998
 
8) Noguchi S, Kasugai T, Miki Y, et al:Clinicopathologic analysis of BRCA1-or BRCA2-associated hereditary breast carcinoma in Japanese Women. Cancer 85:2200-2205, 1999
PubMed
9) Katagiri T, Kasumi F, Yoshimoto M, et al:High proportion of missense mutations of the BRCAl and BRCA2 genes in Japanese breast cancer families. J Hum Genet 43:42-48, 1998
 
10) 池田宜子, 三好康夫, 野口眞三郎:家族性乳癌, 臨床病理学的特徴.日本臨牀 58 (増刊号):533-536, 2000
 
11) Szabo CI, King MC:Population genetics of BRCAl and BRCA2. Am J Hum Genet 60:1013-1020, 1997
 
12) 霞富士雄:両側乳癌.日外会誌86:266-279, 1985
 
13) Early Breast Cancer Trialisits:Collaborative Group:Systemic treatment of eraly breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339:1-15, 1992
 
14) 阿部力哉, 佐藤寿雄, 吉田弘― ほか:乳癌の集団検診-早期発見の試み.日外会誌86:941-947, 1985
 
15) 池田宜子, 野口眞三郎:家族性乳癌の遺伝子診断と治療.臨外56:629-635, 2001
 
16) Fisher B, Costantino JP, Wickerham DL, et al:Tamoxifen for prevention of breast cancer:Report of the National Surgical A adjuvant Breast and Bowel Proj ect P-1 Study. J Natl Cancer Inst 90:1371-1388, 1998
 
17) King MC, Wieand S, Hale K, et al:Tamoxifen and breast cancer incidence among women with inherited mutations in BRCAI and BRCA2:National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial. JAMA 286:2251-2256, 2001
 
18) Fisher B, Costantino JP, Redmond CK, et al:Endometrial cancer in tamoxifen treated breast cancer patients:findings from the National Surgical adjuvant Breast and Bowel Project (NSABP) B-14. JNatl Cancer Inst 86:527-537, 1994
PubMed
19) Cummings SR, Eckert S, Krueger KA, et al:The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA 281:2189-2197, 1999
PubMed
20) 池田 正, 坂田道生:乳癌に対する化学予防の現状.Molecular Medicine 33:450-456, 1996
 
21) 石川秀樹:家族性腫瘍に対する化学予防.臨外56:617-621, 2001
 
22) Hartmann LC, Schaid DJ, Woods JE, et al:Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340:77-84, 1999
PubMed
23) Curry P, Fentiman IS:Management of women with afamily history of breast cancer. Int J Clin Pract 53:192-196, 1999
 
24) Willemsen HW, Kaas R, Peterse JH, et al:Breast carcinoma in residural breast tissue after prophylactic bilateral subcutaneous mastectomy. Eur J Surg Oncol 24:331-338, 1998
 
25) Schrag D, Kuntz KM, Garber JE, et al:Decision analysis-effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCAI or BRCA2 mutations. N Engl J Med 336:1465-1471, 1997
PubMed
26) Rebbeck TR, Levin AM, Eisen A, et al:Breast cancer risk after bilateral prophylactic oophorectomy in BRCAl mutation carriers J Natl Cancer Inst 91:1475-1479, 1999
 
27) Meijers-Heijboer EJ, Verhoog LC, Klijin JGM, et al:Presymptomatic DNA testing and prophylactic surgery in families with a BRCAI or BRCA2 mutation. Lancet 355:2015-2020, 2000
PubMed
28) Lynch HT, Watson P, Narod S, et al:An update on DNA-based BRCAIIBRCA2 genetic counseling in hereditary breast cancer. Cancer Genet Cytogenet 109:91-98, 1999
PubMed
29) 野水 整, 伊藤康平:家族性乳癌, 予防.日本臨牀58 (増刊号):537-541, 2000
 
30) Yasui Y, Potter JD, Stanford JL, et al:Breast cancer risk and delayed primary Epstein-Barr virus infection. Cancer Epidemiol Biomark Prev 10:9-16, 2001
 
P.184 掲載の参考文献
1) Lynch HT, Lynch JF:Breast cancer genetics in an oncology clinic;328 consecutive patients. Cancer Genet Cytogenet 22:369-371, 1986
 
2) 駿地眞由美:遺伝カウンセリングと心理臨床, 山中康裕監修:魂と心の知の探求, 創元社, 大阪, p242-248, 2001
 
3) 家族性腫瘍研究会:家族性腫瘍における遺伝子診断の研究とこれを応用した診療に関するガイドライン (2000年版) , http://jsft. bacasj. or. Jpguidline-top2000. htm
 
4) 野水 整, 土屋敦雄, 阿部力哉:家族性乳癌:BRCA1, BRCA2遺伝子, 宇都宮譲二監修:Molecular Medicine 別冊 家族性腫瘍-新しい研究動向と診療指針, 中山書店, 東京, p198-201, 1998
 
5) Benett RI, Steinhaus KA, Uhrich SB, et al:Recommendations for standardized human pedigree nomenclature. Am J Hum Genet 56:745-752, 1995
 
6) 玉井真理子:遺伝カウンセリング, 宇都宮譲二監修:Molecular Medicine別冊 家族性腫瘍-新しい研究動向と診療指針, 中山書店, 東京, p148-152, 1998
 
7) 田村智英子, 恒松由記子:がん遺伝カウンセリングの考え方, 宇都宮譲二監修:家族性腫瘍遺伝カウンセリング-理論と実際-, 金原出版, 東京, p149-163, 2000
 

第6章 治療に関する最近の動向

P.189 掲載の参考文献
1) Vycital RO, Schrek R, Clarrke TH:Unstained cell counts as a method of evaluating cancerocidal agents. Cancer Res 12:304, 1952
 
2) Kondo T, Imamura T, Ichihashi H:In vitro test for sensitivity of tumor to carcinostatic agents. Gann 57:113-121, 1966
PubMed
3) Mosmann T:Rapid colorimetric assay for cellular growth and survival:application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63, 1983
PubMed
4) Koezuka M, Imamura T, Ichihashi H, et al:Drug sensitivity test for primary culture of human cancer cells using collagen embedded culture and image analysis. Int J Oncol 2:953-959, 1993
 
5) Freeman AE, Hoffman RM:In vivo-like growth of human tumors in vitro. Proc Natl Acad Sci USA 83:2694-2698, 1986
PubMed
6) Kubota T, Sasano N, Abe O, et al:Potential of the histoculture drug-response assay to contribute to cancer patient survival. Clin Cancer Res 1:1537-1543, 1995
 
7) Furukawa T, Kubota T, Watanabe M, et al:High in vitro-in vivo correlation of drug response using sponge-gel-supported three-dimensional histo-culture and the MTT end point. Int J Cancer 51:489-498, 1992
 
8) Tanino H, Oura S, Hoffman RM, et al:Acquisition of multidrug resistance in recurrent breast cancer demonstrated by the histoculture drug response assay. Anticancer Res 21:4083-4086, 2001
PubMed
9) Yoshimasu T, Oura S, Maebeya S, et al:Histoculture drug response assay on non-small cell lung cancer. Gan To Kagaku Ryoho 27:717-722, 2000
PubMed
10) Jones SE, Dean JC, Young LA, et al:The human tumor clonogenic assay in human breast cancer. J Clin Oncol 3:92-97, 1985
PubMed
11) 石井誠―郎:ヒト乳癌に対するHuman Tumor Clonogenic Assayを用いた薬剤感受性に関する実験的ならびに臨床研究.慶應医66:1013-1028, 1989
 
12) Takamura Y, Kobayashi H, Taguchi T, et al:Prediction of chemotherapeutic response by collagen gel droplet embedded culture-drug sensitivity test in human breast cancers. Int J Cancer 98:450-455, 2002
PubMed
13) 谷野裕―, 久保田哲朗, 尾浦正二 ほか:抗癌剤感受性試験の結果からみた再発乳癌の化学療法.乳癌の臨床13:719-725, 1998
 
14) Furukawa T, Kubota T, Tanino H, et al:Chemosensitivity of breast cancer lymph node metastasis compared to the primary tumor from individual patients tested in the histoculture drug response assay. Anticancer Res 20:3657-3658, 2000
 
P.193 掲載の参考文献
1) 小澤英浩, 川島博行, 高橋俊二:尾形悦郎監修, World of bisphosphonate;illustrated mechanism of action and clinical use, メディカルビュー, P16-25, 2001
 
2) Fleisch H:Bisphosphonates in bone disease from the laboratory to the patient, 4th Ed, Academic Press, San Diego, p27-26, 2000
 
3) Alnerican society of clinical oncology guideline on the role of bisphosphonates in breast cancer. J Clin Oncol 18:1378-1391, 2000
PubMed
4) Hortobagyi GN, Theriault RL, Lipton A, et al:Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 16:2038-2044, 1998
PubMed
5) Theriault R, Lipton A, Hortobagyi G, et al:Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions:Arandomized, placebo-controlled trial-Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 17:846-854, 1999
 
6) Conte PF, Latreille J, Mauriac L, et al:Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate:Results from a multinational randomized controlled trial. J Clin Oncol 14:2552-2559, 1996
PubMed
7) Hultbom R, Gundersen S, Ryden S, et al:Efficacy of pamidronate in breast cancer with bone metastases:Arandomized, double-blind placebo-controlled multicenter study. Anticancer Res 19:3383-3392, 1999
 
8) Paterson AHG, Powles TJ, Kamis JA, et al:Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11:59-65, 1993
 
9) van Holten-Verzantvoort ATM, Kroon HM, Bijvoet OLM, et al:Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 11:491-498, 1993
 
10) Ali SM, Esteva FJ, Hortobagyi GN, et al:Safty and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol 19:3434-3437, 2001
 
11) Kanis JA, Powles T, Paterson AHG, et al:Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 19:663-667, 1996
 
12) Diel IJ, Solomayer EF, Costa SD, et al:Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339:357-363, 1998
PubMed
13) Powels TJ, Paterson S, Kanis JA, et al:Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 20:3219-3224, 2002
 
14) Saarto T, Blomqyist C, Virkkunen P, et al:A(ljuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients:5-year results of a randomized controlled trial. J Clin Oncol 19:10-17 2002
 
15) The ATAC (Arimidex, Tamoxifen Alone or In Combination) Trialists:Group:Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of post menopausal women with early breast cancer:first results of ATAC randomised trial. Lancet 359:2131-2139, 2002
 
P.198 掲載の参考文献
1) Sackett DL:Evidence-based Medicine:what it is and what it isn:t. BMJ 312:71-72, 1996
 
2) Sackett DL, Richardson WS, Rosenberg W, et al:Evidence-based Medicine. Churchill Livingstone 312:71-72, 1997
 
3) Goldhirsch A, Glick JH, Gelber RD, et al:Meeting highlights:International Consensus Panel on the Treatment of Primary Breast Cancer. Journal of the National Cancer Institute 90:1601-1608, 1998
PubMed
4) Oxford, Centre for Evidence-Based Medicineのホームページhttp://www.cebm.net/
 
5) ASCO (American Society of Clinical Oncology) ホームページ http://www.asco.org/ac/1,1003,-12-002130,00.asp
 
6) Cancer Care Ontario's Program in Evidence-Based Care (PEBC) のホームページ http://www.ccopebc.ca/
 
7) National Comprehensive Cancer Network (NCCN) のホームページhttp://www.nccn.org/
 
8) United States Preventive Services Task Forceのガイドライン http://www.guideline.gov/BROWSE/alphabrowse.asp?orgid=345
 
9) U. S. Preventive Services Task Force:Screening for breast cancer:recommendations and rationale. Amals of Intemal Medicine 137 (5 Part 1):344-6, 2002
 
10) U. S. Preventive Services Task Force:Chemoprevention of breast cancer:recommendations and rationale. Amals of Intemal Medicine 137 (1):56-8, 2002
 
11) NIH Consensus Development Program http://consensus.nih.gov/
 
12) コクランライブラリーホームページ http://www.cochranelibrary.com/日本代理店 (南江堂洋書部)
 
13) クリニカル・エビデンスホームページ http://www.clinicalevidence.com/lpBinCE/lpext.dll?f=templates&fn=main-h.htm&2.0, クリニカル・エビデンス日本語版, 日経BP社
 
14) Up To Dateホームページhttp://www.uptodate.com/, 日本代理店 (ユサコ株式会社ホームページ http://www.usaco.co.jp/top.html)
 
15) 山崎茂明:学術情報センター紀要第9号:233-239, 1997
 
16) Daugherty C, Ratain MJ, Grochowski E, et al:J Clin Oncol 13:1062-1072, 1995
PubMed
17) Itoh K, Sasaki Y, Fujii H, et al:Patients in phase I trials of anti-cancer agents in Japan:motivation, comprehension and expectations. Br J Cancer 76:107-113, 1997
PubMed
P.206 掲載の参考文献
1) Folknan J:Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 333:1757-1763, 1995
 
2) Toi M, Matsumoto T, Bando H:Vascular endothelial growth factor:its prognostic, predictive, and therapeutic implications. Lancet Oncol 2:667-673, 2001
PubMed
3) Leung DW, Cachianes G, Kuang WJ, et al:Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306-1309, 1989
PubMed
4) Keck PJ, Hauser SD, Krivi G, et al:Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246:1309-1312, 1989
PubMed
5) Joukov V, Pajusola K, Kaipainen A, et al:Anovel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VE GFR-2) receptor tyrosine kinases. EMBO J 15:290-298, 1996
 
6) Toi M, Bando H, Ogawa T, et al:Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer. Int J Cancer 98:14-18, 2002
PubMed
7) Stacker SA, Caesar C, Baldwin ME, et al:VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 7:186-191, 2001
PubMed
8) Skobe M, Hawighorst T, Jackson DG, et al:Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 7:192-198, 2001
PubMed
9) Asahara T, Murohara T, Sullivan A, et al:Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964-967, 1997
PubMed
10) Takahashi T, Kalka C, Masuda H, et al:Ischemia-and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 5:434-438, 1999
PubMed
11) Lyden D, Hattori K, Dias S, et al:Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7:1194-1201, 2001
PubMed
12) Foekens JA, Peters HA, Grebenchtchikov N, et al:Cancer Res 61:5407-5414, 2001
PubMed
13) Linderholm BK, Lindahl T, Holmberg L, et al:Cartcer Res 61:2256-2260, 2001
PubMed
14) Buteau-Lozano H, Ancelin M, Lardeux B, et al:Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells:acomplex interplay between estroge receptors alpha and beta. Cancer Res 62:4977-4984, 2002
 
15) Logothetis CJ, Wu KK, Finn LD, et al:Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clin Cancer Res 7:1198-1203, 2001
PubMed
16) Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al:Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with HJ/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60-65, 2003
 
17) Singhal S, Mehta J:Thalidomide in cancer:potential uses and limitations. Bio Drugs 15:163-172, 2001
 
18) Davies G, Martin LA, Sacks N, et al:Cyclooxygenase-2 (COX-2), aromatase and breast cancer:apossible role for COX-2 inhibitors in breast cancer chemoprevention. Ann Oncol 13:669-678, 2002
 
19) Chandrasekharam NV, Dai H, Roos KL, et al:COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs:cloning, structure, and expression. Proc Natl Acad Sci USA 99:13926-13931, 2002
 
20) Saji S, Toi M:Aromatase inhibitors and related topics in breast cancer treatment. Expert Opinion on Emerging Drugs 7:303-319, 2002
 
P.213 掲載の参考文献
1) Y Shimada, K Shirao, A Ohtsu, et al:Phase III study of UFT + MMC versus 5-FU + CDDP versus 5-FU alone in patients with advanced gastric cancer:JCOG study 9205. Proc ASCO 18:1043, 1999
 
2) Burris III HA, Moore MJ, Andersen J, et al:Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer:arandomized trial. J Clin Oncol 15:2403-2413, 1997
 
3) Simon R:Design and Analysis of Clinical Trials:CANCER Principles and Practice of Oncology:Edited by Devita VT, Hellman S, Rosenberg SA:JB Lippincott Co, Philadelphia, 1995
 
4) O:Shaughnessy J, Blum J, Moiseyenko V, et al:Randomized, open-label, phase H trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Annals of Oncology 12 (9):1247-1254, 2001
 
5) Talbot DC, Moiseyenko V, Van Belle S, et al:Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. British Joumal of Cancer 86 (9):1367-1372, 2002
 
6) Blum JL, Jones SE, Buzdar AU, et al:Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. Journal of Clinical Oncology 17 (2):485-93, 1999
PubMed
7) Blum JL, Dieras V, Lo Russo PM, et al:Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patie ts. Cancer 92 (7):1759-1768, 2001
 
8) O' Shaughnessy J, Miles D, Vukelja S, et al:Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-retreated Patients With Advanced Breast Cancer:Phase III Trial Results. Joumal of Clinical Oncology 20 (12):2812-2823, 2002
 
9) Fumoleau P, Delgado FM, Delozier T, et al:Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 11 (7):1245-1252, 1993
PubMed
10) Weber BL, Vogel C, Jones S, et al:Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol 13 (11):2722-2730, 1995
PubMed
11) Jones S, Winer E, Vogel C, et al:Randomized Comparison of Vinorelbine and Melphalan in Anthracycline-Refractory Advanced Breast Cancer. J Clin Oncol 13:2567-2574, 1995
PubMed
12) Burstein HJ, Kuter I, Campos SM, et al:Clinical Activity of Trastuzumab and Vinorelbine in Women With HER2-Overexpressing Metastatic Breast Cancer. Journal of Clinical Oncology 19 (10):2722-2730, 2001
 
13) Blackstein M, Vogel CL, Ambinder R, et al:A Gemcitabine as first-line therapy in patients with metastatic breast cancer:a phase II trial. Oncology 62 (1):2-8, 2002
PubMed
14) Kornek GV, Haider K, Kwasny W, et al:Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stkmulating factor. Clin Cancer Res 8 (5):1051-1056, 2002
PubMed
15) Sanchez-Rovira P, Jaen A, Gonzalez E, et al:Phase II trial of gemcitabine/doxorubicin/paclitaxel administered every other week in patient with metastatic breast cancer. Clin Breast Cancer 1 (3):226-232, 2000
 
16) O' Shaughnessy J, Vukelja SJ, Marsland T, et al:Phase II trial of gemcitabine plus trastuzumab in metastatic breast cancer patient previously treated with chemotherapy:preliminary results. Clin Breast Cancer 3 Suppl 1:17-20, 2002
 
17) 向井博文, 渡辺 亨, 勝俣範之:分子標的治療薬の臨床評価法のあり方.内科88 (5):900-904, 2001
 

第7章 乳腺内視鏡手術

P.217 掲載の参考文献
1) 玉木康博, 先田 功, 門田雅生 ほか:乳癌に対する内視鏡手術.外科治療81:683-689, 1999
 
2) Tamaki Y, Nakano Y, Sekimoto M, et al:Transaxillary endoscopic partial mastectomy for comparatively early-stage breast cancer. Surg Laparosc Endosc 8:308-312, 1998
PubMed
3) 山形基夫, 三上 元, 梶原崇弘 ほか:内視鏡下円状部分切除と郭清術.内視鏡外科6:45-51, 2001
 
4) 北村 薫, 石田真弓, 木下旬子 ほか:乳癌に対する内視鏡補助下乳腺全切除と生理食塩水バッグを用いた同時再建術.内視鏡外科 6:61-65, 2001
 
5) 丹黒 章, 為佐卓夫, 松岡功治 ほか:乳房温存手術における内視鏡下腋窩郭清術.内視鏡外科 6:66-73, 2001
 
6) 沢井清司, 中嶋啓雄, 水田成彦 ほか:広背筋脂肪弁を用いた再建術.内視鏡外科 6:46-60, 2001
 
7) Tamaki Y, Tsukamoto F, Miyoshi Y, et al:Overview:video-assisted breast surgery. Biomed Phammacother 56:187s-191s, 2002
PubMed
8) 玉木康博, 大岡 勝, 野口眞三郎:乳腺切除術-吊り上げ法による内視鏡併用乳腺部分切除術-内視鏡外科 6:39-44, 2001
 
9) 玉木康博, 先田 功, 野口眞三郎:鏡視下乳腺部分切除術.外科治療 83:660-664, 2000
Medical*Online
10) Tamaki Y, Sakita I, Miyoshi Y, et al:Transareolar endoscopy-assisted partial mastectomy. A preliminary report of six cases. Surg Laparosc Endosc Precutan Tech 11:356-362, 2001
PubMed
11) 玉木康博, 先田 功, 門田守人:吊り上げ法による鏡視下乳腺部分切除術, 沢井清司, 福間英祐編集:鏡視下乳腺手術の実際, 金原出版株式会社, 東京, P94-103, 2002
 
12) 玉木康博, 三好康雄, 野口眞三郎:画像で決める手術の切除範囲, 癌内視鏡併用乳腺部分切除術 臨床外科 56:374-37, 2001
 
13) Shimazu K, Tamaki Y, Taguchi T, et al:Comparison between periareolar and peritumoral injection of radio tracer for sentinel lymph node biopsy in patients with breast cancer. Surgery 131:277-286, 2002
 
P.226 掲載の参考文献
1) 福間英祐:"内視鏡下手術の再評価" 乳腺手術.外科治療 83 (4):435-442, 2000
 
2) 福間英祐, 和田守憲二, 比嘉国基, 加納宣康, 山川達郎:"乳腺疾患に対する内視鏡手術" 外科治療 86増刊:333-340, 2002
 
3) 沢井清司, 福間英祐 編集:鏡視下乳腺手術の実際, 金原出版, p88-93, 2002
 
4) 福間英祐, 宇井義典, 館花明彦, German Pinares, 山川達郎:乳癌に対する鏡視下乳腺全摘術と再建術.帝京医学会誌 21 (6):497-503, 1999
 
5) Price CI, Eaves FF, Nahai F:Endoscopic tansaxillary subpectral breast augmentation. Plastic Reconstructive Surgery 94:612-619, 1994
 
6) Johnson GW, Christ JE:The endoscopic breast augmentation:the transumblical insertion of saline-filled breast implants. Plast Reconstr Surg 92:801-808, 1992
 
7) Dunn MD, Portis AJ, Shalhav AL, et al:Laparoscopic versus open radical nephrectomy:A 9-year expenence. J Urol 164:1153-1159, 2000
 
8) 沢井清司, 福間英祐 編集:鏡視下乳腺手術の実際.金原出版, p146-150, 2002
 
P.231 掲載の参考文献
1) 駒木幹正:温存療法に必要な解剖学, 渡辺 弘 監修, 福田 護 編集:乳房温存療法のすべて, メジカルビュー社, p22-29, 1994
 
2) 佐藤達夫:解剖, 乳房の解剖と生理, 泉雄 勝, 妹尾亘明 編集:乳線疾患, 金原出版, p1-35, 1995
 
3) 園尾博司:乳房温存術式, 泉雄 勝, 妹尾亘明 編集:乳線疾患, 金原出版, p524-534, 1995
 
4) 高塚雄―:リンパ節郭清術, 渡辺 弘 監修, 福田 護 編集:乳房温存療法のすべて, メジカルビュー社, p91-100, 1994
 
5) 山形基夫:気嚢下腋窩リンパ節郭清術, 沢井清治, 福間英祐 編集:鏡視下乳腺手術の実際, 金原出版, P155-164, 2002
 
P.239 掲載の参考文献
1) 沢井清司, 中嶋啓雄, 水田成彦ほか:広背筋脂肪弁を用いた再建術.日鏡外会誌6:56-60, 2001
 
2) 北村 薫, 石田真弓, 木下旬子ほか:乳癌に対する内視鏡補助下乳腺全摘術と生理食塩水バッグを用いた同時再建術.日鏡外会誌 6:61-65, 2001
 
3) 植野 映, 呉 文文, 菅間 博ほか:乳房温存療法における抜芯術, 第8回日本乳癌学会プログラム, p99, 2000
 
4) 沢井清司, 福田 護, 中嶋啓雄:我が国におけるセンチネルリンパ節生検の現状と展望.日本外科系連合学会誌 26 (2):182-187, 2001
 

第8章 乳房温存療法

P.243 掲載の参考文献
1) Mc Whirter R:The value of simple mastectomy and radiotherapy in the treatment of cancer of the breast. Br J Rodiol 21:599-610, 1948
 
2) Keynes G:Conservative treatment of cancer of the breast. Br Med J 2:643-647, 1937
PubMed
3) Crile G Jr:How much surgery for breast cancer? Modem Mediune 33:32-38, 1973
 
4) Veronesi U, Salvadori B:Breast Conservation Trials From the Milan National Cancer Institute, Harris J R, Lippman M E, Morrow M, Hellman S edited:Diseases of the Breast, Lippencott-Raven pub, p579-584, 1996
 
5) Fletcher GH:History of Irradiation in the Primary Management of Apparently Regionally Confined Breast Cancer. Int J Radiat Biol Phys 11:2133-2142, 1985
 
6) Veronesi U:personal communication
PubMed
7) 光森通英, 根来慶春, 山内智香子ほか:PSCによる放射線治療の現状.癌の臨床 47 (8):643-650, 2001
 
8) 稲治英生:厚生労働省助成, 稲治班報告6th Breast Cancer Up to Date Meeting
 
9) 霞 富士雄, 高橋かおる, 西村誠―郎ほか:乳癌手術の現況とその根拠 7. 照射非併用温存手術.日外会誌103 (11):816-820, 2002
 
10) Silverstein M:Chapter2 Current Management of Noninvasive (In Situ) Breast Cancer. Advances in Surgery 34:17-41, 2000
PubMed
P.248 掲載の参考文献
1) Kasumi F, Iwase T, Yoshimoto M, et al:Experience of quadrantectomy with axillary dissection without radiotherapy sustained by serial pathological examination for stage I breast cancer. J Cancer Res Clin Oncol 121:549-554, 1995
 
2) 秋山 太, 坂元吾偉, 難波 清 ほか:照射を行わない乳房温存術に対する病理学的保証.乳癌の臨床5:95-102, 1990
 
3) 高嶋成光, 土井原博義, 万代光― ほか:特異な局所再発をきたした乳房温存1剖検例.乳癌の臨床8:303-309, 1993
 
4) Muir R, Aitkenhead AC:The healing of intraductal carcinoma of the nanna. J Pathol Bacteriol 38:117-127, 1934
 
P.254 掲載の参考文献
1) NIH Consensus Conference:Treatment of early-stage breast cancer. JA]MLA, 265:391-395, 1991
 
2) The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer:The palpable breast hump:information and recommendations to assist decision-making when a breast lump is detected. Can Med Assoc J; 158 (3Suppl):3-8, 1998
 
3) 馬場紀行, 菅野隆行, 上野貴史 ほか:針生検法.外科治療 74 (5):687-609, 1996
Medical*Online
4) Veronesi U, Luini A, Galimberti V, Zurrida S:Conservation approaches for the management ofstage I/II carcinoma of the breast:Milan Cancer Institute Trials. World J Surg 18:70-75, 1994
 
5) Morrow M, Harris JR:Primary treatment ofinvasive breast cancer, Harris JR, Lippman ME, Morrow M, Osborne CK eds:Diseases of the Breast, 2nd ED, Lippincot Williams & Wilkins, Philadelphia, p515-560, 2000
 
6) Early Breast Cancer Trialists:Collaborative Group:Effects of radiotherapy and surgery in early breastcancer;An overview of the randomized trials. New Eng J Med 333:1444-1452, 1995
 
7) Cox CE, Pedans S, Cox JM, et al:Guidelines forsentinel node biopsy and lymphatic mapping ofpatients with breast cancer. Ann Surg 227:645-653, 1998
 
8) 馬場紀行, 山口 悟, 矢部清壽 ほか:ICGを用いたセンチネルリンパ節生検による腋窩リンパ節郭清の省略の合理性, 第50回共済医学会シンポジウム「各科領域における低侵襲的治療」, 共済医報 51巻2号:178-181, 2002
 
9) Fisher B, Anderson S, Redmond C:Reaiialysis and results after 12 years of follow-up in a randomizedclinical trial comparing total mastectomy withlumpectomy with or without irraditation in thetreatment of breast cancer. New Eng J Med 333:1456-1461, 1995
 
10) Peterson ME, Shultz DJ, Reynolds C, et al:Outcomes in breast cancer patients relative to margis status after treatment with breast conserving surgery and radiation therapy:The University of Pensylvania Experience. Int J Radiation Oncology Biol Phys 43:1029-1035, 1999
 
P.260 掲載の参考文献
1) 秋山 太, 坂元吾偉, 岩瀬拓士 ほか:Probe lumpectomy-乳房温存療法の新しい試み-乳癌の臨床 8:409-414, 1993
Medical*Online
2) Warren JL, Riley GF, Potosky M, et al:Trends and outcomes of outpatient mastectomy in elderly woman. J Natl Cancer lnst 90:833-840, 1998
 
3) Ferrante J, Gonzalez E, Pal N, et al:The use and outcome of outpatient mastectomy in Florida. Am J Surg 179:253-259, 2000
 
4) Barillari P, Leuzzi R, Bassiri-Gharb A, et al:Ambulatory surgical treatment for breast carcinoma:Minerva Chir 56:55-59, 2001
PubMed
5) Classe JM, Dupre PF, Francois T, et al:Axillary padding as an alternative to closed suction drain for ambulatory axillary lymphadenectomy:Arch Surg 137:169-173, 2002
PubMed
6) 日馬幹弘, 中山 俊, 海瀬博史 ほか:Probe lumpectomyとDay surgery.臨床外科 57:313-319, 2002
 
7) Seltzer MH:Partial mastectomy and limited axillary dissection performed as a same day surgical procedure in the treatment of breast cancer. Int Surg 80:79-81, 1995
PubMed
8) Tan LR, Guenther JM:Outpatient difinitive breast cancer surgery. Am Surg 63:865-867, 1997
 
9) Coveney E, Weltz CR, Greengrass R, et al:Use of paravertebral block anesthesia in the surgical management of breast cancer;Experience in 156 cases. Ann Surg 227:496-501, 1998
PubMed
10) Bariallari P, Leuzzi R, Bassiri-Ghaeb A, et al:Ambulatory surgical treatment for breast carcinoma. Minerva Chir 56:55-59, 2001
 
11) 加納大典, 竹内 恵, 稲本 俊 ほか:全身麻酔による1泊入院手術治療.第2回乳癌最新情報カンファランス抄録集:p4445, 2001
 
12) Kusama M, Nakayama S, Kaise H, et al:Partial mastectomy the use of local anesthesia with/without a prophylaxis axillary irradiation performed as a same day surgical procedure in the treatment of early breast cancer. J Breast 7:24, 2001
 
13) 高橋かおる, 林孝子, 斉藤光江ほか:乳癌 day surgery. 日本臨床 58:545-550, 2000
Medical*Online
14) 日馬幹弘, 中山 俊, 海瀬博史 ほか:乳癌手術における色素法sentinel lymph node生検の意義と方法に関する検討.リンパ学 24:9-12, 2001
 
15) 河本敦夫, 柿崎 大, 沼尻光一 ほか:フルデジタル超音波装置を用いた乳腺超音波検査.映像情報32:511-516, 2000
 
16) 日馬幹弘, 小柳泰久, 中山 俊 ほか:Day Surgery:手術のコツとピットフォール1.乳癌 (センチネルリンパ節生検を伴う) 手術.手術56:427-433, 2002
 
17) Fisher B, Bryant J, Wolmark N, et al:Effort of preoperative chemotherapy on the outcome of woman with operable breast cancer. J Clin Oncol 16:2672-2685, 1998
 
18) van der Hage JA, van de Velde CJH, Julien J-P, et al:Peoperative chemotherapy in primary operable breast cancer:Results from the European Organization for Research and Treatment of Cancer Trial 10902. J Clin Oncol 19:4224-4237, 2001
 
19) Breslin TM, cohen L, Sahin A, et al:Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol 18:3480-3486, 2000
PubMed
20) Fisher B:From Halsted to preventional and beyond:Advances in the management of breast cancer during the twentieth century. Eur J Cancer 35:1963-1973, 1999
 
P.265 掲載の参考文献
1) Wellings SR, Jensen HM, Marcum RG:An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. JNatl Cancer Inst 55:231-273, 1975
PubMed
2) Ohuchi N, Abe R, Kasai M:Possible cancerouschange of intraductal papilloma of the breast:A3-Dreconstruction study of 25 cases. Cancer 54:605-611, 1984
 
3) Ohuchi N, Furuta A, Mori S:Management of ductalcarcinoma in situ with nipple discharge:intraductalspreading of carcinoma is unfavorable psthologicfactor for breast conserving surgery. Cancer 74:1294-1302, 1994
 
4) Ohuchi N, Harada Y, Ishida T, et al:Breastconserving surgery for primary breast cancer:immediate volume replacement using lateral tissueflap. Breast Cancer 4:59-65, 1997
 
5) Ohuchi N:Breast-conserving surgery for invasivecancer:Aprinciple based on segmental anatomy. Tohoku J Exp Med 188:103-118, 1999 (大内憲明, 石田孝宣, 大平広道, 増田真幸)
 
P.270 掲載の参考文献
1) Veronesi U, Cascinelli N, Mariani L, et al:Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347:1227-1232, 2002
PubMed
2) Fisher B, Anderson S, Bryant J, et al:Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347:1233-1241, 2002
PubMed
3) Holland R, Veling SHJ, Mravunac M, et al:Histologic multifocality of Tis, Tl-2 breast carcinomas:Implications for clinical trials of breast-conserving surgery. Cancer 59:979-990, 1985
 
4) 高橋かおる, 西村誠―郎, 多田敬―郎 ほか:乳房温存療法の適応と限界.癌と化学療法 29:1125-1131, 2002
 
5) Huang E, Buchholz T, Meric F, et al:Classifying local disease recurrence after breast conservation therapy based on location and histology. New primary tumors have favorable outcomes than true local recurrences. Cancer 95:2059-2067, 2002
PubMed
6) 坂元吾偉:術前術後療法の併用による乳房温存療法の適応拡大と再発予防に関する研究, 厚生労働省, がん研究助成金による研究報告集 平成12年度
 
7) 大住省三:我が国の放射線治療併用の乳房温存療法.臨外 57:289-295, 2002
 
8) Komoike Y, Motomura K, Inaji H, et al:Long-temm results of breast conserving surgery for Stages I and II breast cancer:Experiences at Osaka Medical Center for Cancer and Cardiovascular Diseases. Breast Cancer 9:248-253, 2002
 
9) Fisher B, Anderson S, Fisher E, et al:Significance of ipsilateral breast tumour recurrence after lumpectomy. Lancet 338:327-331, 1991
PubMed
10) Fisher E, Anderson S, Tan-Chiu E, et al:Fifteen-year prognostic discriminants for invasive breast carcinoma. Cancer 91:1679-1687, 2001
PubMed
11) Fortin A, Larochelle M, Laverdiere J, et al:Local failure is responsible for the decrease in survival for patients with breast cancer treated with conservative surgery and postoperative radiotherapy. J Clin Oncol 17:101-109, 1999
PubMed
12) Fowble B:Ipsilateral breast tumor recurrence following breast-conserving surgery for early-stage invasive cancer. Acta Oncologica Suppl 13:9-17, 1999
 
13) Freedman G, Fowble B:Local recurrence after mastectomy or breast-conserving surgery and radiation. Oncology 14:1561-1581, 2000
 
14) Querci G, Benson J:Ipsilateral local recurrence of breast cancer:determinant or indicatou of poor prognosis. Lancet Oncol 3:183-187, 2002
PubMed
15) Le MG, Arriagata R, Spielmann M, et al:Prognostic factors for death after an isolated local recurrence in patients with early-stage breast carcinoma. Cancer 94:2813-2820, 2002
 
16) 菰池佳史, 稲治英生, 元村和由 ほか:乳房温存療-法局所再発に対する対策-Breast Cancer Today l 7:2-7, 2001
 
17) Nishimura R, Koyama H, Kasumi F, et al:Acase control study on risk factors involved in inflammatory breast recurrence after breast-conserving surgery. Oncology 55:391-399, 1998
 
18) 稲治英生, 菰池佳史, 元村和由 ほか:乳房内再発-特に炎症性乳癌型再発についての考察.癌の臨床46:677-682, 2000
 
19) Haffty BG, Fischer D, Beirfield M, et al:Prognosis following local recurrence in the conservatively treated breast cancer patient. Int J Radiat Oncol Biol Phys 21:293-298, 1991
 
20) Komoike Y, Motomura K, Inaji H, et al:Repeat lumpectomy for patients with ipsilateral breast tumor recurrence after breast-conserving surgery. Preliminary results. Oncology 64:1-6, 2003
PubMed
21) Resch A, Fellner C, Mock U:Locally recurrent breast cancer:Pulse dose rate brachytherapy for repeat irradiation following lumpectomy-A second chance to preserve the breast. Radiology 225:713-718, 2002
PubMed

第9章 内分泌療法

P.274 掲載の参考文献
1) Cole MP, Jones CT, Todd ID:Anew anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer 25:270-275, 1971
 
2) Kato K, Kitamoto T, Masuhiro Y, et al:Molecular mechanism of a cross-talk between estrogen and growth-factor signaling pathways. Oncology 55 (1):5-10, 1998
 
3) Early breast cancer trialists:collaborative group:Tamoxifen for early breast cacner:an overview or the randomized trials. Lancet 351:1451-1467, 1998
 
4) Bryant J, Fisher B, Dignam J:Duration of Adj uvant Tamoxifen Therapy. J Natl Cancer Inst Monogr 30:56-61, 2001
 
5) Fisher B, Bryant J, Dugban JJ, et al:Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol 20:4141-4149, 2002
PubMed
6) Fisher B, Costantino JP, Wichkerham DL, et al:Tamoxifen for prevention of breast cancer:Report of the National Surgical A adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 90, 8:1371-1388, 1998
 
7) Rutqvist LE, Johansson HJ, Signomklao T, et al:Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 87:645-651, 1995
 
8) Matsuyama Y, Tominaga T, Nomura Y, et al:Second cancers after a adjuvant tamoxifen therapy for breast cancer in Japan. Ann Oncol 11:1537-1543, 2000
PubMed
9) Jonat W, Kaufmann M, Sauerbrei W, et al:Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer:The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 20:4628-4635, 2002
PubMed
10) Klijn JG, Blamey RW, Boccardo F, et al:Combined tamoxifen and Iuteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer:a meta-analysis of four randomized trials. J Clin Oncol 19:343-353, 2001
 
11) Buzdar AU, Robertson JF, Eiermann W, et al:An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer 95:2006-2016, 2002
PubMed
12) The ATAC (Arimidex, Tamoxifen Alone or in Combination) trialists:group:Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for a adjuvant treatment of post menopausal women with early breast cancer:first results of ATAC randomised trial. Lancet 359:2131-2139, 2002
 
13) Ellis MJ, Coop A, Singh B, et al:Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer:evidence from a phase III randomized trial. J Clin Oncol 19:3808-3816, 2001
PubMed
14) Omoto Y, Hayashi S:Astudy of estrogen signaling using DNA microarray in hunlan breast cancer. Breast Cancer 9:308-311, 2002
 
P.279 掲載の参考文献
1) Beatson GW:On the treatment of inoperable cases of carcinoma of the mamma:Suggestion for a new method of treatment with illustrative cases. Lancet II:104-107, 162-165, 1895
 
2) Belchetz PE, Plant TM, Nakai Y, et al:Hypophysial responses to continuous and intermittent delivery of hypopthalamic gonadotropin-releasing hormone. Science 202:631-633, 1978
PubMed
3) Miller WR, Scott WN, Morris R, et al:Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature 313:231-233, 1985
PubMed
4) Koibuchi Y, Sugamata N, Iino Y, et al:The mechanisms of antitumor effects of luteinizing hormone-releasing hormone agonist (buserelin) in 7, 12-dimethylbenz (a) anthracene-induced rat mammary cancer. Int J Mol Med 4:145-148, 1999
PubMed
5) Early Breast Cancer Trialists:Collaborative Group:Ovarian ablation in early breast cancer:Overview of the randomized trials. Lancet 348:1189-1196, 1996
 
6) Scottish Cancer Trials Breast Group and ICRF Breast Unit:A adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma:the Scottish trial., Guys Hospital, London. Lancet 341:1293-1298, 1993
 
7) Ejlertsen B, Dombernowsky P, Mouridsen HT, et al:Compareble effect of ovarian ablation (OA) and CMF chemotherapy in premennopausal hormone receptor positive breast cancer patients (PRP). Proc Am Soc Clin Oncol 18:66a (abstr 248), 1999
 
8) Jonat W, Kaufmann M, Sauerbrei W, et al:Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer:The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 20:4628-4635, 2002
PubMed
9) Schmid P, Untch M, Wallwiener D, et al:Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients:preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate). Anticancer Res 22:2325-2332, 2002
PubMed
10) Taylor CW, Green S, Dalton WS, et al:Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer:an intergroup study. J Clin Oncol 16:994-999, 1998
PubMed
11) Matsumoto H, Koibuchi Y, Horiguchi J, et al:Combined effects of lutenizing hormone-releasing hormone analogue with antiestrogen on rat mammary tumors. Oncol Rep 9:145-151, 2002
PubMed
12) Klijn JG, Beex LV, Mauriac L, et al:Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer:a randomized study. J Natl Cancer Inst 92:903-911, 2000
PubMed
13) Klljn JG, Blamey RW, Boccardo F, Tominaga T, et al:Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer:ameta-analysis of four randomized trials. J Clin Oncol 19:343-353, 2001
 
14) Boccardo F, Rubagotti A, Amoroso D, et al:Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positivepre-/perimenopausal breast cancer patients:resultsof the Italian Breast Cancer A (Uuvant Study Group 02 randomized trial. J Clin Oncol 18:2718-2727, 2000
 
15) Roche HH, Kerbrat P, Bonneterre J, et al:Completehormonal blockade versus chemotherapy inpremenopausal early-stage breast cancer patientswith positive hormone-receptor and 1-3 nodepositive tumor:results of the FASG O6 Trial. Proc Am Soc Clin Oncol 19, 72a (abstr 278), 2000
 
16) Jakesz R, Hausmaninger H, Kubista E, et al:Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil:evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer-Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol 20:4621-4627, 2002
 
17) Goldhirsch A, Glick JH, Gelber RD, et al:Meeting highlights:International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh Intemational Conference on A adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 19:3817-3827, 2001
 
P.284 掲載の参考文献
1) Buzdar AU, Jonat W, Howell A, et al:Anastozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma:results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 83:1142-1152, 1998
 
2) Dombernowsky P, Smith I, Falkson G, et al:Letrozole, a new oral aromatase inhibitor for advanced breast cancer:double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16:453-461, 1998
PubMed
3) Kaufmann M, Baj etta E, Dirix LY, et al:Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer:results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 18:1399-1411, 2000
 
4) Nabholtz JM, Buzdar A, Pollak M, et al:Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women:results of a North American multicenter randomised trial. J Clin Oncol 18:3758-3767, 2000
 
5) Bonneterre J, Thurlimann B, Robertson JF, et al:Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma:results of two randomised trials designed for combined analysis. Cancer 92:2247-2258, 2001
 
6) Mouridsen H, Gershanovich M, Sun Y, et al:Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer:results of a phase III study of the International I. etrozole Breast Cancer Group. J Clin Oncol 19:2596-2606, 2001
 
7) Dirix L, Piccart M, Lohrisch C, et al:Efficacy of and tolerance to exemestane versus tamoxifen in first-line hormone therapy of postmenopausal patients with metastatic breast cancer:a European Organization for the Research and Treatment of Cancer randomised phase II trial. Proc Am Soc Clin Oncol 20:29a, 2001
 
8) 小山博記, 阿部力哉, 冨永 健 ほか:閉経後乳癌患者におけるアナストロゾール (新規第4世代アロマターゼ阻害剤) の第I相試験.乳癌の臨床 15:577-583, 2000
 
9) 野村雍夫, 冨永 健, 榎本耕治 ほか:新規アロマターゼ阻害剤CGS20267 (Letrozole) の閉経後進行・再発乳癌女性に対する前期臨床第II相試験.癌と化療 29:551-562, 2002
 
10) The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists:Group:Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer:first results of the ATAC randomised trial. Lancet 359:2131-2139, 2002
 
11) Buzdar AU:The ATAC ('Arimidex:Tamoxifen Alone or in Combination) trial in postmenopausal women with early breast cancer:updated efficacy results of a median follow-up of 47 months. Proc San Antonio Breast Cancer Symposium 76 (suppl1):abs 13, 2002
 
12) Winer EP, Hudis C, Burstein HJ, et al:American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer:status report 2002. J Clin Oncol 20:3317-3327, 2002
 
13) Dixon JM, Renshaw L, Bellamy C, et al:The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer:arandomized, double-blind, single-center study. Clin Cancer Res 6:2229-2235, 2000
 
14) Ellis MJ, Coop A, Singh B, et al:Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for erbB-1 and/or erbB-2-positive, estrogen receptor-positive primary breast cancer:evidence from a phase III randomized trial. J Clin Oncol 19:3808-3816, 2001
PubMed
P.290 掲載の参考文献
1) Eifel P, Axelson JA, Costa J, et al:National Institutes of Health Consensus Development Conference Statement:a adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 93:979-989, 2001
PubMed
2) Goldhirsch A, Glick JH, Gelber RD, et al:Meeting Highlights:International Consensua Panel on the Treatment of Primary Breast Cancer. J Clin Oncology 19:3817-3827, 2001
 
3) Ciocca DR, Elledge R:Molecular markers for predicting response to tamoxifen in breast cancer patients. Endocrine 13:1-10, 2000
PubMed
4) Kuiper GG, Enmark E, Pelto-Huikko M, et al:Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 93:5925-5930, 1996
PubMed
5) 林 慎―, 大本陽子:新たなるエストロゲン受容体とヒト悪性腫瘍.病理と臨床20:425-430, 2002
 
6) Saji S, Omoto Y, Shimizu C, et al:Expression of Estrogen Receptor (ER) βcx Protein in ER?-positive Breast Cancer:Specific Correlation with Progesterone Receptor. Cancer Res 62:4849-4853,2002
 
7) 林 慎―, 吉田 崇:乳癌の発生・進展におけるER (estrogen receptor) 遺伝子の発現制御機構.日本臨床58:495-503, 2000
 
8) 林慎―:癌におけるエストロゲンレセプター機能のモジュレーター.Molecular Medicine 37:1162-1168, 2000
 
9) 1noue A, Yoshida N, Omoto Y, et al:Developmentof cDNA microarray for expression profiling ofestrogen-responsive genes. J Mol Endocrinol 29:175-192, 2002
 
10) The ATAC Trialists:Group:Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer:first results of the ATAC randomised trial. Lancet 359:2131-2139, 2002
 
11) Mouridsen H, Gershanovich M, Sun Y, et al:Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer:results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncology 19:2596-2606, 2001
 
12) Pasqualini JR, Chetrite G, Blacker C, et al:Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre-and postmenopausal breast cancer patients. J Cin Endocrinol Metab 81:1460-1464, 1996
 
13) Simpson ER, Davis SR:Aromatase and the regulation of estrogen biosynthesis-some new perspectives. Endocrinology 142:4589-4594, 2001
PubMed
14) Sorlie T, Perou CM, Tibshirani R, et al:Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869-10874, 2001
PubMed
15) Veer LJ, Dai H, Vijver MJ, et al:Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-535, 2002
 
16) 林慎―, 山口ゆり:核内レセプターとホルモン依存性癌.遺伝子医学6:618-623, 2002
 

第10章 薬物療法

P.294 掲載の参考文献
1) Morrow M, Strom EA, Bassett LW, et al:Standard for the Management of Ductal Carcinoma In Situ of the Breast (DCIS) . CA Cancer J Clin 52:256-276, 2002
PubMed
2) Morrow M, Strom EA, Bassett LW, et al:Standard for Breast Conservation Therapy in the Management of Invasive Breast Carcinoma. CA Cancer J Clin 52:277-300, 2002
PubMed
3) Early Breast Cancer Trialists:Collaborative Group:Polychemotherapy for early breast cancer:an overview of the randomised trials. Early Breast Cancer Trialists Collaborative Group. Lancet 352:930-942, 1998
 
4) Early Breast Cancer Trialists:Collaborative Group:Tamoxifen for early breast cancer:an overview of the randomised trials. Lancet 351:1451-1467, 1998
 
5) Clinical Evidence (issue 8. O, March 2003). London, BMJ Publishing Group, 2003
 
6) Mauriac L, Durand M, Avril A, et al:Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre. Ann Oncol 2:347-354, 1991
 
7) Scholl SM, Fourquet A, Asselain B, et al:Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery:preliminary results of a randomised trial:S6. European Joumal of Cancer 30A:645-652, 1994
 
8) Powles TJ, Hickish TF, Makns A, et al:Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 13:547-552, 1995
PubMed
9) Fisher B, Bryant J, Wolmark N, et al:Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. Journal of Clinical Oncology 16:2672-2685, 1998
PubMed
10) van der Hage JA, van de Velde CJ, Julien JP, et al:Preoperative chemotherapy in primary operable breast cancer:results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 19:4224-4237, 2001
 
11) Broet P, Scholl SM, de la Rochefordiere A, et al:Short and long-term effects on survival in breast cancer patients treated by primary chemotherapy:an updated analysis of a randomized trial Breast Cancer Res Treat 58:151-156, 1999
 
12) Mauriac L, MacGrogan G, Avril A, et al:Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm:aunicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 10:47-52, 1999
PubMed
13) Makris A, Powles TJ, Ashley SE, et al:Areduction in the requirements for mastectomy in a randomized trial of neoa adjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 9:1179-1184, 1998
 
14) Buzdar AU, Singletary SE, Theriault RL, et al:Prospective Evaluation of Paclitaxel Versus Combination Chemotherapy With Fluorouraci 1, Doxorubicin, and Cyclophosphamide as Neoadjuvant Therapy in Patients With Operable Breast Cancer. J Clin Oncol 17:3412-3417, 1999
 
15) Green MC, Buzdar AU, Smith T, et al:Weekly (wkly) paclitaxel (P) followed by FAC as primary systemic chemotherapy (PSC) of operable breast cancer improves pathologic complete remission (pCR) rates when compared to every 3-week (Q3wk) Ptherapy (tx) followed by FAC-final results of a prospective phase III randomized trial. Proc Am Soc Clin Oncol:Abstr#135, 2002
 
16) Smith IC, Heys SD, Hutcheon AW, et al:Neoadjuvant Chemotherapy in Breast Cancer:Significantly Enhanced Response With Docetaxel. J Clin Oncol 20:1456-1466, 2002
PubMed
17) Mukai H, Watanabe T, Ando M, et al:Standardization of definition of pCR is nessessary among various clinical trial groups. Proc Am Soc Clin Oncol 39:333, 2002
 
18) Mamounas E, Fisher B:Preoperative (neoadjuvant) chemotherapy in patients with breast cancer. Seminars in Oncology 28:389-399, 2001
PubMed
19) Kuerer HM, Newman LA, Smith TI., et al:Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoa adjuvant Chemotherapy. J Clin Oncol 17:460, 1999 (渡辺 亨, 清水千佳子, 安藤正志,
 
P.300 掲載の参考文献
1) Fisher B, Bryant J, Wolmark N, et al:Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 8:2672-2685, 1998
PubMed
2) Cocconi G, di Blasio B, Bisagni G, et al:Neoadjuvant chemotherapy or chemotherapy and endocrine therapy in locally advanced breast carcinoma. A prospective, randomized study. Am J Clin Oncol 13:226-232, 1990
 
3) Kuerer HM, Newman LA, Smith TL, et al:Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17 (2):460-469, 1999
PubMed
4) Buzdar AU, Singletary SV, Theriault RL, et al:Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicine, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 17:3412-3417, 1999
 
5) Gvon Minckwitz, G Raab, M Schuette, et al:Dose dense versus sequential adriamcycin/docetaxel combination as preoperative chemotherapy (pCHT) in operable breast cancer (T2-3, NO-2, MO)-primary endpoint analysis of the GEPARDUO-Study. Proc Am Soc Clin Oncol 21:abstract 168, 2002
 
6) Scholl SM, Fourquet A, Asselain B, et al:Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery:preliminary results of a randomised trial:S6. Eur J Cancer 30A (5):645-652, 1994
PubMed
7) Semiglazov VF, Topuzov EE, Bavli JL, et al:Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer. Ann Oncol 7:591-595, 1994
PubMed
8) Wolmark N, Wang J, Mamounas E, et a Preoperative chemotherapy in patients with operable breast cancer:nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer lnst Monogr 30:96-102, 2001
 
9) Jos A van der Hage, Cornelis J H van de Velde, Jean-Pierre Julien, et al:Preoperative chemotherapy in primary operable breast cancer:results from the European organization for research and treatment of cancer trial 10902. J Clin Oncol 19:4224-4237, 2001
 
10) Vinholes J, Bouzid K, Salas F, et al:Preliminary results of a multicentre phase m trial of taxotere and doxorubicin versus 5 fluorouracil, doxorubicin and cyclophosphamide in patients with unresectable locally advanced breast cancer. Proc Am Soc Clin Oncol 20:abstract 101, 2001
 
11) Smith IC, Heys SD, Hutcheon AW, et al:Neoadjuvant chemotherapy in breast cancer:significantly enhanced response with docetaxel. J Clin Oncol 20:1456-1466, 2002
PubMed
12) Green MC, Buzdar AU, Smith T, et al:Weekly paclitaxel followed by FAC as primary systemic chemotherapy of operable breast cancer improves pathologic complete remission rates when compared to every 3 week paclitaxel therapy followed by FAC-Final results of a prospective phase III randomized trial. Proc Am Soc Clin Oncol 21:abstract 135, 2002
 
13) Burstein HJ, Harris LN, Kaelin CM, et al:Preoperative Herceptin and paclitaxel for HER2 overexpressing stage II/III breast cancer. Proc Am Soc Clin Oncol 20:abstract 100, 2001
 
14) Ellis MJ, Coop A, Singh B, et al:Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer:evidence from a phase m randomised trial. J Clin Onco119:3808-3816, 2001
PubMed
15) Hoff PM, Valero V, Buzdar AU, et al:Combined modality treatment of locally advanced breas carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy. Cancer 88:2054-2060, 2000
PubMed
16) Dixon JM, Renshaw L, Bellamy C, et al:The effects of neoa adjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer:arandomized, double-blind, single-center study. Clin Cancer Res 6:2229-2235, 2000
 
17) Mauriac L, MacGrogan G, Avril A, et al:Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm:aunicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 10 (1):47-52, 1999
PubMed
18) Harry D Bear:The effect on primary tumor response of adding sequential taxotere to adriamycin and cyclophosphamide:preliminary results from NSABP protocol B-27. 24th and al San Antonio Breast Cancer symposium. abstract 5, 2001
 
19) Mukai H, Watanabe T, Ando M, et al:Standardization of definition of pathologically complete response (pCR) to primary chemotherapy for breast cancer is necessary among clinical trial groups. Proc Am Soc Clin Oncol 21:abstract 264, 2002
 
P.306 掲載の参考文献
1) Miller AB, Hogestraeten B, Staquet M, et al:Reporting results of cancer treatment, Cancer 47:207-214, 1981
 
2) Patrick T, Susan GA, Elizabeth AE, et al:New Guidelines to Evaluate the Response to Treatment in Solid Tumors, J Natl Cancer Inst 92:205-216, 2000
 
3) James K, Eisenhauer E, Christian M, et al:Measuring response in solid tumors:unidimensional versus bidimensional measurement. J Natil Canceer Inst 91:523-528, 1999
 
4) 西條長宏, 下山正徳, 福田治彦 ほか:固形がんの治療効果判定のための新ガイドライン (RECISTガイドライン)―日本語訳JCOG版―, Exceipta Medica, 東京, p1-18, 2002
 
5) Nakamura S, Kenj o H, Nishio T, et al:Efficacy of 3D-MR mammography for Breast Conserving Surgery after Neoadjuvant Chemotherapy, Breast Cancer 9:15-19, 2002
 
6) Nakamura S, Kenjo H, Nishio T, et al:3D-MR mammography-Guided Breast Conserving Surgery after Neoa (加vant Chemotherapy:Clinical Results and Future Perspectives with Reference to FDG-PET:Breast Cancer 8:351-354, 2001
 
7) 乳癌学会編:臨床・病理乳癌取り扱い規約, 第14版, 金原出版, p70, 2000
 
8) Fisher B, Bryant J, Walmark N, et al:Effect of preoerative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685, 1998
 
9) 向井博文, 渡辺 亨:乳癌治療における術前化学療法のめざすもの.血液・腫瘍科46:60-65, 2003
 
P.314 掲載の参考文献
1) Clark GM:Prognostic and predictive factors, chapter 32, in Harris JR, Lippman ME, Morrow M ed:Disease of the Breast, 2nd ed, Lippincott Williams & Wilkins, p489-514, 1999
 
2) Goldhirsh A, Glick GH, Gelber RD, et al:Meeting highlights:international consensus panel on the treatment of primary breast cancer. J Clin Oncol 19:3817-3827, 2001
 
3) Early Breast Cancer Trialists:Collaborative Group:Polychemotherapy for early breast cancer:an overview of the randomised trials. Lancet 352:930-942, 1998
 
4) Bonadonna G, Valagussa P, Moliterni A, et al:Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer:the results of 20 years of follow-up. N Engl J Med 332:901-906, 1995
PubMed
5) Fisher B, Brown AM, Dimitrov NV, et al:Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors:results from the National Surgical A (lluvant Breast and Bowel Project B-15. J Clin Oncol 8:1483-1496, 1990
PubMed
6) Fisher B, Anderson S, Tan-Chiu E, et al:Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer:findings from National Surgical A (lluvant Breast and Bowel Project B-23. J Clin Oncol 19:931-942, 2001
 
7) Hutchins L, Green S, Ravdin P, et al:CMF versus CAF With and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients:First results of Intergroup Trial INT 0102. Proc Am Soc Clin Oncol 17:1a, 1998 (abstr)
 
8) Henderson IC, Berry D, Demetri G, et al:Improved disease free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer. Proc Am Soc Clin Oncol 17:390a, 1998 (abstr)
PubMed
9) Levine MN, Bramwell VH, Pritchard KI, et al:Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute Canada Clinical Trials Group. J Clin Oncol 16:2651-2658, 1998
 
10) Mouridsen HT, Andersen J, Andersson M, et al:Adjuvant anthracycline in breast cancer:improved outcome in premenopausal patients following substitution of methotrexate in the CMF combination with epirubicin. Proc Am Soc Clin Oncol 18:68a, 1999 (abstr)
 
11) Piccart; MJ, Di Leo A, Beauduin M, et al:Phase HI trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J Clin Oncol 19:3103-3110, 2001
 
12) Tancini G, Bonadonna G, Valagussa P, et al:Adjuvant CMF in breast cancer:comparative 5-year results of 12 versus 6 cycles. J Clin Oncol 1:2-10, 1983
 
13) Eifel P, Axelson JA, Costa J, et al:National Institutes of Health Consensus Development Conference Statement:adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 93:979-989, 2001
PubMed
14) Buzdar AU, Singletary SE, Valero V, et al:Evaluation of Paclitaxel in adjuvant chemotherapy for patients with operable breast cancer:preliminary data of a prospective randomized trial. Clin Cancer Res 8:1073-1079, 2002
PubMed
15) Nabholtz JM, Pienkowski T, Mackey J, et al:Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node-positive breast cancer patients:interim analysis of the BCIRG OOI study. Proc Am Soc Clin Oncol 21:36a, 2002 (abstr)
 
16) Paik S, Bryant J, Tan-Chiu E, et al:HER2 and choice of adjuvant chemotherapy for invasive breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 92:1991-1998, 2000
PubMed
17) Early Breast Cancer Trialists:Collaborative Group:Tamoxifen for early breast cancer:an overview of the randomised trials. Lancet 351:1451-1467, 1998
 
18) Hutchins L, Green S, Ravdin P, et al:CMF versus CAF tamoxifen in high-risk node-negative breast cancer patients and a natural history of follow-up study in low-risk node negative patients:Update of tamo) dfen results. Breast Cancer Res Treat 57:25, 1999 (abstr)
 
19) Fisher B, Dignam J, Bryant J, et al:Five versus more than five years of tamoxifen for 1ymph node-negative breast cancer:Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 93:684-690, 2001
 
20) Stewart HJ, Prescott RJ, Forrest AP, et al:Scottish adjuvant tamoxifen trial:arandomized study updated to 15 years. J Natl Cancer Inst 93:456-462, 2001
 
21) Davidson N, O:Neill A, Vukov A, et al:Effect of chemohormonal therapy in premenopausal, node (+), receptor (+) breast cancer:An Eastern Cooperative Oncology Group Phase m Intergroup Trial (E5188, INT-0101). Proc Am Soc Clin Oncol 18:67a, 1999 (abstr)
 
22) Bianco AR, Costanzo R, Di Lorenzo G, et al:The Mam-1 GOCSI trial:a randomized trial with factorial design of chemoendocrine adjuvant treatment in node-positive early breast cancer. Proc Am Soc Clin Oncol 20:27a, 2001 (abstr)
 
23) Albain K, Green S, Ravdin P, et al:Overall survival after cyclophosphamide, adriamycin, 5-FU and tamoxifen (CAFT) is superior to tamoxifen alone in postmenopausal receptor (+), node (+) breast cancer:new findings from phase In Southwest Oncology Group Intergroup Trial S8814 (INT O100). Proc Am Soc Clin Oncol 20:24a, 2001 (abstr)
 
24) Fisher B, Redmond C, Legault-Poisson S, et al:Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen:results from the National Surgical A adjuvant Breast and Bowel Project B-16. J Clin Oncol 8:1005-1018, 1990
PubMed
25) Fisher B, Dignam J, Wolmark N, et al:Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 89:1673-1682, 1997
PubMed
26) Albain KS, Green SJ, Ravdin PM, et al:Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent:initial results from intergroup trial O100 (SWOG-8814). Proc Am Soc Clin Oncol 21:37a, 2001 (abstr)
 
27) Early Breast Cancer Trialists:Collaborative Group:Ovarian ablation in early breast cancer:overview of the randomized trials. Lancet 348:1189-1196, 1999
 
28) Aebi S, Gelber S, Castiglione-Gertsch M, et al:Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 355:1869-1874, 2000
PubMed
29) Taylor CW, Green S, Dalton WS, et al:Multicentere randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer:An intergroup study. J Clin Oncol 16:994-999, 1998
 
30) Klijn JGM, Blamey RW, Boccardo F, et al:Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer:ameta-analysis of four randomized trials. J Clin Oncol 19:343-353, 2001
 
31) Jonat W, Kaufmann M, Sauerbrei W, et al:Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer:The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 20:4628-4635, 2002
PubMed
32) Jakesz R, Hausmaninger H, Kubista E, et al:Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil:evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer-Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol 20:4621-4627, 2002
 
33) Nabholtz JM, Buzdar A, Pollak M, et al:Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women:results of a north american multicenter randomized trial. J Clin Oncol 18:3758-3767, 2000
 
34) Bonneterre J, Thurlimann B, Robertson JF, et al:Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women:results of the tamoxifen or arimidex randomized group efficacy and tolerability study. J Clin Oncol 18:3748-3767, 2000
PubMed
35) Mouridsen H, Gershanovich M, Sun Y, et al:Superior efficacy of letrozole (Femara) versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer:rsults of a phase m study of the International Letrozole Breast Cancer Group. J Clin Oncol 19:2596-2606, 2001
 
36) The ATAC trialists:group:Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer:first results of the ATAC randomised trial. Lancet 359:2131-2139, 2002
 
37) Fisher B, Constantino JP, Wickerham DL, et al:Tamoxifen for prevention of brast cancer:report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 90:1371-1388, 1998
 
38) Hortobagy GN:Treatment of Breast Cancer. N Engl JMed 339:974-984, 1998
 
39) Falkson G, Gelman RS, Tormey DC, et al:Treatment of metastatic breast cancer in premenopausal women using CAF with or without oophorectomy:an Eastern Cooperative Oncology Group Study. J Clin Oncol 5:881-889, 1987
 
40) Clark GM, McGuire WL:Steroid receptors and other prognostic factors in primary breast cancer. Semin Oncol 15:20-25, 1988
PubMed
41) Fossati R, Confalonierie C, Torri V, et al:Cytotoxic and hormonal treatment for metastatic breast cancer:asystematic review of published randomized trials involving 31, 510 women. J Clin Oncol 16:3439-3460, 1998
 
42) Kaufmann M, Baj etta E, Dirix LY, et al:Exemestane Is Superior to Megestrol Acetate After Tamoxifen Failure in Postmenopausal Women With Advanced Breast Cancer:Results of a Phase III Randomized Double-Blind Trial. J Clin Oncol 18:1399-1411 2000
 
43) Stuart NS, Warwick J, Blackledge GR, et al:A randomized phase III cross-over study of tamoxifen versus megesterol acetate in advanced and recurrent breast cancer. Eur J Cancer 32A:1888-1892, 1996
 
44) Van Veelen H, Willemense PHB, Tj abbes T, et al:Oral high-dose medroxyprogesterone acetate versus tamoxifen. A randomized cross-over trial in postmenopausal patients with advanced breast cancer. Callcer 58:7-13, 1986
 
45) Geels P, Eisenhauer E, Bezjak A, et al:Palliative Effect of Chemotherapy:Objective Tumor Response is Associated with Symptom Improved in Patients with Metastatic Breast Cancer. J Clin Oncol 18:2395-2405, 2000
 
46) Tranum BL, McDonald B, Thigpen T, et al:Adriamycin combinations in advanced breast cancer. A Southwest Oncology Group Study. Cancer 49:835-839, 1982
 
47) Smalley RV, Lefante J, Bartolucci A, Carpenter J, et al:A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednidolone (CMFVP) in patients with advanced breast cancer. Breast Cancer Res Treat 3:209-220, 1983
 
48) Aisner J, Weinberg V, Perloff M, Weiss R, et al:Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each+/-MER) for metastatic carcinoma of the breast:aCALGB study. Cancer and Leukemia Group B. J Clin Oncol 5:1523-1533, 1987
 
49) Fossati R, Confalonieri C, Torri V, et al:Cytotoxic and hormonal treatment for metastatic breast cancer:asystematic review of published randomized trials involving 31, 510 women. J Clin Oncol 16:3439-3460, 1998
 
50) Cocconi G, Fossati R, Confalonieri C, et al:Chemotherapy With and Without Anthracycline. J Clin Oncol 18:1392-1393, 2000
 
51) French Epirubicin Study Group:Aprospective randomized phase m trial comparing with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. J Clin Oncol 6:679-688, 1988
PubMed
52) Perez DJ, Harvey VJ, Robinson BA, et al:A randomized comparison of single-agent doxorubicin and epirubicin as first-line cyctotoxic therapy in advanced breast cancer. J Clin Oncol 9:2148-2152, 1991
 
53) Stewart DJ, Evans WK, Shepherd FA, et al:Cyclophosphamide and fluorouracil combined with mitozantrone versus doxom[bicin for breast cancer:superiority of doxorubicin. J Clin Oncol 15:1897-1905, 1997
 
54) Hortobagyi GN, Bodey GP, Buzdar AU, et al:Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units:aprospective randomized study. J Clin Oncol 5:354-364, 1987
 
55) Focan C, Andrien JM, Closon MT, et al:Dose-response relationship of epirubicin-based first-1ine chemotherapy for advanced breast cancer:a prospective randomized trial. J Clin Oncol 11:1253-1263, 1993
 
56) Dieras V, Marty M, Tubiana N, et al:Phase H randomized study of paclitaxel versus mitomycin in advanced breast cancer. Semin Oncol 22:33-39, 1995 (Suppl 8)
 
57) Nabholtz JM, Senn HJ, Bezwoda WR, et al:Prospective Randomized Trial of Docetaxel Versus Mitomycin Plus Vinblastine in Patients With Metastatic Breast Cancer Progressing Despite Previous Anthracycline-Containing Chemotherapy. J Clin Oncol 17:1413-1424, 1999
PubMed
58) Paridaens R, Biganzoli L, Bruning P, et al:Paclitaxel Versus Doxorubicin as First-Line Sigle-Agent Chemotherapy for Metastatic Breast Cancer:AEuropean Organization for Research and Treatment of Cancer Randomized Study With Cross-Over. J Clin Oncol 18:724-733, 2000
 
59) Chan S, Friedrichs K, Noel D, et al:Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group. J Clin Oncol 17:2341-2354, 1999
 
60) Jassem J, Pienkowski T, Pluzanska A, et al:Doxorubicin and Paclitaxel Versus Fluorouracil, Doxorubicin, and Cyclophosphamide as First-1. ine Therapy for Women With Metastatic Breast Cancer:Final Results of a Randomized Phase III Multicenter Trial. J Clin Oncol 19:1707-1715, 2001
 
61) Mackey JR, Paterson A, Dirix LY, et al:Final results of the phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclo-phosphamide (C) to FAC as frrst lne chemotherapy (CT) for patients (pts) with metastatic bre cancer (MBC). Proc Am Soc Clin Oncol 21:35a, 2001 (abstr)
 
62) Smith RE, Brown AM, Mamounas EP, et al:Randomized Trial of 3-Hour Versus 24-Hour Infusion of High-Dose Paclitaxel in Patients With Metastatic or Locally Advanced Breast Cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-26. J Clin Oncol 17:3403-3411, 1999
PubMed
63) Winer E, Berry D, Duggan D, Henderson IC, et al:Failure of Higher Dose Paclitaxel to Improve Outcome in Pateints With Metastatic Breast Cancer-Results from CALGB 9342. Proc Am Soc Clin Oncol 17:101a, 1998 (abstr)
 
64) Salminen E, Bergman E, Huhtala S, et al:Docetaxel:Standard Recommended Dose of 100 mg/m21s Effective But Not Feasible for Some Metastatic Breast Cancer Patients Heavily Pretreated With Chemotherapy-A Phase H Single-Center Study. J Clin Oncol 17:1127-1131, 1999
 
65) Ando M, Watanabe T, Nagata K, et al:Efficacy of Docetaxel 60 mg/m2 in Patients With Metastatic Breast Cancer According to the Status of Anthracycline Resistance. J Clin Oncol 19:336-342, 2001
 
66) Perez EA, Vogel CL, Irwin DH, et al:Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 19:4216-4223, 2001
 
67) Burstein HJ, Manola J, Younger J, et al:Docetaxel Administered on a Weekly Basis for Metastatic Breast Cancer. J Clin Oncol 18:1212-1219, 2000
PubMed
68) Smith RE, Powles TJ:MMM (mitomycir V-mitoxantrone/methotrexate):an effective new regimen in the treatment of metastatic breast cancer. Oncology 50:9-15, 1993
 
69) Jones SE, Mennel RG, Brooks B, et al:Phase H study of mitoxantrone, leucovorin, and infusional fluorouracil for treatment of metastatic breast cancer. J Clin Oncol 9:1736-1739, 1991
 
70) Blum JL, Jones SE, Buzdar AU, et al:Amulticenter phase H study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17:485-493, 1999
 
71) Weber BL, Vogel C, Jones S, et al:Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol 13:2722-2730, 1995
PubMed
72) Muss HB, Case LD, Richards F 2nd, et al:Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. N Engl J Med 325:1342-1348, 1991
PubMed
73) Coates A, Gebski V, Bishop JF, et al:Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med 317:1490-1495, 1987
PubMed
74) Salmon DJ, Leyland-Jones B, Shak S, et al:Use of chemohterapy plus a monoclonal antibody against HER2 for metastatic breast cancer that Overexpresses HER2. N Engl J Med 344:783-792, 2001
 
75) Vogel CL, Cobleigh MA, Tripathy D, et al:Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer. J Clin Oncol 20:719-726 , 2002
PubMed
76) Seidman AD, Fomier MN, Esteva FJ, et al:Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by HER2 1mmunophenotype and Gene Arnplification. J Clin Oncol 19:2587-2595, 2001
 
77) Burstein HJ, Kuter I, Campos SM, et al:Clinical Activity of Trastuzumab and Vinorelbine in Women With HER2-Overexpressing Metastatic Breast Cancer. J Clin Oncol l 9:2722-2730, 2001
 
P.324 掲載の参考文献
1) Early Breast Cancer Trialists:Collaborative Group:Polychemotherapy for early breast cancer:an overview of the randomised trials. Lancet 352:930-942, 1998
 
2) The National Institute of Health Consensus Development Conference:Adjuvant Therapy for Breast Cancer. J Natl Cancer Inst Monographs 30:1-152, 2001
 
3) Goldhirsch A, et al:Meeting highlights:International Consensus Panel on the 1. Treatment of Primary Breast Cancer. Seventh International Conference on 3. Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 19:3817-3827, 2001
 
4) Levine MN, et al:Arandomized trial comparing 12weeks versus 36 weeks of 4. adjuvantchemotherapy in stage II breast cancer. J Clin Oncol 8:1217-1225, 1990
 
5) 1ntemational Breast Cancer Study Group:Durationand reintroduction of a adjuvant chemotherapy fornode-positive premenopausal breast cancerpatients. J Clin Oncol 14:1885-1894, 1996
 
6) Fisher B, et al:Two months of doxorubicincyclophosphamide with and without intervalreinduction therapy compared with 6 months ofcyclophosphamide, methotrexate, andfluorouracil in positive-node breast cancerpatients with tamoxifen-nonresponsive tumors:results from the National Surgical Adjuvant Breastand Bowel Prject ject B-15. J Clin Oncol 8:1483-1496, 1990
 
7) Fisher B, et al:Increased intensification and totaldose of cyclophosphamide in a doxorubicincyclophosphamide regimen for the treatment ofprimary breast cancer:findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 15:1858-1869, 1997
 
8) Budman DR, et al:Dose and dose intensity asdetenminants of outcome in the adjuvant treatmentof breast cancer. The Cancer and Leukemia GroupB J Natl Cancer lnst 90:1205-1211, 1998
 
9) Henderson IC, et al:Improved Disease-Free And Overall Survival From The Addition of Sequential Paclitaxel But Not From The Escalation of Adriamycin Dose Level in The Adjuvant Chemotherapy of Patients With Node-Positive Primary Breast Cancer. Proc Am Soc Clin Oncol 17:101a (abstr390A), 1998
PubMed
10) Citron M, et al:Superiority of dose-dense (DD) over conventional scheduling (CS) and equivalence of sequential (SC) vs. combination adjuvant chemotherapy (CC) for node-positive breast cancer (CALGB 9741, INT C9741). The Sam Antonio Breast Cancer Symposium#15, 2002
 
11) 伊藤良則:タキサン系薬剤-適応とレジメン-泉雄勝 編:乳癌診療の最前線, 癌の臨床46:725-731, 2000
 
12) Nabholtz J-M, et al:Phase m trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5fluorouracil, doxorubicin, cyclophosphamide) in the a adjuvant treatment of node positive breast cancer (BC) patients:interim analysis of the BCIRG OOI study Proc Am Soc Clin Oncol 21:36a (abstr 141), 2002
 
13) Fisher B, et al:Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer J Natl Cancer Inst 89:1673-1682, 1997
PubMed
14) Hutchins L, et al:CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients:Firstresults of Intergroup Trial INT O102. Proc Am Soc Clin Oncol 17:1a (abstr2), 1998
 
P.329 掲載の参考文献
1) 医療のリスクマネジメント構築に関する研究.平成11年度医療技術評価総合研究事業総括報告書 2000
 
2) 川村治子:注射エラーの発生要因とその対策看護の注射に関するニアミス多数事例の分析から-癌と化療 28:304-309, 2001
 
3) 特集セーフティーマネージメント (第10回日本乳癌学会総会より) .乳癌の臨床 17 (5):2002
 
P.335 掲載の参考文献
1) Early Breast Cancer Trialists:Collaborative Group:Tamoxifen for early breast cancer:an ovelview of randomized trials. Lancet 351:1451-1467, 1998
 
2) Early Breast Cancer Trialists:Collaborative Group:Polychemotherapy for early breast cancer:an overview of randomized trials. Lancet 352:930-942, 1998
 
3) Goldhirsh A, Glick JH, Gelber RD, et al:Meeting Highlights:International consensus panel on the treatment of primary breast cancer. J Clin Oncol 19:3817-3827, 2001
 
4) Jakesz R, Hausmaninger H, Kubista E, et al:Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil:Evidence for the superiority of treatment with endocrine blockade in premonopausal patients with hormone-responsive breast cancer-Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol 20:4621-4627, 2002
 
5) Houghton J, Baum M, Rutqvist B, et al:The ZIPP trial of adjuvant Zoladex in premenopausal patients with early breast cancer:An update at 5 years. Proceedings of ASCO 2000:93a, #359, 2000
 
6) Jonat W, Kaufmann M, Sauerbrei W, et al:Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer. J Clin Oncol 20:4628-4635, 2002
PubMed
7) Davidson N, O'Nill A, Vukov A, et al:Effect of chemohormonal therapy in premenopausal, node (+), receptor (+) breast cancer:An Eastern Cooperative Oncology Group Phase III Trial (E5188, INT-0101). Proceedings of ASCO 99:67a, #249, 1999
 
8) The ATAC Trialists:Group:Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer:first results of the ATAC randomized trial. Lancet 359:2131-2139, 2002
 
9) Early Breast Cancer Trialists, Collaborative Group:Analysis of overview results. Presented at the fifth meeting of Early Breast Cancer Trialists:Collaborative Group, Oxford, United Kingdom, September 21-23, 2000
 
10) D'Ozario AI:Paclitaxel in the adjuvant settings:Results so far are inconclusive. Clinical Breast Cancer April 27-29, 2001
 
11) Nabholtz JM, Pienkowski T, Mackey J, et al:Phase III trial comparing TAC with FAC in adjuvant treatment of node positive breast cancer patients:iterium analysis of the BCIRG 001 study. Proceedings of ASCO 21:36a, #141, 2002
 
12) Kasumi F, Yoshimoto M, Uchino J, et al:Meta-analysis of five studies on tegafur plus uracil (UFT) as post-operative adjuvant chemotherapy for breast cancer. Oncology 64:146-153, 2003
PubMed
13) Tan-Chiu E, Piccart M:forward:Herceptin in the a adjuvant setting. Oncology 63:57-63, 2002
PubMed

第11章 放射線療法

P.339 掲載の参考文献
1) The Japanese Breast Cancer Society:Results of questionnaires concerning breast cancer surgery in Japan:an update in 2000. Breast Cancer 9:1,2002
 
2) Joslyn SA:Radiation therapy and patient age in the survival from early-stage breast cancer.Int J Radiat Oncol Biol Phys 44:821-826,1999
PubMed
3) Schnitt SJ, Hayman J, Gelman R, et al:A prospective study of conservative surgery alone in the treatment of selected patients with stage I breast cancer. Cancer 77:1094-1100,1996
 
4) Veronesi U, Salvadori B, Luini A, et al:Breast conservation is a safe method in patients with small cancer of the breast. Long-term results of three randomised trials on 1,973 patients. Eur J Cancer 31A:1574-1579,1995
PubMed
5) Liljegren G, Holmberg L, Bergh J, et al:10-Year results after sector resection with or without postoperative radiotherapy for stage I breast cancer:arandomized trial. J Clin Oncol 17:2326-2333,1999
 
6) Keisch M, Vicini F, Kuske RR, et al:Initial clinical experience with the Mammo Site breast brachytherapy applicator in women with early-stage breast cancer treated with breast-conserving therapy.Int J Radiat Oncol Biol Phys 55:289-293, 2003
 
7) Vicini FA, Chen PY, Fraile M, et al:Low-dose-rate brachytherapy as the sole radiation modality in the management of patients with early-stage breast cancer treated with breast-conserving therapy:preliminary results of a pilot trial.Int J Radiat Oncol Biol Phys 38:301-310,1997
PubMed
8) Wazer DE, Berle L, Graham R, et al:Preliminary results of a phase I/II study of HDR brachytherapy alone for T1/T2 breast cancer.Int J Radiat Oncol Biol Phys 53:889-897,2002
PubMed
9) Baglan KL, Martinez AA, Frazier RC, et al:The use of high-dose-rate brachytherapy alone after lumpectomy in patients with early-stage breast cancer treated with breast-conserving therapy. In J Radiat Oncol Biol Phys 50:1003-1011,2001
 
10) Veronesi U, Orecchia R, Luini A, et al:A preliminary report of intraoperative radiotherapy (IORT)in limited-stage breast cancers that are conservatively treated. Eur J Cancer 37:2178-2183, 2001
PubMed
11) Vaidya JS, Baum M, Tobias JS, et al:Targeted intraoperative radiotherapy (Targit):an innovative method of treatment for early breast cancer. Ann Oncol 12:1075-1080,2001
PubMed
12) Fisher B, Anderson S, Redmond CK, et al:Reanalysis and results after 12 years of follow-up in arandomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 333:1456-1461,1995
PubMed
13) Forrest AP, Stewart HJ, Everington D, et al:Randomised controlled trial of conservation therapy for breast cancer:6-year analysis of the Scottish trial. Scottish Cancer Trials Breast Group.Lancet 348:708-713,1996
PubMed
14) Clark RM, Whelan T, Levine M, et al:Randomized clinical trial of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer:an update. Ontario Clinical Oncology Group. J Natl Cancer Inst 88:1659-1664,1996
 
15) Renton SC, Gazet JC, Ford HT, et al:The importance of the resection margin in conservative surgery for breast cancer. Eur J Surg Oncol 22:17-22,1996
PubMed
P.344 掲載の参考文献
1) Freedman G, Fowble B, Hanlon A, et al:Patients with early stage invasive cancer with close or positive margins treated with conservative surgery and radiation have an increased risk of breast recurrence that is delayed by adjuvant systemic therapy. Int J Radiat Oncol Biol Phys 44:1005-1015, 1999
PubMed
2) Smitt MC, Nowels KW, Zdeblick MJ, et al:The importance of the lumpectomy surgical margin status in long-term results of breast conservation. Cancer 76:259-267, 1995
PubMed
3) Solin LJ, Fowble BL, Schultz DJ, et al:The significance of the pathology margins of the tumor excision on the outcome of patients treated with definitive irradiation for early stage breast cancer. Int J Radiat Oncol Biol Phys 21:279-287, 1991
PubMed
4) Fisher B, Anderson S, Bryant J, et al:Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347:1233-1241, 2002
PubMed
5) Early Breast Cancer Trialists:Collaborative Group:Favourable and unfavourable effects on long-temm survival of radiotherapy for early breast cancer:an overview of the randomised trials. Lancet 355:1757-1770, 2000
 
6) Ribeiro GG, Magee B, Swindell R, et al:The Christie Hospital breast conservation trial:an update at 8 years from inception. Clin Oncol 5:278-283, 1993
PubMed
7) Whelan T, MacKenzie R, Julian J, et al:Randomizedtrial of breast irradiation schedules afterlumpectomy for women with lymph node-negativebreast cancer. J Natl Cancer Inst 94:1143-1150, 2002
 
8) Romestaing P, Lehingue Y, Carrie C, et al:Role of a 10-Gy boost in the conservative treatment of earlybreast cancer:results of a randomized clinical trialin Lyon, France. J Clin Oncol 15:963-968, 1997
 
9) Bartelink H, Horiot JC, Poortmans P, et al:Recurrence rates after treatment of breast cancerwith standard radiotherapy with or without additional radiation. N Engl J Med 345:1378-1387, 2001
PubMed
10) Fisher B, Redmond C, Fisher ER, et al:Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 312:674-681, 1985
PubMed
11) Das IJ, Cheng CW, Fein DA, et al:Pattems of dose variability in radiation prescription of breast cancer. Radiother Oncol 44:83-89, 1997
 
12) van Tienhoven G, van Bree NA, Mljnheer BJ, et al:Quality assurance of the EORTC trial 22881/10882:"assessment of the role of the booster dose in breast conserving therapy":the Dummy Run. EORTC Radiotherapy Cooperative Group. Radiother Oncol 22:290-298, 1991
 
13) Recht A, Come SE, Henderson IC, et al:The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med 334:1356-1361, 1996
PubMed
14) 関口建次:乳房温存療法 X線シミュレータを用いた照射手技.臨床放射線45:1393-1403, 2000
 
15) Klein EE, Taylor M, Michaletz-Lorenz M, et al:A mono isocentric technique for breast and regional nodal therapy using dual asymmetric jaws. Int J Radiat Oncol Biol Phys 28:753-760, 1994
PubMed
16) Solin LJ, Kurtz J, Fourquet A, et al:Fifteen-year results of breast-conserving surgery alld definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast. J Clin Oncol 14:754-763, 1996
 
17) Fisher B, Dignam J, Wolmark N, et al:Lumpectomy and radiation therapy for the treatment of intraductal breast cancer:findings from National Surgical A (lluvant Breast and Bowel Project B-17. J Clin Oncol 16:441-452, 1998
PubMed
18) Julien JP, Bijker N, Fentiman IS, et al:Radiotherapy in breast-conserving treatment for ductal carcinoma in situ:first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radio therapy Group. Lancet 355:528-533, 2000
 
19) Fisher B, Dignam J, Wolmark N, et al:Tamo) dfen in treatment of intraductal breast cancer:National Surgical A adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353:1993-2000, 1999
 
20) Morrow M, Strom EA, Bassett LW, et al:Standard for the management of ductal carcinoma in situ of the breast (DCIS) . CA Cancer J Clin 52:256-276, 2002
PubMed
P.351 掲載の参考文献
1) Early Breast Cancer Trialists:Collaborative Group:Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer:an overview of the randomised trials. 1 Lancet 355:1757-1770, 2000
 
2) Overgaard M, Christensen JJ, Johansen H, et al:Postmastectomy irradiation in high-risk breast cancer patients. Present status of the Danish Breast Cancer Cooperative Group trials. Acta Oncol 27:707-714, 1988
PubMed
3) Overgaard M, Hansen PS, Overgaard J, et al:Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 337:949-955, 1997
 
4) Ragaz J, Jackson SM, Le N, et al:Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl JMed 337:956-962, 1997
 
5) Tennvall-Nittby L, Tengrup I, Landberg T:The total incidence of loco-regional recurrence in a randomized trial of breast cancer TNM stage II. The South Sweden Breast Cancer Trial. Acta Oncol 32:641-646, 1993
 
6) Griem KL, Henderson IC, Gelman R, et al:The 5-year results of a randomized trial of adjuvantradiation therapy after chemotherapy in breastcancer patients treated with mastectomy. J Clin Oncol 5:956-962, 1987
 
7) Velez-Garcia E, Moore M, Vogel CL, et al:Postmastectomy adjuvant chemotherapy with orwithout radiation therapy in women with operablebreast cancer and positive axillary lymph nodes:the Southeastem Cancer Study Group experience. Breast Cancer Res Treat 3:S49-60, 1983
 
8) Cuzick J, Stewart H, Rutqvist L, et al:Causespecific mortality in long-teum survivors of breastcancer who participated in trials of radiotherapy. J Clin Oncol 12:447-453, 1994
 
9) Recht A, Edge SB, Solin L J, et al:Postmastectomyradiotherapy:clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1539-1569, 2001
 
10) Dubey A, Recht A, Come SE, et al:Concurrent CMF and radiation therapy for early stage breast cancer:results of a pilot study. Int J Radiat Oncol Biol Phys 45:877-884, 1999
PubMed
11) Markiewicz DA, Fox KR, Schultz DJ, et al:Concurrent chemotherapy and radiation for breast conservation treatment of early-stage breast cancer. Cancer J Sci Aln 4:185-193, 1998
 
12) Stefanik D, Goldberg R, Byrne P, et al:Local-regional failure in patients treated with adjuvan chemotherapy for breast cancer. J Clin Oncol 3:660-665, 1985
 
13) Harris JR, Halpin-Murphy P, McNeese M, et al:Consensus Statement on postmastectomy radiation therapy. Int J Radiat Oncol Biol Phys 44:989-990, 1999
PubMed
14) Marks LB, Herbert ME, Bentel G, et al:To treat or not to treat the internal mammary nodes;a possible compromise. Int J Radiat Oncol Biol Phys 29:903-909, 1994
PubMed
15) Holland R, Connolly J, Gelman R, et al:The presence of an extensive intraductal component following a limited excision correlates with prominent residual disease in the remainder of the breast. J Clin Oncol 8:113-118, 1990
PubMed
16) Chu JCH, Solin LJ, Hwang CC, et al:Anondivergent three field matching technique for breast irradiation. Int J Radiat Oncol Biol Phys 19:1037-1040, 1990
 

第12章 疫学・予防と患者ケア

P.357 掲載の参考文献
1) The Research Group for Population-based Cancer Registration in Japan:Cancer incidence and incidence rates in Japan in 1997:Estimates based on data from 12 population-based cancer registries. Jpn J Clin Oncol 32:318-322, 2002
 
2) 厚生統計協会 (編):国民衛生の動向.臨時増刊 49 (9):2002
 
3) Quinn M, Babb P, Brock A, et al:Caner trends in England and Wales 1950-1999. Studies on Medical and Population Subjects No. 66. The Stationery Office, London, 2001
 
4) Howe HL, Wingo PA, Thun MJ, et al:Annual report to the Nation on the Status of Cancer (1973-1998), featuring cancers with recent increasing trends. J Natl Cancer lnst 93:824-842, 2001
 
5) 厚生労働省大臣官房統計情報部編:平成12年都道府県別年齢調整死亡率, 人口動態特殊報告2002
 
6) 厚生労働省大臣官房統計情報部編:平成7年都道府県別年齢調整死亡率, 人口動態特殊報告1997
 
7) 大阪府健康福祉部, 大阪府医師会, 大阪府立成人病センター:大阪府におけるがん登録第65報.大阪府, 2002
 
8) Parkin DM, Whelan SL, Ferlay J, et al (eds):Cancer Incidence in Five Continents, Vol. VII. IARC Scientific Publication No. 143, IARC, Lyon, 1997
 
9) U. S. Department of Health and Human Services:SEER*Stat 4. 2, SEER Cancer Incidence Public-Use Database, 1973-99. NIH, Bethesda, 2001
 
10) 北川貴子, 津熊秀明, 味木和喜子ほか:日本のがん罹患の将来の予測-1975-93年全国罹患率 (推計値) に基づく将来推計.がん・統計白書-罹患/死亡/予後-1999, p159-170, 篠原出版, 東京, 1999
 
11) Fisher B, Costantino JP, Wickerham DL, et al:Tamoxifen for prevention of breast cancer:report of the National Surgical A (lluvant Breast and Bowel Pr (>ject P-1 Study. J Natl Cancer Inst 90:1371-1388, 1998
 
12) Ueda K, Tsukuma H, Tanaka H, et al:Estimation of individualized probabilities of developing breast cancer for Japanese women. Breast Cancer 10:54-62, 2003
PubMed
P.363 掲載の参考文献
1) Parkin DM, et al:Cancer Incidence in Five Continents, Vol. 7, IARC Scientific Publication 143, IARC, Lyon, 1997
 
2) Kelsey JL, Gammon MD, John EM:Reproductive factors and breast cancer. Epidemiol Rev 15:36-47, 1993
PubMed
3) McPherson K, Steel CM, Dixon JM:Breast cancer-epidemiology, risk factors, and genetics. BMJ 321:624-628, 2000
PubMed
4) Lipworth L, Bailey LR, Trichopoulos D:History of breast-feeding in relation to breast cancer risk:a review of the epidemiologic literature. J Natl Cancer Inst 92:302-312, 2000
 
5) Hirose K, Tajima K, Hamajima N, et al:Alarge-scale, hospital-based case-control study of risk factors of breast cancer according to menopausal status. Jpn J Cancer Res 86:146-154, 1995
 
6) Hirose K, Tajima K, Hamajima N, et al:Impact of family history on the risk of breast cancer among the Japanese. Jpn J Cancer Res 88:1130-1136, 1997
PubMed
7) Hirose K, Tajima K, Hamajima N, et al:Effect of body size on breast-cancer risk among Japanese women. Int J Cancer 80:349-355, 1999
PubMed
8) Hirose K, Tajima K, Hamajima N, et al:Impact of established risk factors for breast cancer in nulligravid Japanese women. Breast Cancer 10:45-53, 2003
PubMed
9) Hirose K, Tajima K, Hamajima N, et al:Association of family history and other risk factors with breast cancer risk among Japanese premenopausal and postmenopausal women. Cancer Causes Control 12:349-358, 2001
PubMed
10) Hunter DJ, Willett WC. Diet, body build, and breast cancer. Annu Rev Nutr 14:393-418, 1994
PubMed
11) Suga K, Imai K, Eguchi H, et al:Molecular significartce of excess body weight in postmenopausal breast cancer patients, in relation to e) q) ression of insulin-like growth factor I receptor and insulin-like growth factor n genes. Jpn J Cancer Res 92:127-134, 2001
 
12) Nagata C, Shimizu H, Takami R, et al:Relations of insulin resistance and serum concentrations of estradiol and sex hormone-binding globulin to potential breast cancer risk factors. Jpn J Cancer Res gl:948-953, 2000
 
13) Hirose K, Hamaj ima N, Takezaki T, et al:Physical exercise reduces risk of breast cancer in Japanese women. Canncer Science 94:193-199, 2003
 
14) World Cancer Research Fund and American Institute for Cancer Research:Food, Nutrition and the Prevention of Cancer:AGlobal Perspective. The American Institute for Cancer Research, Washington DC, p252-287, 1997
 
15) Gandini S, Merzenich H, Robertson C, et al:Meta-analysis of studies on breast cancer risk and diet:the role of fruit and vegetable consumption and the intake of associated micronutrients. Eur J Cancer 36:636-646, 2000
PubMed
16) Smith-Warner SA, Spiegelman D, Yaun SS, et al:Intake of fruits and vegetables and risk of breast cancer:apooled analysis of cohort sutides. JAMA 285:769-776, 2001
 
17) Smith-Wamer SA, Spiegelman D, Adami H-0, et al:Types of dietary fat and breast cancer:Apooled analysis of cohort studies. Int J Cancer 92:767-774, 2001
 
18) Trichopoulous A, Katsouyanni K, Stuver S, et al:Consumption of olive oil and specific food groups in relation to breast cancer in Greece. J Natl Cancer Inst 87:110-116, 1995
 
19) Kaizer L, Boyd NF, Kriukov V, et al:Fish consumption and breast cancer risk:an ecological study. Nutr Cancer 12:61-68, 1989
PubMed
20) Ellison RC, Zhang Y, McLennan CE, et al:Exploring the relation of alcohol consumption to risk of breast cancer. Am J of Epidemiology 154:740-747, 2001
 
21) Collaborative Group on Hormonal Factors in Breast Cancer:Breast cancer and hormone replacement therapy:collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 350:1047-1059, 1997
 
22) Rossouw JE, Anderson GL, Prentice RL, et al:Risks and benefits of estrogen plus progestin in healthy postmenopausal women:principal results from the Women's Health Initiative randomized control trial. JA]>LA 288:321-333, 2002
 
23) Preston DL, Pierce DA, Shimizu Y:Age-time patterns for cancer and noncancer excess risks in the atomic bomb survivors. Radiat Res 154:734-735, 2000
 
24) 黒石哲生:日本の乳癌の動向とリスク因子.癌の臨床46:423-431, 2000
 
P.369 掲載の参考文献
1) Susan M Love:Living with Breast Cartcer. Life after breast cancer. The follow-up. Dr Susan Love's Breast Book. third edition. Perseus, USA, p517-521, 2000
 
2) Yamamoto N, Katsumata N, Watanabe T, et al:Clinical characteristics of patients with metastatic breast cancer with complete remission following systemic treatment. Jpn J Clin Oncol 28:368-373, 1998
PubMed
3) Tomin R, Donegan WL:Screening for recurrent breast cancer-Its effectiveness and prognostic value. J Clin Oncol 5:62-67, 1987
PubMed
4) Zwaveling A, Albers GH, Felthuis W, et al:An evaluation of routine follow-up for detection of breast cancer recurrences. J Surg Oncol 34:194-197, 1987
PubMed
5) Stierer M, Rosen HR:Infiuence of early diagnosis on prognosis of recurrent breast cancer. Cancer 64:1128-1131, 1989
 
6) 三浦重人:術後追跡-私の考え方.乳癌の臨床4:181-190, 1989
 
7) Del Turco MR, Palli D, Cariddi A, et al:Intensive diagnostic follow-up after treatment of primary breast cancer. Randomized trial. JAMA 271:1593-1597, 1994
 
8) The GIVIO investigators:Impact of follow-up testing on survival alld health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. JAMA 271:1587-1592, 1994
 
9) Smith TJ, Davidson NE, Schapira DV, et al:American society of clinical oncology 1998 update of recommended breast cancer surveillance guidelines. J Clin Oncol 17:1080-1082, 1999
 
10) Schapira DV, Urban N:Aminimalist policy for breast cancer surveillance. JAMA 265:380-382, 1991
PubMed
11) Ciatto S, Cataliotti I., Pacini P, et al:Cancer recurrence in the conserved breast:Diagnostic features in a consecutive series of 102 cases. Intl J Oncol 3:337-339, 1993
 
12) Bissett D, Davis JA, George WD:Gynecological monitoring during tamoxifen therapy. Lancet 344:1244, 1994
 
13) Fisher B, Costantino JP, Redmond CK, et al:Endometrial cancer in tamoxifen-treated breast cancer patients;Findings from National Surgical A adjuvant Breast and Bowel Project (NSABP) B-14. JNatl Cancer Inst 86:527-537, 1994
PubMed
14) ACOG committee opinion:Tamoxifen and endometrial cancer. Committee opinion on gynecological practice. American College of Obstetricians and Gynecologists. Number 169, February 1996
 
15) Pedrazzini A, Gelbes R, Isley M, et al:First repeated bone scan in the observation of patients with operable breast cancer. J Clin Oncol 4:389-394, 1986
 
16) Bast RC, Ravdin P, Hayes DF, et al:2000 update of recommendations for the use of tumor markers in breast and colorectal cancer:clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1865-1878, 2001
 
17) 雄西智恵美:手術を受ける乳がん患者の希望に関する研究.平成3年度北里大学大学院看護学研究科修士論文, 1994
 
18) 雄西智恵美:術後 (退院後) の日常生活とフォローアップ.がん看護 2 (2) p97-102, 1997
 
19) Harris JR, Lippman ME, Morrow M, et al:Disease of the Breast, second edition, Lippincott Williams & Wilkins, p 1035, 2000
 
20) Gelber S, Coates AS, Goldhirsch A, et al:Effect of pregnancy on Overall survival after the diagnosis of early-stage breast cancer. J Clin Oncol 19:1671-1675, 2001
 
P.375 掲載の参考文献
1) Hensley ML, Reichman:Fertility and pregnancy after adjuvant chemotherapy for breast cancer. Critical Reviews in Oncology/Hematology 28:121-128, 1998
PubMed
2) Collicio FA, Agnello R, Staltzer J:Pregnancy after breast cancer:From psychosocial issues through conception. Oncology 12:759-769, 1998
 
3) Koyama H, Wada T, Nishizawa Y, et al:Cyclo-phosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer 39:1403-1409, 1977
 
4) Sutton R, Buzdar AU, Hortobagyi GN:Pregnancy and offspring after adjuvant chemotherapy in breast cancer patients. Cancer 65:847-850, 1990
PubMed
5) Surbone A, Petrek J:Childbearing issues in breast carcinoma survivors. Cancer 79:1271-1278, 1997
PubMed
6) Raybum WF:Recommendations during pregnancy:An Evidence-based approach. Clin Obst and Gyne 45:1-5, 2002
 
7) Ebert U, Loffler H, Kirch W:Cytotoxic therapy and pregnancy. Pharmacol Ther 74:207-220, 1997
PubMed
8) 加藤健志, 高塚雄―, 津村 勲 ほか:乳癌術後妊娠の検討.乳癌の臨床6:561-565, 1991
 
9) Reichman BS, Green KB:Breast cancer in young women:Effect of chemotherapy on ovarian function, fertility and birth defects. J Natl Cancer Inst 16:125-129, 1994
 
10) Malmmos NA, Stathopulos GP, Keramopolos, et al Pregnancy and Offspring after the appearance of breast cancer. Oncology 53:471-475, 1996
 
11) Helewa M, Levesque P, Provencher D, et al:Breast cancer, pregnancy, and breastfeeding. J Obstet Gynaecol Can 24:164-180, 2002
PubMed
12) 土屋敦雄, 福富隆志, 野水 整 ほか:乳癌手術後の妊娠-全国のアンケート調査より-乳癌の臨床 9:129-134, 1994
Medical*Online
13) 河村節子, 対馬健―, 坂田 優:癌化学療法後の妊娠と出産.癌と化学療法 23:821-826, 1996
Medical*Online
14) Recchia F, Sica G, De Filippis S, et al:Goserelin as ovarian protection in the adjuvant treatment of premenopausal breast cancer:aphase H pilot study. Anticancer Drugs 13:417-424, 2002
 
15) Seymour J:Ovarian tissue cryopreservation for cartcer patients:who is appropriate? Reprod Fertil Dev 13:81-89, 2001
PubMed
16) Ives A, Semmens J, Saunders C, et al:Agrowing dilemma-breast cancer and pregnancy. Aust Fam Physician 31:929-932, 2002
 
17) De Santtis M, Lucchese A, De Carolis S, et al:Metastatic breast cancer in pregnancy:first case of chemotherapy with docetaxel. European J Cancer care 9:235-237, 2000
 
18) Minton SE, Munster PN:Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control 9:466-472, 2002
PubMed
P.380 掲載の参考文献
1) Ong LML, De Haes JCJM, Hoos AM:Doctor-patients communication:A review of the literature. Soc Sci Med 40:903-918, 2000
 
2) Gray RE, Fitch M, Greenberg M, et al:The information needs of well longer-term survivors of breast cancer. Patient Educ Counsel 33:245-255, 1998
 
3) Rees CE, Bath PA:The information needs and source preferences of women with beast cancer and the family members:a review of the literature published between 1988 and 1998. J Adv nurs 31:833-841, 1998
 
4) Derogatis LR, Morrow GR, Fetting J, et al:The prevalence of psychiatric disorders among cancer patients. JAMA 249:751-757, 1983
PubMed
5) Fallowfield LJ, Hall A, Maguire GP, et al:Psychological outcomes of different treatment policies in women with early breast cancer outside aclinical trial. BMJ 301:575-580, 1990
 
6) Ganz PA, Shag CA, Fred C, et al:Breast cancer survivors:psychosocial concerns and quality of life. Breast Cancer Res Treat 38:183-199, 1996
 
7) Spiegel D:Psychosocial aspects of breast cancer treatment. Semin Oncol 24:S1-36-47, 1997
 
8) McArdle JM, George WD, McArdle CS, et al:Psychological support for patients undergoing breast cancer surgery:arandomized study. BMJ 312:813-817, 1996
 
9) Okamura H et al:Psychological distress following first recurrence of disease in patients with breast camcer. Prevalence and risk factors. Breast Cancer Res Treat 61:131-137, 2000
 
10) Holzner B, et al:Qality of life in breast cancer patients-not enough attention for long-term survivors?Psychosomatics 42:117-123, 2001
 
11) Stewait DE, Cheung AM, Duff S:Long-teum breast cancer survivors:confidentiality, disclosure, effects of work and insurance. Psychooncology 10:259-263, 2001
 
12) Kristj anson LJ, Axhcroft T:The family:scancer joumey:Aliterature review. Cancer Nurs 17:1-17, 1994
 
13) Northouse LL, Swain MA:Adjustment of patients and husbands to the initial impact of breast cancer. Nurs Res 36:221-225, 1987
 
14) Maguire P:The repercussions of mastectomy on the family. Int J Farn Psychiatr 1:485-503, 1981
 
15) Vachon ML, Freedman K, Formo A:The final illness in cancer:the widow:sperspective. Can Med Assoc J 117:1151-1153, 1977
 
16) Pederson Lm, Valanis BG:The effects of breast cancer on the family:areview of the literature. J Psychosoc Onco16:199-211, 1988
 
17) Compas BE, Worsham NL, Ey S, et al:When mom or dad has cancer:II. Coping, cognitive appraisals, and psychological distress in children of cancer patients. Health Psycho115:167:175, 1996
PubMed
18) Issel LM, Eserk M, Lwwis FM:How children cope with mother:sbreast cancer. Oncol Nurs Forum 17:5-10, 1990
 
19) Massie MJ, Holland JC:Overview of normal reactions and prevalence of psychiatric disorders. Holland JC, Rowland JH eds:Handbook of psychooncology, 1st Ed, Oxford University Press, New York, p273-282, 1990
 
20) Spiegel D, Bloom JR, Kraemer H, et al:Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet 14:889-891, 1989
 
21) Maunsell E, Brisson J, Deschenes L, et al:Randomized tria of a psychologic distress screening program after breast cancer:effects on quality of life. J Clinic Oncol 14:2747-2755, 1996
 
22) Allen SM, Shah AC, Nezu AM, et al:A problem-solving approach to stress reduction among younger women with breast carcinoma. A randomized trial. Cancer 94:3089-3100, 2002
PubMed
23) Goodwin PJ, Leszcz M, Ennis M, et al:The effect of group Psychosocial support on survival in metastatic breast cancer. New Engl J Med 345:1719-1726, 2001
PubMed
24) Fukui S, Kamiya, Koike M, et al:Applicability of a Westem-developed psychosocial group intervention for Japanese patients with primary breast cancer. Psycho-Oncology 9:169-177, 2000
 
25) Hosaka T:Apilot study of a structured psychiatric intervention for Japanese women with breast cancer. Psycho-oncology 5:59-64, 1996
 
P.388 掲載の参考文献
1) 大川智彦, 喜多みどり, 田中真喜子ほか:癌・放射線治療におけるインフォームド・コンセント (IC) .癌の臨 39:1339-1343, 1993
Medical*Online
2) 平田公―:Q&A, セカンドオピニオンを求められたときに, どう対応すればよい? 乳癌診療 Tips & Traps No. 7, 4-5, Torre Lazur McCann Healthcare Worldwide lnc, 東京, 2002
 
3) 森岡恭彦:インフォームド・コンセント (IC) の概念とその社会的背景.癌の臨 39:1321-1324, 1993
Medical*Online
4) 芳賀駿介, 清水忠夫, 梶原哲郎:乳癌治療におけるインフォームド・コンセント.癌の臨 39:1371-1376, 1993
Medical*Online
5) 小山博記, 稲治英生, 元村和由ほか:乳房温存療法をめぐる諸問題, 適応拡大のための前治療.癌の臨 46:671-675, 2000
 
6) 飯野佑―:インフォームド・コンセント, 森下靖雄, 飯野佑編集:乳癌の治療-基礎と臨床-,メディカル・レビュー社, 東京, p222-229, 2002
 
7) Iino Y, Ishikita T, Takeo T, et al:Subcutaneous mastectomy with axillary dissection for early breast cancer. Anticancer Res 13:1183-1186, 1993
PubMed
8) 飯野佑―, 堀口 淳, 森下靖雄:やさしい乳癌の画像診断, 外科治療の現状.臨床画像 11:70-77, 1995
 
9) Horiguchi J, Iino Y, Takei H, et al:Comparison of breast-conserving therapy with mastectomy for treatment of early breast cancer. Anticancer Res 17:3849-3856, 1997
PubMed
10) 飯野佑―, 鯉淵幸生:補助内分泌療法:閉経前症例の場合.乳癌の臨 15:267-272, 2000
Medical*Online
11) 園尾博司:補助内分泌療法:閉経後症例の場合.乳癌の臨15:273-278, 2000
 
12) Buzdar AU on behalf of the ATAC Trialists:Group:ATAC (:Arimidex:, Tamoxifen, Alone or in Combination) trial in postmenopausal women with early breast cancer-Updated efficacy results based on a mediam follow-up of 47 months. 25th Annual San Antonio Breast Cancer Symposium December, San Antonio, Texas, USA, 11-14, 2002
 
13) 正 村 滋, 池田 正, 北島政樹:補助化学療法の適応と標準的なレジメン.乳癌の臨 15:251-254, 2000
Medical*Online
14) 飯野佑一, 鯉淵幸生:術後フォローアップの仕方.日本臨床2000年増刊号, 乳癌の診断と治療 58:228-233, 2000
 

技術資料編

P.394 掲載の参考文献
1) Vogel CI., Cobleigh MA, Tripathy D, et al:First-line Herceptin monotherapy in metastatic breast cancer. Oncology 61:37-42, 2001
 
2) Yamamoto T, Ikawa S, Akiyama T, et al:Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature 319:230-234, 1986
 
3) Slamon DJ, Clark GM, Wong SG, et al:Human breast cancer:correlation of relapse and survival with amplification of the HER-2/ne2L oncogene. Science 235:177-182, 1987
PubMed
4) Press MF, Bemstein L, Thomas PA, et al:HER-2/ne2L gene amplification characterized by fluorescence in situ hybridization:Poor prognosis in node-negative breast carcinomas. J Clin Oncol 15:2894-2904, 1997
 
5) Muss HB, Thor AD, Berry DA, et al:c-erb-B-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260-1266, 1994
 
6) D. J. Slamon, et al:Use of chemotherapy and monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
 
7) 1 (allioniemi O, Kallioniemi A, Kurisu W, et al:ERBB2 arnplification in breast cancer analyzed by fluorescence in sit2L hybridization. Proc Natl Acad Sci 89:5321-5325, 1992
 
8) Press MF, Hung G, Godolphin W, et al:Sensitivity of HER-2/ne2L antibodies in archival tissue samples:potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 54:2771-2777, 1994
PubMed
9) Press MF, Zhou JY, Ma Y, et al:Evaluation of HER-2/neu gene amplification by fluorescence in situ hybridization in invasive breast carcinoma. In:FISH:Clinical Applications in Cancer and Genetics. February 8-11, Lake Tahoe, CA, 1994
 
10) Pauletti G, Singh R, Press MF, et al:HER-2/neu Gene Amplification Detected by Fluorescence in situ Hybridization:Acomparative study With other techrtiques. Abstract 3247, Proceedings of the American Association for Cancer Research 35:545, 1994
 
11) Szoelloesi J, Balazs M, Feuerstein BG, et al:Phenotype genotype relationship in erbB-2 amplification. International Society for Analytical Cytology. Abstracts 92:Abstract 536D, 1994
 
12) Persons DL, Bui MM, Lowery MC, et al:Fluorescence in sitzt hybridization (FISH) for detection of HER-2/ne2L amplification in breast cancer:amulticenter portability study. Ann Clin Lab Science 30:41-48, 2000
 
13) Masood S, Bui MM, Yung J-F, et al:Reproducibility of LSI HER-2/neu Spectrum Orange and CEP 17 Spectrum Green Dual Color Deoxyribonucleic Acid Probe Kit. Annals Clin Lab Sci 28 (4):215-223, 1998
 
14) Mass RD, Sanders C, Kasian C, et al:The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials (abstract). Proceedings of ASCO 19:291, 2000
 
15) Mass RD, Press M, Anderson M, et al:Improved survival benefit from Herceptin (Trastuzumab) in patients selected by fluorescence in situ hybridization (FISH). Proceedings of ASCO 20:22a abstract 85, 2001
 
16) Vogel CL, Cobleigh M, Tripathy R, et al:Superior outcomes with Herceptin (Trastuzumah) in fiuorescence in situ hybridization (FISH)-selected patients. Proceedings of ASCO 20:22a abstract 86, 2001
 
P.399 掲載の参考文献
1) Semba K, Kamata N, Toyoshima K, et al:AveγbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci US 82:6497-6501, 1985
 
2) Yamamoto T, Ikawa S, Akiyama T, et al:Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature 319:230-234, 1986
 
3) Akiyama T, Sudo C, Ogawara H, et al:The product of the human c-eγbB-2 gene:A185 kilodalton glycoprotein with tyrosine kinase activity. Science 232:1644-1646, 1986
 
4) Coussens L, Yang-Feng T I., Liao Y C, et al:Tyrosine kinase receptor with extensive homology to EGF receptor shares chromo-somal location with neu oncogene. Science 230:1132-1139, 1985
 
5) Slamonv DJ, Clark GM, Wongv SG, etal:Human breast cancer:Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
 
6) Yamada Y, Yoshimoto M, Murayama Y, et al:Association of elevated expression of the cerbB-2 protein with spread of breast cancer. Jpn J Cancer Res 80:1192-1198, 1989
 
7) Tsuda H, Hirohashi S, Shimosato Y, et al:Immunohistochemical study on overexpression of c-erbB-2 protein in human breast cancer:Its correlation with gene amplification and long-term survival of patients. Jpn J Cancer Res 81:327-332, 1990
 
8) Clark G M and McGuire W L:Follow-up study of HER-2/nθ2L amplification in primary breast cancer. Cancer Res 51:944-948, 1991
 
9) Cobleigh M A, Vogel C L, Tripathy D, et al:Multinational study of the efficacy and safety of humanized anti-Her2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648, 1999
PubMed
10) Masuko T, Sugahara K, Kozono M, et al:A murine monoclonal antibody that recognizes an extracellular domain of the human c-erbB-2 protooncogene product. Jpn J Cancer Res 80:10-14, 1989
 
11) Saga T, Endo K, Akiyama T, et al:Scintigraphic detection of overexpressed c-erbB-2 protooncogene products by a class-switched murine anti-c-eγbB-2 protein monoclonal antibody. Cancer Res 51:990-994, 1991
 
12) Mori S, Mori Y, Mukaiyama T, et al:In vitro and in vivo release of soluble erbB-2 protein from human carcinoma cells. Jpn J Cancer Res 81:489-494, 1990
PubMed
13) 菅野康吉, 北島政樹, 石井勝ほか:乳癌における抽出液中ErbB-2蛋白測定とc-erbB-2遺伝子増幅および免疫染色による臨床検討.癌と化学療法 21:1957-1966, 1994
Medical*Online
14) 菅野康吉, 河合忠, 大倉久直ほか:サンドイッチRIAキットによる血清ErbB-2の臨床的検討.癌と化学療法 21:1245-1253, 1994
 
15) 菅野康吉, 河合忠, 石井 勝 ほか:EIAキットによる血清ErbB-2の臨床検討.癌と化学療法 21:1255-1262, 1994
 
16) 稲治英生, 小山博記, 塚田敏彦ほか:乳頭分泌液中のErbB-2測定による乳癌診断能の検討.乳癌の臨床 9:449-454, 1994
 
17) Imoto S, Ohkura H, Sugano I, et al:Determination of Cytosol c-erbB-2 Protein in Breast Cancer by Sandwich Enzyme Immunoassay. Jpn J Clin Oncol 28:92-96, 1998
 
18) Imoto S, Kitoh T, Hasebe T:Serum c-erbB-2 levels in monitoring of operable breast cancer. Jpn J Clin Oncol 29:336-339, 1999
 
19) Sugano K, Ushiama M, Fukutomi T, et al:Combined measurement of the c-erbB-2 protein in breast carcinoma tissues and sera is useful as a sensitive tumor marker for monitoring tumor. Int J Cancer 89:329-336, 2000
 
20) Kitoh T, Sugano K, Ushiama M, et al:Serum ErbB-2 as a sensitive marker for monitoring recurrent breast cancer. Clin Chem 45:Suppl 391, 1999
 
21) Shin E, Takatsuka Y, Nishisho I, et al:Prognostic significance of c-erbB-2 status using enzyme immunoassay in breast cancer. Int J Clin Oncol 5:12-17, 2000
 
22) 井本 滋, 和田徳昭, 佐伯俊昭ほか:腫瘍および血清c-erbB-2蛋白発現を指標とした乳癌の抗体療法.乳癌の臨床 17:187-192, 2002
Medical*Online
P.405 掲載の参考文献
1) Baselga J, Norton L, Albanell J, et al:Recombinant humanized anti-HER2 antibody (Herceptin) enhances the anti-tumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58:2825-2831, 1998
PubMed
2) Joensuu H, Roberts PJ, Sarlomo-Rikka M, et al:Effect of the tyrosine kinase inhitor STI571 in a patient with metastatic gastrointestinal stromal tumor. N Eng J Med 344:1052-1056, 2001
 
3) 鎌野世民, 矢野誠一, Dong Rui-Ping:上皮成長因子受容体 (EGFR) チロシンキナーゼ阻害剤ZD1839について.細胞 34 (4):170-173, 2002
 
4) Rhodes A, Jasani B, Balaton AJ, et al:Study of interlaboratory reliability and reproducibility of estrogen and progesterone assays in Europe:Documentation of poor reliability and identification of insufficient microwave antigen retrieval time as a maj or contributory element of unreliable assays. Am J Clin Pathol 115:44-58, 2001
PubMed
5) Goulding H, Pinder S, Cannon P, et al:Anew immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples. Hum Pathol 26:291-294, 1995
 
6) Ferrero-Pous M, Trassard M, Le Doussal V, et al:Comparison of enzyme immunoassay and immunohistochemical measurements of estrogen and progesterone receptors in breast cancer patients. Appl Immunohistochem Mol Morphol 9:267-275, 2001
PubMed
7) Detre S, Saclani Jotti G, Dowsett M:A "quick Score"method for immmunohistochemical semiquantitation:validation for oestrogen receptor in breast carcinomas. J Clin Pathol 48:876-878, 1995
 
8) Goldhirsch A, Glick JH, Gelber RD, et al:Meeting highlights:International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh Intemational Conference on A adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 19:3817-3827, 2001
 
9) Elston CW, Ellis IO, Goulding H, et al:Role of pathology in the prognosis and management of breast cancer. In:Elston CW, et al eds:The Breast:Systemic Pathology, 3rd Ed, volume 13. Churchill Livingstone, Edinburgh, UK, p384-433, 1998
 
10) Snead DR, Bell JA, Dixon AR, et al:Methodology of immunohistological detection of oestrogen receptor in human breast carcinoma in formalin-fixed, paraffin-embedded tissue:acomparison with frozen section methodology. Histopathology 23:233-238, 1993
 
11) Press MF, Pike MC, Chazin VR, et al:Direct tissue quantitation by computerzed image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 53:4960-4970, 1993
PubMed
12) Hatanaka Y, Hashizume K, Kamihara Y, et al:Quantitative immunohistochemical evaluation of HER2/neu expression with Hercep Test in breast carcinoma by image analysis. Pathology Intemational 51:33-36, 2001
 
P.412 掲載の参考文献
1) TM Kolb, J Lichy, JH Newhouse:Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of the factors that influence them:an analysis of 27, 825 patient evaluations. Radiology 225:165-175, 2002
 
P.421 掲載の参考文献
1) 蒔田益次郎:乳管造影と乳管内視鏡-異常乳頭分泌症例の診断.INNERVISION 12 (2):25-28, 1997
 
P.427 掲載の参考文献
1) Nabholtz JM, et al:Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women:results of a North American Multicenter randomized trial. J Clin Oncol 18:3758-3767, 2000
 
2) Bonneterre J, et al:Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women:results of the tamoxifen or Arimidex randomized group efficacy and tolerability study. J Clin Oncol 18:3748-3757, 2000
PubMed
3) Bonneterre J, et al:Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma:results of two randomized trials designed forcombined analysis. Cancer 92:2247-2258, 2001
PubMed
4) The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists:Group:Anastrozolealone or in combination with tamoxifen versustamoxifen alone for adjuvant treatment ofpostmenopausal women with early breastcancer:first results of the ATAC randomisedtrial. Lancet 359:2131-2139, 2002
 
5) Santen RJ, et al:Use of aromatase inhibitors inbreast carcinoma. Endocrine-Related Cancer 6:75-92, 1999
 
6) Dowsett M, et al:Effects of the aromataseinhibitor anastrozole on serum oestrogens in Japanese and Caucasian women. Cancer Chemother Pharmacol 46:35-39, 2000
 
7) Watanabe T, et al:Abridging of the efficacy ofanastrozole (Arimidex) between Japaneseand Caucasian patients with breast cancer:apotential method for accelerating the drugdevelopment process. Proc ASCO 19:103a, Abs 396, 2000
 
8) Geisler J, et al:Influence of anastrozole (Arimidex), aselective, non-steroidalaromatase inhibitor, on in vivo aromatisationand plasma oestrogen levels in postmenopausal women with breast cancer. Br JCancer 74:1286-1291, 1996
 
9) 小山博記ほか:閉経後乳癌患者におけるアナストロゾール (新規第4世代アロマターゼ阻害剤) の第I相試験.乳癌の臨床 15:577-583, 2000
 
10) Geisler J, et al:Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clin Cancer Res 7:1230-1236, 2001
PubMed
11) Buzdar AU, et al:Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast cancer. Results of a survival update based on a combined analysis of data from two mature Phase III trials. Cancer 83:142-1152, 1998
 
12) Buzdar AU:The ATAC (?Arimidex' Tamoxifen, Alone or in Combination) trial in post-menopausal women with early breast cancer-updated efficacy results based on a median follow-up of 47 months. Proc San Antonio Breast Cancer Symposium 76 (Suppl 1):Abs 13, 2002
 
13) Sainsbury R:Beneficial side-effect profile of anastrozole compared with tamoxifen confirmed by additional 7 months of exposure data:asafety update from the`Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial. Proc San Antonio Breast Cancer Symposium 76 (Suppl 1):Abs 633, 2002
 
14) Dewar JA, et al:the effect of anastrozole (Arimidex) on serum lipids-arandomised comparison of anastrozole vs. tamoxifen in postmenopausal women with advanced breast cancer. Eur J Cancer 37 (Suppl 5):5, 2001
 
15) Eastell R, et al:Results of the`Arimidex' (anastrozole, A), tamoxifen (T), alone or in combination (C) (ATAC) trial:Effects on bone mineral density (BMD) and bone tumover (ATAC Trialists:Group) . Am Oncol 13 (Suppl 5):Abs 113PD, 2002
 
P.432 掲載の参考文献
1) Cole MP, et al:Anew anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI 146474. Br J Cancer 25:270-275, 1971
 
2) Patterson JS, et al:癌の臨床別冊「乳癌・内分泌療法」, 篠原出版, 東京, p157, 1981
 
3) 和田富雄ほか:Tamoxifenによる進行・再発乳癌のホルモン療法.日癌治 14:819-824, 1979
 
4) Buchanan RB, et al:Arandomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J Clin Oncol 4:326-1330, 1986
 
5) Ingle JN, et al:Randomized trial of bilateral oophorectomy versus tamoxifen in pre-menopausal women with metastatic breast cancer. J Clin Oncol 4:178-185, 1986
 
6) Klijn JGM, et al:Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer:a meta-analysis of four randomized trials. J Clin Oncol 19:343-353, 2001
 
7) Bonneterre J, et al:Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma:results of two randomized trials designed for combined analysis. Cancer 92:2247-2258, 2001
PubMed
8) The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists:Group:Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer:first results of the ATAC randomised trial. Lancet 359:2131-2139, 2002
 
9) Early Breast Cancer Trialists, Collaborative Group:Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339:1-15, 1992
 
10) Early Breast Cancer Trialists:Collaborative Group:Tamoxifen for early breast cancer:an overview of the randomised trials. Lancet 351:1451-1467, 1998
 
11) The Swedish Breast Cancer Cooperative Group:Randomized trial of two versus five years of adjuvant tamoxifen for post-menopausal early stage breast cancer. J Natl Cancer Inst 88:1543-1549, 1996
 
12) Jakesz R, et al:Randomized a adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil:evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer-Austrian Breast and Colorectal Cancer Study Group-Trial 5. J Clin Oncol 20:4621-4627, 2002
 
13) Davidson NE, et al:Effect of chemohormonal therapy in premenopausal, node-positive, receptor-positive breast cancer:Eastern Cooperative Oncology Group Phase III Intergroup Trial (E5188, INT-0101). Breast 8:232-233, Abs O69, 1999
 
14) Fisher B, et al:Tamoxifen for prevention of breast cancer:report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. JNatl Cancer Inst 90:1371-1388, 1998
PubMed
P.438 掲載の参考文献
1) Belchetz PE, et al:Hypophysial responses to continuous and intermittent delivery of hypothalamic gonadotropin releasing hormone. Sience 202:631-633, 1979
 
2) 阿部令彦 ほか:閉経前乳癌に対するLH-RH agonist (ICI 118, 630, Zoladex(R))の臨床効果-前期第II相試験-乳癌の臨床 7:447-454, 1992
Medical*Online
3) 阿部令彦 ほか:閉経前進行・再発乳癌患者に対するLH-RH agonist, goserelin (Zoladex(R)) の用量比較試験.乳癌の臨床 7:551-565, 1992
Medical*Online
4) 阿部令彦 ほか:閉経前進行・再発乳癌患者に対するLH-RH agonist, goserelinの長期投与試験.乳癌の臨床 7:567-581, 1992
Medical*Online
5) Taylor CW, et al:Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer:an intergroup study. J Clin Oncol 16:994-999,
PubMed
6) Klijn JGM, et al:Combined tamoxifen andluteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alonein premenopausal advanced breast cancer:ameta-analysis of four randomized trials. J Clin Oncol 19:343-353, 2001
 
7) Jonat WJ, et al:Goserelin versus cyclophosphamide, methotrexate, andfluorouracil as adjuvant therapy inpremenopausalpatients with node-positivebreast cancer:the Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 20:4628-4635, 2002
 
8) de Haes H, et al:Early benefits in quality of life observed in Zoladex TM-treated versus CMF-treated pre-/perimenopausal patientswith node-positive early breast cancer. Proc ASCO 20:35a, Abs 138, 2001
 
9) Jakesz R, et al:Randomized a adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil:evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer-Austrian Breast and Colorectal Cancer Study Group-Tiral 5. J Clin Oncol 20:4621-4627, 2002
 
10) Baum M, et al:Management of premenopausal women with early breast cancer:is there a role for goserelin? Proc ASCO 20:27a, Abs 103, 2001
 
11) Davidson NE, et al:Effect of chemohomlonal therapy in premenopausal, node-positive, receptor-positive breast cancer:an Eastern Cooperative Oncology Group Phase III Intergroup Trial (E5188, INT-0101). Breast 8:232-233, Abs O69, 1999
 

書評

最近チェックした商品履歴

Loading...